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I Introduction 
Luteinising hormone-releasing hormone (LHRH), a neurohormone released from the 
hypothalamus, is the key regulator of the reproductive processes in vertebrates. It controls the 
release of follicular stimulating hormone (FSH) and luteinising hormone (LH) from the 
pituitary gland, which in turn affects the gonadal functions. Manipulation of the 
neuroendocrine cascade by LHRH intervention leads to down regulation of the sex steroids 
levels and has been widely used in any situation where pharmacological castration, providing 
androgen and estrogen ablation, is required. The neuroendocrine axis can be obliterated by 
synthetic LHRH analogues. While the LHRH agonists cause pituitary desensitisation due to 
sustained stimulation, the LHRH antagonists compete with native LHRH for the same 
receptor causing an immediate cessation of the release of the sex steroids.  LHRH analogues 
are routinely being used in the clinic as one of the means for the treatment of cancers of the 
reproductive organs namely breast and prostate carcinoma, central precocious puberty, in 
vitro fertilisation procedures and many benign gynaecological disorders.  
The neuroendocrine axis can also be disrupted by neutralising anti-LHRH antibodies either 
induced by active immunization or when administered passively. The action of neutralising 
anti-LHRH antibodies is similar to the antagonists of LHRH in causing an immediate 
disruption of the hormonal secretion. Active immunization has been proposed as a cheap and 
convenient alternative to the use of LHRH analogues. Although LHRH vaccines have shown 
promise in clinical trials on prostate cancer patients, they are limited by the variation in the 
immune response from patient to patient and the lag period in the build-up of effective 
antibody titres, delaying the onset of therapeutic effects. These two shortcomings can be 
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circumvented if pre-made, bio-effective antibodies are administered passively either as a 
supplement to active immunization or as a single treatment modality. Although the response 
from passive immunization would be for a finite duration, the effective dose can be given, 
ensuring an immediate and desirable therapeutic effect. A pre-requisite for such a therapeutic 
approach is the low immunogenicity and mass production at a low cost of the antibody in 
question. While recombinant DNA technology has made possible the generation of 
humanised antibodies, production of the same in plants provides a tangible evidence for the 
bulk production of the antibody of interest at a low cost.   
I.1 LHRH structure  
LHRH is a decapeptide that was isolated and characterised by the groups of Schally and 
Guillemin (AMOSS et al., 1971; MATSUO et al., 1971). LHRH is also known as 
gonadotropin releasing hormone (GnRH) and has a pyroglutamic acid at the N terminal and a 
glycine amide residue on the C terminal end. Thus both the N and C termini of the 
neurohormone are modified (Fig. I-1). 
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Fig.  I-1: Primary structure of LHRH hormone.  
The glutamate residue at the N terminal cyclices to form the pyroglutamate while the glycine at 
the C terminal has an amide group. 
Although the function of LHRH as the prime regulator of the reproductive function has been 
highly conserved during 500 million years of vertebrate evolution, eleven naturally occurring 
structural variants have been identified in animals ranging from protochordates through fish, 
amphibians, reptiles and birds (Table I.1). All the isoforms are decapeptides that are 
conserved as much as 50-90% in comparison to the mammalian LHRH (SHERWOOD et al., 
1993; MILLAR and KING, 1988). Sequence comparison of naturally occurring LHRH 
  
 
I Introduction 3
isoforms have revealed that the N-and C-terminal sequences, PyroE-H-W-S and P-G-NH2 
respectively are highly conserved whereas some variations occur within the central Y-G-L-R 
domain of LHRH (KING et al., 1995; SEALFON et al., 1997). The conserved regions are 
thought to have important functional roles while the non-conserved residues are either 
unimportant or confer specificity to a particular LHRH receptor. 
Table I-1: Comparison of the structures of naturally occurring LHRH variants.  
Conserved features of LHRH structure are indicated in the white boxes, while non-conserved residues 
are indicated in shaded boxes. 
Mammal pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly NH2 
Chicken 1 pGlu His Trp Ser Tyr Gly Leu Gln Pro Gly NH2 
Seabream pGlu His Trp Ser Tyr Gly Leu Ser Pro Gly NH2 
Catfish pGlu His Trp Ser His Gly Leu Asn Pro Gly NH2 
Salmon pGlu His Trp Ser Tyr Gly Trp Leu Pro Gly NH2 
Dogfish pGlu His Trp Ser His Gly Trp Leu Pro Gly NH2 
Chicken II pGlu His Trp Ser His Gly Trp Tyr Pro Gly NH2 
Lamprey I pGlu His Tyr Ser Leu Glu Trp Lys Pro Gly NH2 
Lamprey III pGlu His Trp Ser His Asp Trp Lys Pro Gly NH2 
Tunicate I pGlu His Trp Ser Asp Tyr Phe Lys Pro Gly NH2 
Tunicate II pGlu His Trp Ser Leu Cys His Ala Pro Gly NH2 
  
I.2 Physiological function of LHRH 
LHRH is the master molecule of the neuroendocrine reproductive hormone cascade. It is 
synthesised in the neurosecretory cells located in the preoptic area of the hypothalamus and 
then transported by the axons to the neuronal terminal, where it is released into the capillaries 
of the pituitary-portal circulation system. LHRH is eventually transported to the anterior 
pituitary gland (Fig. I-2). The function of LHRH and its analogues is mediated by high-
affinity, G protein-coupled receptors (GPCRs) (KAKAR et al., 1992) expressed on the 
plasma membrane of the gonadotropes (STOJILKOVIC et al., 1994). Gonadotropes are the 
population of cells in the pituitary gland that synthesise and release the gonadotropins - LH 
and FSH (CONN and CROWLEY, 1994; SCHALLY et al., 1973). 
Gonadotropins are secreted into the systemic circulation and act on the gonads to regulate 
steroidogenesis and gametogenesis. LH stimulates ovulation and corpus luteum formation in 
females and androgen secretion in males. FSH stimulates the growth and maturation of 
ovarian follicles in females and spermatogenesis in males. Gonadal steroids and peptides that 
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are secreted into the systemic circulation act to modulate hypothalamic and pituitary function 
in both positive and negative feedback loops. The operation of short and ultra-short loop 
feedback mechanisms within the hypothalamus itself and between the pituitary gland and the 
hypothalamus respectively has also been postulated (TILBROOK et al., 2001). The schematic 
outline of the reproductive hormonal cascade is shown in Fig. I-2.   
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Fig. I-2: Spatial location of the hypothalamus and pituitary gland and the schematic 
outline of the reproductive hormonal cascade. 
LHRH is synthesised in the neurosecretory cells located in the preoptic area of the hypothalamus 
and then transported by the axons to the neuronal terminal, where it is released into the capillaries 
of the pituitary-portal circulation system that transports LHRH to the anterior pituitary gland. 
LHRH: luteinising hormone releasing hormone; LH: luteinising hormone; FSH: follicular 
stimulating hormone. 
In addition to the hypothalamus, which is considered to be the main source of the decapeptide, 
recent observations have shown the presence of LHRH and LHRH-like molecules in extra 
hypothalamic sites such as the placenta, ovary, myometrium, endometrium, prostate and 
blood mononuclear cells (KANG et al., 2000; CHENG et al., 2000; CHEGINI et al., 1996). 
The biological role of the decapeptide made in situ in these organs is not fully known 
although an autocrine paracrine role is indicated. In humans controversial data has been 
obtained for extra-pituitary expression of mRNA for LHRH-receptor in ovary, testis, breast, 
endometrium, myometrium, placenta and prostate and in the various cancers of these tissues 
and their associated cell lines (LAU et al., 2001; MINARETZIS et al., 1995). 
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I.3 Mammalian isoforms of LHRH  
Until recently, LHRH was thought to be the sole hypothalamic messenger regulating 
reproductive processes in mammals. However, a form of LHRH originally isolated from 
chicken hypothalamus (cGnRH II, Fig. 1-3) (MIYAMOTO et al., 1984) has been shown to be 
the most widely expressed LHRH isoform among vertebrates (SHERWOOD et al., 1993) 
including humans (CHEN et al., 1998; WHITE et al., 1998). The cGnRH II is now designated 
as mammalian GnRH-II (SEALFON et al., 1997) while the hypothalamic LHRH is also 
called GnRH-I.  
GnRH-I 
GnRH-II 
s-GnRH  
l-GnRH-III  
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 
pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH2 
pGlu-His-Trp-Ser-Tyr-Gly-Trp-Leu-Pro-Gly-NH2 
pGlu-His-Trp-Ser-His-Asp-Trp-Lys-Pro-Gly-NH2 
  
Fig. I-3: The amino acid sequence of the three isoforms of LHRH found 
in mammals. 
GnRH-I: the classical hypothalamic hormone found in the mammalian hypothalamus (also 
referred to as LHRH); GnRH-II: the LHRH isoform originally found in the chicken hypothalamus 
and later showed to be the most widely expressed LHRH isoform amongst vertebrates; sGnRH: 
GnRH originally found in the salmon hypothalamus, probable existence in the mammalian brain; 
l-GnRH-III: The third of the isoforms found in the lamprey brain also shown to be present in 
the rat brain. 
The GnRH-II gene has been cloned and expressed from human brain and localised on the 
chromosome 20p13 (WHITE et al., 1998), distinct from the hypothalamic LHRH, which is 
located on 8p21-p11.2 (YANG-FENG et al., 1986). The GnRH-II genomic and mRNA 
structures resemble those of GnRH-I but in contrast to GnRH-I, GnRH-II is expressed in 
significantly higher levels outside the brain (WHITE et al., 1998). GnRH-II selectively binds 
to the type II receptor that is distinct from the type I receptor to which the hypothalamic 
LHRH binds. The GnRH-II receptor gene has been cloned from monkeys (NEILL et al., 
2001) and marmosets (MILLAR et al., 2001). A putative GnRH-II receptor gene on human 
chromosome 1 has been found by homology search of the human genome sequence (NEILL, 
2002). The type II receptor in mammals is more widely distributed than the type I receptor. It 
is expressed throughout the brain, including the pituitary and areas associated with sexual 
arousal, and also in diverse non-neural and reproductive tissues, suggesting various functions 
(MILLAR et al., 2001). The conserved structure of the neuropeptide GnRH II from the 
primitive fish to the human suggests that this neuropeptide has been subject to extremely 
stringent selective pressures and thus may possess vital bioactivities. The widespread 
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expression of GnRH-II in organs other than the brain is also an indication that the peptide 
may possess multiple functions. 
There have been reports about the presence of a third isoform of LHRH in the mammalian 
brain. However, controversial data exists about the nature of the third isoform. While one 
research group has reported expression of salmon GnRH (s-GnRH) in human, bovine and rat 
brain (YAHOLAM et al., 1999) the other has shown the presence of lamprey GnRH-III (l-
GnRH-III) in the rat brain (HINEY et al., 2002). Furthermore, the l-GnRH-III has been shown 
to be a potent, selective inducer of FSH release as shown in the rat (YU et al., 1997) and cow 
(Dees et al., 1999). These findings point to the presence of a separate hypothalamic control of 
FSH. There have been several compelling evidences in the past from physiological studies for 
the presence of a distinct FSH-releasing factor (FHSRF) (DEES et al., 1985; LUMPKIN 
et al., 1984), but this is the first time that an isoform of LHRH has been shown to cause 
preferential FSH release. The matters get further complicated as a third research group has 
completely denied the presence of any third LHRH isoform as determined by homology 
search of the human genome although the authors do caution about the 5-7% of the human 
genome that still remains unsequenced, leaving room for doubt (NEILL, 2002).  
The physiological significance of the existence of multiple isoforms of LHRH in the brain is 
not yet clear although there are some hypotheses and studies that point to a distinct function 
for each of the isoforms. LHRH was previously suggested to be involved in the induction of 
sexual behaviour, since the administration of the peptide into the midbrain central gray of rats 
has been demonstrated to facilitate sexual behaviour (SAKUMA and PFAFF, 1980). However 
high doses of LHRH (µM range) were needed to elicit this effect. The discovery of the other 
two forms of LHRH in the midbrain raises the possibility that either of these may serve as the 
physiological regulator of reproductive behaviour. The two GnRHs and GnRH receptor 
systems, along with different signalling pathways, provide the potential for differential FSH 
and LH secretion (MILLAR et al., 2001). 
I.4 LHRH manipulation  
LHRH is released from a group of hypothalamic neurons into the hypophyseal portal blood in 
discrete, periodic bursts. Studies have shown that for continuous stimulation the pituitary 
gonadotroph must be exposed to small pulses of LHRH at a frequency of one every 60-120 
minutes which appears to be the pattern of normal hypothalamic activity as reflected by the 
frequency of LH pulses from the pituitary gland and from what is known from measuring 
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LHRH in the hypophysial portal blood (SANDOW, 1983; FRASER, 1982; CLARKE and 
CUMMINS, 1982).  
In contrast to the stimulatory effect of pulsatile GnRH, sustained exposure to high 
concentrations of LHRH or its agonists reduces the response of gonadotropes to subsequent 
stimulation with LHRH (homologous desensitisation) leading to suppression of gonadotropin 
secretion (KERI et al., 1983). Pituitary suppression can also be brought about by blockage of 
LHRH receptor by LHRH antagonists or by neutralization of endogenous LHRH by 
antibodies (Fig. I-4). The immediate effect of the cascade disruption is the drop in the levels 
of sex hormones to near castration levels. This effect has been widely used for treatment of 
sex-hormone sensitive clinical conditions. The concept of LHRH manipulation has been 
recapitulated in Fig. I-4. 
(a) PULSATILE LHRH
RELEASE
PULSATILE LH, FSH
PITUITARY STIMULATION
GONADAL STIMULATION
(b) LHRH AGONISTS
EXCESSIVE LH, FSH
PITUITARY DESENSITISATION
GONADAL DESENSITISATION
(c) LHRH ANTAGONISTS
OR ANTI-LHRH
ANTIBODIES
REDUCED LH, FSH
PITUITARY SUPPRESSION
GONADAL SUPPRESSION  
Fig. I-4: LHRH manipulation  
Diagram to illustrate how (a) physiological pulses of LHRH stimulate the pituitary gonadaotroph 
while this can be prevented by (b) chronic over stimulation of the pituitary to cause target-organ 
desensitisation; and (c) neutralization of LHRH by antibodies or receptor occupancy by LHRH 
antagonists to reduce LH and FSH release. 
I.5 LHRH analogues  
LHRH agonists and antagonists are synthetic analogues of LHRH. In the past 30 years, more 
than 3000 analogues of LHRH have been synthesised (SCHALLY et al., 2001). All LHRH 
analogues are small synthetic peptides that are structurally similar to native human LHRH but 
are more efficient than endogenous LHRH as they have greater resistance to peptidase 
activity, while the LHRH peptide is highly prone to degradation, having a serum half-life of 
less than 10 minutes in humans (BENNET et al., 1979). 
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The mechanisms of action of the LHRH analogues differ. The agonists first cause the release 
of the sex steroids due to the stimulatory effect and subsequently the desensitisation of the 
pituitary sets in (SCHALLY 1999). The initial increase in the levels of sex hormones caused 
by the LHRH agonists is called the "flare response" (WAXMAN et al. 1985). Antagonists on 
the other hand compete with LHRH for the same receptor. They cause an immediate cessation 
of the release of the sex steroids by blocking the receptor and thereby reduce the time of onset 
of therapeutic effects (KARTEN 1993). The initial hormone flare can be problematic because 
metastatic foci may enlarge during that time, resulting in worsening symptoms and potential 
spinal cord injury if bone metastasis in vertebral bodies is present. Therefore due to the more 
rapid onset of inhibitory effects, LHRH antagonists have advantage over the LHRH agonists 
in the treatment of sex-steroid-dependent disorders. 
Even though the superiority of the antagonists over that of the agonists was known the latter 
has been firmly established in today’s clinical practices as compared to the former. It has 
nearly taken three generations for the antagonists to be termed safe and devoid of any 
histamine release, a property that severely hampered the use of these compounds 
(SUNDARAM et al., 1988).  
I.6 Applications of pituitary suppression by LHRH manipulation 
I.6.1 Sex-steroid dependent cancers 
Reproductive organs are dependent for their growth and development on the sex steroids. The 
dependence for the sex hormones is seen to persist even in the event of some of these tissues 
becoming cancerous. Common sex hormone dependent cancers include prostate and 
breast carcinoma.  
I.6.1.1 Prostate cancer 
Adenocarcinoma of the prostate is now tied with lung cancer as the most common cancer in 
males and the third most common cause of death after lung and colorectal cancer. The major 
risk factor associated with this disease is age and as the demographic pattern is continually 
shifting towards an older population, there has been a substantial increase in the number of 
patients and consequently the cost of medical care (YANCIK and REIS, 1994). It has been 
estimated that by the year 2020, as a result of increasing longevity alone, there will be a 50% 
increase in the incidence of prostate cancer (BOYLE et al., 1995). Annual treatment of all 
prostate diseases in the United States costs in excess of $3 billion per year (VACHER 1995).  
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Androgen-dependent prostate cancer constitutes about 70% of all cases of prostate neoplasms 
(HEGARTY et al., 1999; OH and KANTOFF, 1998; SCHALLY et al., 2000). In the 1980s 
the first medical castration in a man with prostate cancer, using LHRH agonists (TOLLIS 
et al., 1982), marked its usefulness as a non-surgical mode for prostate cancer therapy. LHRH 
agonists have since become the standard of care and have replaced conventional therapies like 
orchiectomy (surgical castration) and estrogen therapy for treatment of prostate cancer. 
Extensive experimental and clinical data have indicated the utility of LHRH antagonists for 
prostate cancer therapy (SCHALLY, 1999; HALMOS et al., 1996; PINSKI et al., 1996). 
Antagonists especially prove beneficial for the patients with advanced prostate cancer with 
metastasis to the spinal cord, bone marrow and other sites, in which LHRH agonists cannot be 
used as single drugs because of the hormone flare-up (GONZALEZ-BARCENA et al., 1995). 
I.6.1.2 Gynaecological cancers 
Breast cancer is the most common malignancy in women. About 30% of all breast cancers 
rely on estrogen for their continued growth (HENDERSON et al., 1980). The goal of 
endocrine therapy in breast cancer is to inhibit the estrogen-stimulated growth of tumour cells. 
The role of aromatase inhibitors (AIs) in the management of post-menopausal breast cancer 
by suppression of estrogen biosynthesis is well established (CLEMONS et al., 2002). In 
menstruating patients estrogen deprivation has been induced by surgical oophorectomy.  
Similar clinical benefit in terms of progression-free and overall survival has been achieved by 
medical castration using LHRH analogues that induce a hormone profile of castration without 
surgical or radiotheapeutic intervention the other advantage being the reversibility of medical 
castration by LHRH analogues (BOCCARDO et al., 1994; JAKESZ et al., 2002). 
Favourable effects of LHRH analogues in treatment of cancers of the ovary and the 
endometrium have been reported (EMONS et al., 2000a; EMONS et al., 2000b). These 
effects have been allocated to both the reduction in the estrogen output as well as on direct 
antiproliferative effects of the LHRH analogues.  
I.6.2 Miscellaneous 
LHRH agonists are the established treatment for central precocious puberty. They act via 
desensitisation of the pituitary to inhibit the prematurely released endogenous LHRH (ROTH 
et al., 2000). Another future indication is the delay of normal puberty in children with short 
stature (KAMP et al., 2001).  
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In vitro fertilisation (IVF) procedures consist of administration of FSH preparations to induce 
ovulation. LHRH analogues are used to down-regulate the pituitary to prevent the occurrence 
of unpredictable responses such as cyst formation, premature ovulation and asynchronous 
follicular growth (HUIRNE and LAMBALK et al., 2001).  
Other indications for the LHRH analogues include benign gynaecological disorders namely 
ovarian hyper stimulation syndrome, polycystic ovary syndrome, endometriosis and 
leiomyoma (HUIRNE and LAMBALK et al., 2001).  
I.7 Immunoneutralisation of LHRH  
Anti-LHRH antibodies operate by inhibiting the hormone from binding to its receptors 
leading to suppression of the hypothalamo-pituitary-goandal axis. The action of neutralising 
anti-LHRH specific antibodies is deemed similar to the antagonists of LHRH in causing an 
immediate disruption of the hormonal secretion unlike the initial hormone flare caused by the 
agonists. Both active and passive immunization against LHRH has been shown 
to be effective. 
I.7.1 Active immunization against LHRH 
The idea of endocrine manipulation by active immunization against LHRH for treatment of 
hormone dependent cancers has been pursued for a long time. Immunization against LHRH 
while being a convenient and inexpensive alternative to the synthetic LHRH analogues also 
overcomes the disadvantages associated with direct LHRH analogue administration namely, 
administration of large and/or toxic drug doses. 
Active immunization against LHRH was established in the 1970s as a potential means by 
which the reproductive system of mammals can be down regulated for practical and clinical 
reasons. Numerous studies in males of various animal species have been performed since then 
to determine the applicability of immunocastration as an alternative to surgical removal of the 
testis. Reasons for such a procedure include improvement of meat and carcass characteristics 
of cattle, sheep, goat and swine; reduction in male aggressive behaviour (HUXOLL et al., 
1998); reductions in male associated odours in goat and swine (DUNSHEA et al., 2001); and 
fertility neutralisation in pet species (LADD et al., 1994). Although application as a fertility 
control agent in men is unlikely due to the simultaneous reduction in the levels of sex 
steroids, there is a prevailing interest in active immunization against LHRH as a means of 
treating prostate cancers and other steroid-dependent pathologies.  
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During the last decade three LHRH vaccines have been approved for clinical trials in prostate 
cancer patients: i) LHRH conjugated to diphtheria toxoid via an exchange of D-Lys with 
glycine at the sixth position (TALWAR et al., 1992), ii) LHRH conjugated to the N-terminus 
of tetanus toxoid (LADD et al., 1985) and iii) a recombinant vaccine, GnRH Pharmaccine that 
consists of the LHRH peptide linked through its amino terminus via a seven amino acid 
spacer to diphtheria toxoid (SIMMS et al., 2000). The clinical trials were performed in 
patients at an advanced stage of carcinoma of the prostate. Results indicated that with the 
production of anti-LHRH antibodies, FSH and LH levels declined and testosterone levels 
decreased to near castration levels. Active immunization against LHRH also causes regression 
of mammary tumours in rats by bringing down the serum estradiol levels (FERRO et al., 
1997; RAVDIN et al., 1988). This indicates that LHRH vaccines could be useful in treatment 
of gynaecological cancers as well as other estrogen-sensitive disorders, namely polycystic 
ovary syndrome, premenstrual syndrome and endometriosis as an alternative to the currently 
used LHRH analogues.  
Although promising the disadvantages of the use of LHRH vaccines include the necessity of 
frequent injections, the lag period before the build-up of antibody titres which delays the onset 
of therapeutic effects, and the variation in the immune response from patient to patient. The 
requirement of frequent injections of the LHRH vaccine has been addressed by encapsulating 
the vaccine in biodegradable microspheres, whereby primary immunization can be completed 
with a single injection (DIWAN et al., 1998). Passive immunization with pre-made, bio-
effective antibodies to bring about immediate effect in all subjects has been proposed to ward 
off the other problems inherent to the active anti-LHRH immunization approach (TALWAR 
1997a). Although the response from passive immunization will be for a finite duration, an 
effective dose can be given to ensure an immediate and desirable therapeutic effect.   
I.7.2 Passive immunization against LHRH 
At the time when LHRH was discovered passive administration of anti-LHRH antibodies 
formed an essential tool to study the physiology of the reproductive cascade. The specificity 
of the antibodies allowed the selective inhibition of LHRH without affecting the other 
elements of the complex hormonal regulatory circuit. It was observed that passive 
immunization with anti-LHRH antibodies blocked ovulation in rats (FRASER and GUNN, 
1973; KOCH et al., 1973) and caused rapid suppression of serum LH and testosterone 
concentrations in rams (LINCOLN et al., 1979). Recent reports of passive immune-
ization against LHRH include reduction in testosterone levels in rams (PARTHASARTHY 
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et al., 2002) and inhibition in the growth of human breast cancer xenografts in mice 
(JACOBS et al., 1999).  
The advent of hybridoma technology saw the development of many bio-effective monoclonal 
anti-LHRH antibodies. Monoclonal antibodies specific to LHRH have been shown to disrupt 
estrus cycle of dogs (TALWAR et al., 1985) and mice (GUPTA et al., 1985), and cause 
resorption of embryos when given to pregnant mice at day seven of pregnancy (GUPTA et al., 
1985). Antibodies administered to baboons in early pregnancy have been shown to bring 
about a sharp decrease in the serum level of chorionic gonadotropin and progesterone, which 
is followed by termination of pregnancy (TALWAR et al., 1984). 
Although the utility and efficacy of passive immunization with anti-LHRH antibodies has 
been demonstrated in many animal experiments, the problem of immunogenicity of mouse 
monoclonal antibodies combined with expenses related to antibody production pose as the 
two major practical hurdles in commercialisation of such products. Development in 
recombinant DNA technology in combination with exploration of the optimal expression host 
could lead to the use of antibodies as a safe and cost effective therapeutic reagent. 
I.8 Recombinant antibodies 
Antibodies have been considered as a powerful tool to recognize and target almost any 
molecule with a high degree of specificity and affinity. For a long time the only source of 
antibodies were antisera from immunised animals. The development of hybridoma technology 
revolutionised the face of immunology as it introduced the possibility to immortalise 
individual antibody producing cells by fusing them with myeloma cells (KÖHLER et al., 
1975). From these stable hybridoma cell lines large quantities of monoclonal antibodies can 
be derived. Clinical medicine has also profited from this technology. Monoclonal anti-
bodies (mAbs) have been used as in vitro diagnostics hence enabling worldwide 
standardisation of reagents for RIA, ELISA immunocytopathology and flow cytometry. 
Monoclonal antibodies have also been extensively used for in vivo localisation of tumour 
antigens and in the immunotherapy of cancer. 
The other significant development in immunology was antibody engineering based on 
recombinant DNA technology. While the hybridoma technology immortalised the antibody 
producing B cell, the gene encoding for the antibody could itself be immortalised and 
manipulated by recombinant DNA technology (PLÜCKTHUN, 1994; NILSSON, 1995).  
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Recombinant DNA technology in the field of immunology has helped to overcome the 
limitations inherent to the murine monoclonal antibodies (I.8.1) and has evolved to a 
sophistication that allows the generation of antibodies of the desired antigenic specificity 
(I.8.2) and tailored to the desired form (I.8.3).   
I.8.1 Humanised antibodies 
The therapeutic use of murine mAbs is limited because they have a short half-life in serum, 
mouse antibodies only weakly recruit the human effector functions and can elicit a human 
anti-mouse antibody (HAMA) response when administered to patients (HASHOLZNER 
et al., 1997). The resulting neutralisation and enhanced clearance of the murine mAb from the 
serum together with hypersensitivity reactions compromise the therapeutic effect of 
the treatment. 
 
Fig. I-5: Schematic representation of the concept of mouse, chimeric, humanised and 
human antibodies. 
Fully murine and human antibodies are represented in the colours white and black respectively. 
Chimeric antibodies are made by splicing the constant region of the human antibody to the light 
and heavy variable domains of the mouse antibody. Humanised antibodies are constructed by 
grafting the murine CDRs of both the variable light and heavy chains onto a human framework. 
Recombinant DNA technology has solved these problems by enabling the engineering of 
antibodies that resemble human antibodies. mAbs can be humanised by transplanting antigen-
binding sites from murine to human antibodies. This method allows the access to a large pool 
of well-characterised murine mAbs for therapy, including those against human antigens that 
in addition to ethical constraints are difficult to elicit in humans (WINTER et al., 1991). The 
concept of humanisation of monoclonal antibody is depicted in the Fig. I-5. 
In Greek mythology, the chimera is a she-monster with a lion’s head, a goat’s body, and a 
dragon’s tail. Chimeric antibodies are similarly put together from diverse gene segments not 
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normally found associated. These antibodies are made by joining the variable domains of a 
murine mAb to the constant domains of a human antibody, thus reducing the immunogenicity 
and ensuring efficient recruitment of effector functions. Additionally, it allows the desired 
function to be selected for application by choosing the appropriate antibody ispotype. The 
construction of chimeric mouse/human monoclonal antibodies usually produces a reagent 
whose plasma half-life is often 3-6 times longer than that of the murine mAb 
(BILLETTA et al., 1992).  
A potential limitation in the use of chimeric mouse/human antibodies in vivo is the HAMA 
response that may arise because of the mouse variable antibody regions. The antigenicity 
caused by the murine variable antibody regions can be minimised by further humanisation of 
the antibodies by CDR (complementarity determining regions) grafting. In this approach the 
six hypervariable regions from the light and heavy chain antibody variable domains are 
grafted onto the framework of a human immunoglobulin molecule (JONES et al., 1986; 
RIECHMANN et al., 1988). This method takes advantage of the conserved structure of the 
antibody immunoglobulin variable domains, with the framework residues serving as a 
scaffold to support the CDR loops that make contact with the antigen. 
Nowadays it has also become possible to generate antibodies completely human in origin. 
Fully human antibodies can be obtained from (a) phage display libraries (see section I.8.2); 
(b) Epstein-Barr virus (EBV) transformation of human B cells from donors (for a review see 
WINTER and MILSTEIN, 1991)) and (c) immunization of transgenic mice (Xeno-mice) that 
carry the repertoire of selected human immunoglobulin germline gene segments 
(DUCHOSAL et al., 1992). 
I.8.2 Phage display  
Phage display is a powerful technique for rapid selection of high affinity recombinant 
antibody fragments to any protein of interest (BARBAS et al., 1991; HOOGENBOOM et al., 
1998). Phage display technology provides a system where a library of antibody fragments is 
displayed on the surface of filamentous phage. This is achieved by cloning the antibody gene 
into the phage genome in fusion with a gene coding for a phage coat protein. Expression of 
the fusion product and its subsequent incorporation into the mature phage coat results in the 
antibody being presented on the phage surface while its genetic material resides within the 
particle. This linkage between genotype and phenotype allows enrichment of specific phages 
(HOOGENBOOM 1997; BARBAS 1993) which are selected on immobilised targets by a 
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simple in vitro selection procedure called ‘biopanning’ whereby phages that display relevant 
binding structures are retained, while non-adherent phage are washed away. 
Phage display libraries can be derived from V-gene repertoires of ‘immunized’ (antigen 
exposed) or ‘naïve’ (antigen unexposed) human or animal donors (CLACKSON et al., 1991; 
MARKS et al., 1991). The phage display libraries from immunised donors are enriched for 
antibodies specific to the antigen of interest. Moreover the antibodies having undergone 
affinity maturation also have high affinity for the antigen. This advantage is offset by the need 
for making a specific phage display library for each antigen. The naïve library on the other 
hand offers the possibility to select antibodies to a large panel of antigens, including self, 
nonimmunogenic and relatively toxic antigens without the need for immunization (Griffiths 
et al., 1993; MARKS et al., 1991); VAUGHAN et al., 1996). Alternatively, synthetic or semi-
synthetic human antibody V-gene repertoires have been made by in vitro assembly of V gene 
segments and D/J fragments (deKRUIF et al., 1995; GRIFFITHS et al., 1994). Therefore, 
with the advent of phage display technology it has become possible to obtain antibodies 
specific to any antigen and in a very short time.  
Besides antibodies a variety of molecules for example enzymes (VEHAERT et al., 2002), and 
hormones (STORTELERS et al., 2002) have also been displayed on phages and variants with 
altered affinity or specificity have been isolated from libraries of random mutants. cDNA 
repertoires of cancer cell lines have also been displayed on phages to analyse the humoral 
immune response in cancer patients (SOMERS et al., 2002). Another useful invention has 
been the display of peptide libraries on the phages. Random peptide libraries displayed on 
phage have been used in a number of applications, including epitope mapping (CWIRLA 
et al., 1990; SCOTT et al., 1990), mapping protein-protein contacts (HONG et al., 1995), and 
identification of peptide mimics of non-peptide ligands (SCOTT et al., 1992). 
I.8.3 Recombinant antibody fragments 
The properties of the antibody molecule make it exquisitely amenable to protein engineering. 
The natural antibody molecule consists of four peptide chains, two light chains and two heavy 
chains, which form a symmetrical Y shape. The basic functions of the antibody reside in 
separate domains: antigen binding in the Fab fragment and the effector functions in the Fc 
portion. Not only are these functions separate but also the genes coding for the respective 
domains are contained on separate exons. This allows their assembly in a multitude of ways to 
produce antibody variants with lower immunogenicity, higher affinity or enhanced stability.  
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Fig. I-6: Recombinant antibody forms  
Some of the various forms of recombinant antibodies are shown where the variable regions have 
been used to design a multitude of binding reagents. 
Antibodies have been reduced in size, dissected into minimal binding fragments, and rebuilt 
into multivalent high-avidity reagents (Fig. I-6). Variable fragments (Fv) which consist of just 
the variable light (VL) and heavy (VH) domains are the smallest immunoglobulin fragments 
containing the whole antigen-binding site. But the non-covalent association of Fv fragments 
renders them unstable particularly at high dilution (GLOCKSHUBER et al., 1990). This 
drawback was overcome by engineering single-chain Fv (scFv) in which the VH and VL 
domain are joined by a flexible peptide linker of 15-20 amino acids (BIRD et al., 1988; 
HUSTON et al., 1988). ScFvs are only half the size of the Fab fragments and thus have lower 
retention times in the non-target tissues, more rapid blood clearance and better 
tumour penetration.  
Single chain Fv antibody fragments are predominantly monomeric when the VH and VL 
domains are joined by polypeptide linkers of more than 15 residues (KORTT et al., 1994; 
WHITLOW et al., 1994). An scFv molecule with a shorter linker cannot fold into a functional 
Fv domain and instead associate with another scFv molecule to form a ~ 60 kDa bivalent 
dimer termed a diabody (HOLLIGER et al., 1993; PERISIC et al., 1994; ATWELL et al., 
1996). Reducing the linker length below three residues results in the formation of ~ 90 kDa 
trimers termed as triabody (ILIADES et al., 1997; KORTT et al., 1994; PEI et al., 1997). The 
most important advantages that the multivalent scFv have over the monovalent scFv are the 
gain in functional binding affinity (avidity) and the reduced rate of clearance (HUDSON et 
al., 1999). Recombinant antibodies have also been linked to a range of molecules including 
radioisotopes for cancer imaging, enzymes for prodrug therapy and toxins for targeted cell 
killing (KUZEL and ROSEN, 1994; GOLDENBEG, 1993).  
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I.9 Recombinant antibodies in therapy 
Currently recombinant antibodies represent 30% of all biological proteins undergoing clinical 
trials (HUDSON & KORTT 1999). They comprise a significant share of the US$3 billion per 
annum immunodiagnostic market, from in vitro immunoassays to in vivo tumour and clot 
imaging reagents. The past few years have seen the development of many antibodies for 
diagnostic and therapeutic purpose and their approval for human use by the FDA.  
 Table I-2: Antibodies for therapeutic applications approved by the FDA. 
Year of FDA 
Approval 
Product Target Application 
1986 Muromonab-CD3 (OKT-3) 
Murine IgG 
CD-3 Transplant rejection 
1994 Abciximab (ReoPro) 
Chimeric Fab 
GP11a/111b Percutaneous transluminal 
coronary angioplasty 
1997 Rituximab (Rituxan) 
Chimeric IgG 
CD20 Non-Hodgkin lymphoma 
 
1997 Dacliximab (Zenepax) 
Humanised IgG 
IL-2r (Interleukin-2 
receptor) 
Transplant rejection 
1998 Basiliximab (Simulect) 
Chimeric IgG 
IL-2r (Interleukin-2 
receptor) 
Transplant rejection 
1998 Infliximab (Remicade) 
Chimeric IgG 
TNF (tumor necrosis 
factor) 
Rheumatoid arthritis  
1998 Pavilizumab (Synagis) 
Humanised IgG 
RSV (respiratory 
syncytial virus) 
RSV in infants 
1998 Trastuzumab (Herceptin) 
Humanised IgG 
HER-2/neu Breast cancer  
2000 Mylotarg (Gemtuzuman 
Ozogamicin, CMA-676) 
Humanised IgG 
CD33 Acute myelogenous  
leukemmia 
2001 Alemtuzumab (Campath) 
Humanised IgG 
CD52 B-CLL 
2002 Ibritumomab tiuxetan (Zevalin) 
Murine IgG 
CD-20 Non-Hodgkin’s 
lymphoma 
2002 Adalimumab (Humira) 
Human IgG 
TNF (tumor necrosis 
factor) 
Rheumatoid arthritis  
The first monoclonal antibody to be licensed for therapy was OrthoClone in 1986, a mouse 
IgG2a antibody reactive against CD3, for prevention of allograft rejection. In the 1990s, 
advances in recombinant DNA technology have lead to the approval of a plethora of chimeric 
and humanised monoclonal antibodies by the FDA. There are currently a total of twelve FDA 
approved therapeutic monoclonal antibody drugs in the market (Table I-2). Clinical studies of 
seven human antibodies, 41 humanized antibodies, four chimeric antibodies, three primate 
antibodies, nine mouse antibodies and one rat antibody is in progress. 
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I.10 Plants as antibody production systems 
Antibodies are required in very large amounts for numerous medical or biotechnological 
applications. In cancer therapy for instance doses of 1 g/patient are commonplace (KUZEL & 
ROSEN 1994). The requirement for bulk quantities of functional recombinant antibodies has 
led to the exploration of many different expression systems.   
To date, bacteria (SKERRA, 1993) and mammalian cell cultures (BEBBINGTON et al., 
1992) are the most established systems for recombinant antibody production while expression 
in yeast and baculovirus-infected insect cell systems contribute in a minor way (TATICEK et 
al., 1994). Bacterial expression systems are limited when it comes to expression of eukaryotic 
proteins (OLINS and LEE, 1993). Bacteria are unable to carry out the co- and post-
translational modifications that eukaryotic proteins require for activity, they lack suitable 
processing pathways, which often leads to misfolded and inactive forms of proteins that are 
deposited in the form of inclusion bodies within the bacterial cell, making necessary their in 
vitro folding which can be labour and cost intensive. The mammalian cell culture system can 
efficiently process eukaryotic proteins but is very cost intensive as it uses expensive 
equipment and media for cultivation. The presence of oncogenic sequences or viral 
contaminants in the mammalian expression cells is another aspect that needs to be taken into 
consideration, particularly for in vivo therapeutic application of antibodies. 
Recently plants have emerged as an attractive alternative for antibody expression. Transgenic 
plants offer a practical approach for mass production of recombinant proteins and antibodies 
at low cost as they can be easily grown, stored and distributed (WHITELAM et al., 1994; 
HIATT and MOSTOV, 1992; FISCHER et al., 1999). Co-purification of blood borne 
pathogens and oncogenic sequences is also entirely avoided during downstream processing of 
plant-expressed recombinant proteins. 
Since the first report of antibody expression in transgenic plants (HIATT et al., 1989), many 
different antibodies have been produced successfully, including full-sized antibodies 
(DÜRING et al., 1990; VOSS et al., 1995; DeWILDE et al., 1996), Fab fragments (DeNEVE 
et al., 1993), scFv (ARTSAENKO et al., 1995; FIEDLER et al., 1997; FIREK et al., 1993; 
TAVLADORAKI et al., 1993), single-domain antibodies (BENVENUTO et al., 1991) and 
bispecific antibody fragments (FISCHER et al., 1999). rAbs have been shown to be 
efficiently folded and assembled within various cellular compartments of plant cells 
(DENECKE et al., 1992; HIATT, 1990; MA and HEIN, 1995). The plant-expressed antibody 
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retains the antigen binding properties of the antibodies produced by plasma or hybridoma 
cells (WHITELAM et al., 1994; HIATT, 1990; HIATT et al., 1989; DÜRING et al., 1990; 
VOSS et al., 1995).  
Agrobacterium mediated gene transfer (HOOYKAAS and SCHILPEROORT, 1992; 
ZAMBRYSKI, 1992; KONCZ and SCHELL, 1986), electroporation of protoplast (FROMM 
1985) and biolistic transformation (CHRISTOU 1993) are the most common methods for 
generation of transgenic plants expressing the rAb of interest. Stable transformation is both 
labour intensive and time consuming. It takes nearly 3 to 9 months to have plants available for 
testing the function and characteristics of the expressed protein.  
A practical variation of Agrobacterium mediated stable expression of the transgene is the 
transient expression system based on the principle of vacuum infiltration of Agrobacterium 
suspension in leaves (KAPILA et al., 1997). Transient gene expression systems offers several 
advantages over stable expression, for example initiation of gene expression, and synthesis of 
the protein can be analysed within a very short time and is not affected by position effects due 
to the large number of independent transformation events. Furthermore gene transfer can be 
assayed independently from regeneration of a transformed cell into a transgenic plant, which 
is especially advantageous for species that are recalcitrant for regeneration (KAPILA et al., 
1997). The Agrobacterium mediated transient gene expression system has additionally been 
shown to express and assemble multi-component protein complexes in amounts that allow 
their detailed analysis (FISCHER and EMANS, 2000; VAQUERO et al., 1999).  
I.11 Research objectives 
The phase I/II clinical trials in patients in an advanced stage of prostatic carcinoma with 
LHRH vaccine have marked immunoneutralisation of LHRH as a feasible therapy for 
treatment of prostate cancer (I.6.1). The two major limitations of the active vaccination 
approach have been the subject-to-subject variation in the attainment of effective antibody 
titers and the lag period required in the build up such a titer (TALWAR, 1997a; TALWAR, 
1997b). Humanisation of an anti-LHRH monoclonal antibody with the aim of using it for 
passive immunization for the treatment of sex-hormone dependent cancers had been 
proposed to circumvent the shortcomings inherent to the active immunization approach 
(TALWAR et al., 1997).   
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The aim of this study was the generation of recombinant anti-LHRH antibodies including an 
scFv, diabody and a mouse/human full sized chimeric antibody from an existing anti-LHRH 
mouse mAb P7278. The P7278 hybridoma cell line secreting the anti-LHRH mAb was 
developed by fusion of SP2/O-Ag 1.4 myeloma cells with splenocytes of mice immunised 
with LHRH conjugated to tetanus toxoid (GUPTA et al., 1985). The isotype of the antibody 
was determined to be IgG2a and kappa. The antibody was shown to be highly specific and 
totally devoid of reactivity with thyrotropin-releasing hormone (TRH) and thyroid-stimulating 
hormone. The association constant (Ka) of the mouse mAb P7278 to LHRH was calculated by 
Scatchard plot to be 2.54 x 109 litres/mole (TALWAR et al., 1985). The antibody was also 
shown to be bio-effective as it caused disruption of estrus cycle in dogs when 
administered passively. 
In this study, the variable region genes of the heavy and light chains of the mouse mAb P7278 
were to be cloned using reverse transcription and polymerase chain reaction. The variable 
antibody gene fragments were to be assembled as an scFv spaced by an 18 amino acid linker, 
expressed in bacteria and checked for binding to LHRH. After determination of antigen 
binding and confirmation of the sequence of the scFv, an anti-LHRH diabody was to be 
constructed by shortening the linker from 18 to eight amino acids.   The scFv and the diabody 
were to be expressed and purified from bacterial periplasmic space. Subsequently a 
mouse/human chimeric antibody was to be constructed by fusing the variable heavy and light 
chain genes to the human heavy and light chain constant region genes (IgGI and Kappa 
chain). The scFv, diabody and chimeric antibody were to be expressed transiently in tobacco 
leaves by agro-infiltration. The antibodies were to be purified by affinity chromatography and 
used for characterisation in vitro and in vivo.  
The in vitro characterisation of the antibodies was to include the basic protein analysis 
methods (SDS-PAGE, immunoblots, ELISA and gel filtration techniques), affinity 
determination of both the chimeric and mouse mAb P7278 and assessment of their stability in 
human serum in vitro by surface plasmon resonance based biosensor assay using the BIAcore. 
The in vivo assay was to demonstrate bioeffect of the immunoneutralisation of LHRH in a 
rodent model. Generation of transgenic tobacco plants expressing the antibodies was to follow 
the initial antibody characterisation.  
Other objectives included the detailed characterisation of the antibody-antigen interaction, i.e. 
the delineation of the residues in LHRH that constitutes the antibody-binding motif. This was 
proposed to be done by using two methodologies. Firstly by analysing binding interaction of 
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the mAb P7278 with LHRH variants and analogues differing in one or more amino acids from 
the native hormone. Secondly by characterisation of antibody binding peptides from a phage 
displayed random peptide library. The two methods were expected to collectively yield 
information about the importance in binding of the amino acid residues of LHRH to the mAb P7278. 
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Transient Expression
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Fig. I-7: Pictorial depiction of the research objectives undertaken in this thesis.
  
 
  
II Materials and Methods 
II.1 Materials 
II.1.1 Chemicals and consumables 
The chemicals used were purchased from the following companies: Bio-Rad (München), 
Boehringer (Mannheim), Fluka (Neu-Ulm), Gibco BRL (Eggenstein), Merck (Darmstadt), 
Pharmacia (Upsalla, Sweden), Roche (Mannheim), Roth (Karlsruhe), Serva (Heigelberg), 
Sigma (Deisenhofen). The consumables used were purchased from: Amicon (Witten), 
Biozym (Oldendorf), Eppendorf (Hamburg), Greiner (Solingen), Kodak (Stuttgart), Millipore 
(Eschborn), Nunc (Biebrich), Schott Glaswerke (Mainz), USB/Amersham (Braunschweig), 
Whatman (Bender & Hobeim, Bruchsal) and Zeiss (Oberkochen). 
II.1.2 Buffers, media and solutions  
All buffers, media and solutions were prepared according to standard protocols, as described 
in Sambrook et al. (1996). The non-standard solutions or buffers are listed at the end of the 
corresponding method description. Media for bacterial cultivation was sterilised by 
autoclaving (25 min/121°C/2 bar). Thermolabile components were filter sterilised by passing 
through a 0.2 µm filter and added to the autoclaved media or buffer after they were cooled 
down to 50°C.  
II.1.3 Matrices and membranes 
Prosep A matrix (BioProcessing, Consett, U.K.) was used for purification of anti-LHRH 
mouse mAb P7278 from hybridoma culture supernatant (II.2.1.2) and chimeric rAb P7278 from 
the plant extract of vacuum assisted agro-infiltrated tobacco leaves (II.2.5.3). Ni-NTA 
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agarose matrix (Bio- RAD) was used for purification of scFv and diabody fragments by 
immobilized metal ion affinity chromatography (IMAC) from upscaled bacterial cultures 
(II.2.4.3) and plant extract of vacuum assisted agro-infiltrated tobacco leaves (II.2.5.3). 
HybondTM-C nitrocellulose membrane (0.45 µm) from Amersham Life Science and Whatman 
3M paper from Whatman (Maidstone, England) was used for Western blot (II.2.3.2) and 
dot blot analysis (II.2.3.3).  
II.1.4 Enzymes and reaction kits 
DNA was digested with restriction enzymes obtained either from New England Biolabs 
(Schwalbach) or GibcoBRL. ExpandTM high fidelity Taq DNA polymerase from Boehringer 
Mannheim was used for SOE-PCR (II.2.2.8.4). Mouse heavy and light chain antibody 
fragments were amplified with Taq DNA polymerase from GibcoBRL (II.2.2.8.3). The same 
enzyme was also used for identification of recombinant DNA by PCR (II.2.2.8.2). 
The following kits were used: 
Kits Company 
Plasmid isolation kits (Mini, Midi)                      
QIAquick gel extraction kit 
QIAquick PCR purification kit 
BCA protein assay kit                                
Thermosequenase cycle sequencing kit 
Oligotex mRNA kit 
SuperscriptTM Preamplification System for  
First Strand cDNA Synthesis 
Qiagen, Hilden 
Qiagen 
Qiagen 
Pierce, Rockford, USA 
USB 
Qiagen 
GibcoBRL, Eggenstein 
II.1.5 Primary antibodies, secondary antibodies and substrates 
Mouse anti-c-myc tag monoclonal antibody (9E10) (Evan et al., 1985; ATCC clone number 
CRL-1729) was used for detection of bacterially expressed scFv P7278 and diabody P7278 in 
Western blot analysis (II.2.3.2) and ELISA (II.2.3.5). The plant expressed scFv and diabody 
fragments were detected with mouse anti-His6 antibody (Qiagen) and mouse anti-KDEL 
antibody (StressGen Biotechnologies Corp. Victoria, Canada). AP-conjugated Fc specific 
goat anti-mouse IgG (GAM-Fc) (Jackson ImmunoResearch, Dianova, Hamburg) was used as 
a secondary antibody for the detection of the mouse anti-KDEL antibody and mouse anti-His6 
antibody. In ELISA and Western blot analysis the mouse mAb P7278 was detected with AP-
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conjugated (GAM-Fc) and AP-conjugated heavy and light chain-specific goat anti-mouse IgG 
(GAM-H+L) (Jackson ImmunoResearch) respectively.  
Fc-specific goat anti-human IgG (GAH-Fc) and F(ab´)2-specific goat anti-human IgG (GAH-
F(ab´)2) (Jackson ImmunoResearch, Dianova, Hamburg) were coated on ELISA plate for 
capturing the plant expressed heavy and light chains of the chimeric rAb P7278 respectively. 
The captured chimeric heavy and light immunoglobulin chains were detected by AP-
conjugated GAH-Fc or GAH-F(ab´)2 antibodies (Jackson ImmunoResearch, Dianova, 
Hamburg) respectively. Mouse anti-KDEL antibody, AP-conjugated GAH-Fc and 
GAH F(ab´)2 were used for detection of the chimeric rAb P7278 in Western blot analysis. AP-
conjugated GAH-Fc and GAH-F(ab´)2 were also used for detection of chimeric rAb P7278 in 
plant extract in dot blot analysis (II.2.3.3). NBT/BCIP (Bio-Rad) and pNPP (Bio-Rad) were 
used as substrate for detection of protein in Western blot and ELISA respectively. 
The immunoblotted phages obtained from the peptide display library were detected with the 
anti-LHRH mouse mAb P7278 antibody. The Western blot was developed with horseradish 
peroxidase (HRP) conjugated goat-anti-mouse IgG antibody (Jackson ImmunoResearch) and 
chemiluminescent substrate (Pierce, München).   
II.1.6 Vectors 
II.1.6.1 Bacterial expression 
pHEN4II phagemid (ZHANG et al., 2001) containing SfiI-BstEII, AscI-NotI cloning sites was 
used for cloning the heavy and light variable domains of the antibody respectively spaced by 
the modified 218 poly-linker based on the 218-Whitlow linker (WHITLOW et al., 1993) for 
construction of the scFv. The pHEN4II is a derivative of the pHEN4C vector 
(HOOGENBOOM et al., 1991).  
For bacterial expression, the scFv and diabody fragments were cloned into the pSynI vector 
(AMERSDORFER et al., 1997). The pSynI vector contains a N-terminal pelB leader peptide 
that targets the expressed protein into the periplasmic space and a C-terminal His6 tag for 
purification via IMAC (Ni-NTA). 
II.1.6.2 Plant expression 
pGEM-3zf (Promega) was used as an intermediate vector for cloning the expression cassettes 
into the pSSH1 plant expression vector. The vector was used for cloning the 5´untranslated 
region (UTR) from the chalcone synthase (CHS) (VOSS et al., 1995) followed by the plant 
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codon-optimised leader peptide derived from the light chain (LPL) or the heavy chain (LPH) 
of the murine mAb24 (VOSS et al., 1995).  
Plant expression vector pSSH1 [10,3 kBp, AmpR CbR, KmR] (BECKER et al., 1992) was used 
for transformation of A. tumefaciens. pSSH1 plasmid is derived from the binary vector 
pPCV002 (KONCZ & SCHELL 1986). It contains the CaMV-35S expression cassette from 
pRT101 (TÖPFER et al., 1988) with a duplicated 35S enhancer region (KAY et al., 1987; 
BECKER 1990) and the CaMV termination sequence preceded by a polyadenylation site. The 
structure of the expression cassette was thus: enhanced CaMV promotor-CHS-signal peptide-
gene of interest-Pw-CaMV termination sequence.    
II.1.7 Biological material 
II.1.7.1 Bacterial strains  
All intermediate constructs generated during the cloning of the antibody fragments were 
transformed into E. coli strains DH5α and XL1-Blue. Soluble scFv and diabody fragments 
were expressed in HB2151 and TG1 strains of E. coli (II.2.4). ER2738 was used for phage 
display of the 12-mer peptide display library (II.2.9). Agrobacterium tumefaciens GV 3101 
was used for agrobacterium-mediated gene transfer into tobacco leaves (II.2.5). 
Table II-1: Names and genotypes of bacterial strains used throughout the work. 
Strain Source Genotype 
DH5α AUSUBEL et al., 
1994 
F- (Φ80d Lac 2∆M15) ∆(LacZYA-argF) U169end 
A1 rec1 hsdR17(rk-mk+)  deoR thi-1 supE44 gyrA96 
relA1λ- 
HB2151 AUSUBEL et al., 
1994 
K12, ara, ∆(lac-pro), thi/ F´ pro A+B+, lacIqz∆M15 
XL1-Blue Stratagene recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
[F′ proAB laclIq Z∆M15 Tn10 (Tetr)] 
TG1 Stratagene 
 
supE thi-1 ∆(lac-proAB) ∆(mcrB-hsdSM) 5(rK- mK-) 
[F´traD36 proAB lacIq Z∆M15] 
ER2738 NEB F´ lacIq ∆(lacZ) M15 proA+B+zzf::Tn10(TetR)/fhuA2 
supE thi ∆(lac-proAB) ∆(hsdMS-mcrB)5 (rk– mk – 
McrBC–) 
Agrobacterium 
tumefaciens GV 
3101 
KONCZ and 
SCHELL, 1986 
pMP90RK GmR, KmR, RifR  
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II.1.7.2 Hybridoma P7278   
The cells of the hybridoma P7278 (GUPTA et al., 1985) were used for isolation of total RNA 
(II.2.2.7.1) for amplification of the variable region genes of the mouse mAb P7278 (II.2.2.8.3). 
Supernatant of the growing hybridoma P7278 culture was used for purification of the mouse 
mAb P7278 via protein A affinity chromatography (II.2.1.2). 
II.1.7.3 Plants 
The leaves of N. tabacum L. cv. Petite Havana SR1 were used for Agrobacterium-mediated 
transient expression of LHRH specific recombinant antibodies (II.2.5) and generation of 
stable transformed plants (II.2.6). Additional plants used for small-scale transient expression 
study of anti-LHRH chimeric antibody were: spinach, lettuce, butterhead lettuce, spinach 
beat, green squash, pumpkin, blooming tobacco, aubergine, bittergourd, ladyfinger, beans, 
sunflower and sponge gourd.    
II.1.7.4 Animals 
6-8 weeks old, female outbred CD1/ Swiss mice and Wistar Rats were used for in vivo studies 
of the anti-LHRH chimeric and monoclonal antibodies respectively (II.2.8.2). Outbred CD1/ 
Swiss male mice were used for pharmacokinetic study of the mouse monoclonal anti-LHRH 
antibody (II.2.8.3).  
II.1.8 Oligonucleotides  
Oligonucleotides used for amplification and sequence analysis of the antibody fragments are 
listed below. All oligonucleotides were synthesised by MWG (Ebersberg, Geramany). 
II.1.8.1 Oligonucleotides used for synthesis of cDNA from mRNA 
COH 32 (CH1 IgG2a/2b) 5´ TAA CCC TWG ACC AGG CAT CC 3´   
Mu PD 31 (CL1 kappa) 5´ GCT GAT GCT GCA CCA ACT GTA TCC GTC GAC GCG GCC GCG ACT AGT 3´ 
II.1.8.2 Oligonucleotides complementary to FW4 of the mouse VL Ab domain  
Name Overhang region Sal and NotI sites  Binding region 
MPDVLB1 5´ CT AGT GGT ACT CCA C GC GGC CGC GTC GAC AGC MCG TTT CAG YTC CAR YTT 3´ 
MPDVLB2 5´ CT AGT GGT ACT CCA C GC GGC CGC GTC GAC AGC MCG TTT KAT YTC CAR YTT 3´ 
MPDVLB3 5´ CT AGT GGT ACT CCA C GC GGC CGC GTC GAC AGC MCG TTT BAK YTC TAT CTT TGT 3´ 
MPDVLB4 5´ CT AGT GGT ACT CCA C GC GGC CGC GTC GAC AGC MCG AGC MCG TTT TAT TTC CAA 
MKT 3´ 
FW: Framework; Degeneracy code: K= G or T; M = A or C; S = C or G; R = A or G; W = A or T 
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II.1.8.3 Oligonucleotides complementary to FW1 of the mouse VL Ab domain 
Name Overhang region AscI site Binding region 
MPDVLF1 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAC ATT GTG MTG WCH CAG TCC CCA 3´ 
MPDVLF2 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAC ATT CAG ATG ATT CAG TCT CC 3´ 
MPDVLF3 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAC ATT GTT CTC WHC CAG TCT CC 3´ 
MPDVLF4 5´CAT GCC ATG ACT CGC GGC GCG CCT GAC ATT GTG MTG WCH CAG TCT CAA 3´ 
MPDVLF5 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAT RTT KTG ATG ACC CAR RCK GCA 3´ 
MPDVLF6 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAT RTT KTG ATG ACC CAR RCK CCA 3´ 
MPDVLF7 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAC ATT GTG ATG ACC CAR BHT G 3´ 
MPDVLF8 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAT ATT KTG ATG ACC CAR AYT CC 3´ 
MPDVLF9 5´ CAT GCC ATG ACT CGC GGC GCG CCT RAM ATT GTG MTG ACC CAA TYT CCW 3´ 
MPDVLF10 5´ CAT GCC ATG ACT CGC GGC GCG CCT SAA AWT GTK CTS ACC CAG TCT CCA 3´ 
MPDVLF11 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAY ATY CAG ATG ACM CAG WCT AC 3´ 
MPDVLF12 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAY ATY CAG ATG ACH CAG WCT CC 3´ 
MPDVLF13 5´ CAT GCC ATG ACT CGC GGC GCG CCT GAC ATT GTG ATG ACT CAG GCT AC 3´ 
FW: Framework; Degeneracy code: K= G or T; M = A or C; S = C or G; R = A or G; W = A or T 
II.1.8.4 Oligonucleotides complementary to FW1 of the mouse VH Ab domain 
Name Overhang region SfiI and NcoI sites  Binding region 
MPDVHF1 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAK GTR CAG CTT CAG GAG 
TCR GGA 3´ 
MPDVHF2 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC CAG GTG MAG CTG AWG GAR 
TCT GG 3´ 
MPDVHF3 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAG GTC CAG CTR CAR CAR 
TCT GGA CC 3´ 
MPDVHF4 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC CAG GTW CAG CTS CAG CAG 
TCT G 3´ 
MPDVHF5 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC SAG GTC CAR CTG CAG SAR YCT 
G 3´ 
MPDVHF6 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAG GTT CAG CTG CAG SAR 
YCT GGR 3´ 
MPDVHF7 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAR GTG AAG CTG GTG GAR 
TCT GGR 3´ 
MPDVHF8 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAG GTG AAG STY MTC GAG 
TCT GGA 3´ 
MPDVHF9 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAR GTG AAG CTK GAK GAG 
WCT GR 3´ 
MPDVHF10 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAV GTG MWG CTK GTG GAG 
TCT GGK 3´ 
MPDVHF11 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAG GTG CAR CTK GTT GAG 
TCT GGK 3´ 
MPDVHF12 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC SAG GTY CAG CTK CAG CAG 
TCT GGA 3´ 
MPDVHF13 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC CAG ATC CAG TTG GTG CAG 
TCT GGA 3´ 
MPDVHF14 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC CAG GTS CAC STG RWG SAG 
TCT GGG 3´ 
MPDVHF15 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC CAG GTT ACT CTR AAA GWG 
TST GGC C 3´ 
MPDVHF16 5´ C ATG CCA TGA CTC GC G GCC CAG CCG GCC ATG GCC GAT GTG AAC TTG GAA GTG 
TCT GG 3´ 
FW: Framework; Degeneracy code: K= G or T; M = A or C; S = C or G; R = A or G; W = A or T 
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II.1.8.5 Oligonucleotides complementary to FW4 of the mouse VH Ab domain 
Name Overhang region BstEII site  Binding region 
MPDVHB1 5´ CTA GTG GTA CTC CAC GGC GCG CCT MRG AGA CDG TGA SMG TRG TC 3´ 
MPDVHB2 5´ CTA GTG GTA CTC CAC GGC GCG CCT MRG AGA CDG TGA SRG TRG TG 3´ 
MPDVHB3 5´ CTA GTG GTA CTC CAC GGC GCG CCT MRG AGA CDG TGA SCA GRG TC 3´ 
MPDVHB4 5´ CTA GTG GTA CTC CAC GGC GCG CCT MRG AGA CDG TGA STG AGG TT 3´ 
MPDVHB5 5´ CTA GTG GTA CTC CAC GGC GCG CCT MRG AGA CDG TGA STG ARA TT 3´ 
FW: Framework; Degeneracy code: K= G or T; M = A or C; S = C or G; R = A or G; W = A or T 
  
II.1.8.6 Oligonucleotides used for sequencing DNA  
pHEN forwVH 5´ 
pHEN backwVL 3´ 
Universe 
Reverse 
pSS 5´ 
pSS 3´ 
-96 gIII 
5´-GCC GCT GGA TTG TTA TTA CTC GC-3´  
5´-TTT CAA CAG TCT ATG CGG CCC C-3´  
5´-GTT GTA AAA CGA CGG CCA GT-3´  
5´-ACA CAG GAA ACA GCT ATG AC-3´ 
5´-ATC CTT CGC AAG ACC CTT CCT CT-3´  
5´-AGA GAG AGA TAG ATT TGT AGA GA-3´  
5´- CCC TCA TAG TTA GCG TAA CG-3´ 
 
II.1.8.7 Oligonucleotides used for construction of the chimeric rAb P7278 
Amplification of the VH antibody fragment of mouse mAb P7278 
Universe 
SOE Vh back 
5´- GTT GTA AAA CGA CGG CCA GT-3´ 
5´- GTG GAG GCT GAG GAG ACG GTG ACC GTG GT-3´ 
Amplification of the VL antibody fragment of mouse mAb P7278 
VL Nco1 forw 
SOE Vl back 
5´- AGG AAT TCC ATG GAT GTT TTG ATG ACC CA-3´ 
5´- GAC AGA TGG TGC AGC CAC AGT ACG TTT GAT CTC CAA-3´ 
Amplification of the constant region of human IgG1 
SOE huIgG1 constant 
CH SalI Back 
5´- ACC GTC TCC TCA GCC TCC ACT AAG GGC CCA TCG-3´ 
5´- ACG CGT CGA CTT TAC CCG GAG ACA GGG AGA G-3´ 
Amplification of the constant region of human Kappa light chain 
SOE huKappa constant 
CL SalI Back 
5´- ACT GTG GCT GCA CCA TCT GTC-3´ 
5´- CAT GCC ATG GGA AAA TGC AGC TGG GTT ATC TTC-3´ 
II.1.8.8 Oligonucleotide used for the construction of the diabody 
RN8 5´- GGC ACC TCA GGC GGC GCG CCA–3´ 
  
 
II Materials and Methods 29
II.1.8.9 Oligonucleotides for PCR based analysis of recombinant 
bacterial clones  
pSSH1 
forward pSS 5′ 
reverse pSS 3′ 
5´- GAC CCT TCC TCT ATA TAA GG-3´  
5´- CAC ACA TTA TTC TGG AGA AA-3´  
pHEN4II and pGEM-3zf 
universe 
reverse 
5´- GTT GTA AAA CGA CGG CCA GT-3´  
5´- ACA CAG GAA ACA GCT ATG AC-3´  
II.1.9 BIAcore reagents 
Sensor chip CM5, surfactant P20, 2-(2-pyridinyldithio) ethanolamine hydrochloride (PDEA), 
amine-coupling kit containing N-hydroxysuccinimide (NHS), N-ethyl-N´ - (3-
diethylaminopropyl) carbodiimide (EDC), and ethanolamine hydroxychloride were obtained 
from Pharmacia Biosensor AB. For all experiments degassed HBS buffer was used.  
II.1.10 Equipment 
BIAcore 2000 (BioSensor, Uppsala, Sweden). 
Cameras: MP4 (Polaroid, Cambridge, MA, USA). E.A.S.Y 429K camera 
(Herolab, Wiesloch). 
Centrifuges: AvantiTM 30 and AvantiTMJ-25 (Beckman, California, USA), Biofuge A 
(Heraeus, Hanau), Sigma 3-10 and Sigma 4-10 (Sigma, St. Louis, Missouri, USA), RC5C and 
RC5B plus  (Sorval instruments, Du Pont, Bad Homburg). Rotors: F0650, F2402H, JLA 
10.500 and JA 25.50 (Beckman), #1140 and #11222 (Sigma), RLA-300, SS-34 and 
GS-3 (DuPont). 
Chromatography equipment: ÄKTA explorer 10xT (Amersham Pharmacia Biotech), Gel 
filtration XK26 column 26 mm inside diameter, 20 cm length (Amersham Pharmacia 
Biotech), 150 ml super-loop (Pharmacia) and UNICORN control, evaluation and 
documentation software (Amersham Pharmacia Biotech). 
DNA gel electrophoresis apparatus: wide mini and mini cells for DNA agarose 
electrophoresis and the power suppliers (Bio-Rad). 
DNA-sequencing: LI-COR IR2-4200 Sequencer (LI-COR MWG-Biotech) and Base 
ImageIRTM 4.0 software (LI-COR). 
  
 
II Materials and Methods 30
Electroporation apparatus: “Gene pulserTM”,  “Pulse controller” unit, Extender unit 
(BioRad) and 0.2 cm or 0.4 cm cuvettes (Bio-Rad). 
InnovaTM 4340 incubator shaker (New Brunswick Scientific, Nürtingen). 
PCR Thermocyclers: Primus and Primus 96 plus (MWG-Biotech). 
Photometers: Spectrophotometer Uvikon 930 (Kontron, Neufahrn) and multi-channel 
spectrophotometer Spectromax 340 (Molecular Devices, Sunnyvale, California, USA).  
Protein gel electrophoresis equipment: Mini PROTEAN IITM from BioRad.  
Softwares: Windows NT 4.0 operating system (Microsoft); Microsoft Office 2000 
(Microsoft); Adobe Photoshop 6.0 (Adobe); Chromas; Origin 6.0 (Data analysis and technical 
graphics, Micrococal software, Inc.); DNAsis. 
UV-Transilluminators: wavelength 302 nm and UVT-20M (Herolab). UV-
chamber (BioRad). 
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II.2 Methods 
All experiments related to genetic engineering were performed according to the regulations of 
“S1-Richtlinien” and were officially approved by the “Regierungspräsidium des Landes 
NRW” (RP-Nr.: 23.203.2 AC 12, 21/95) and “BGA” [AZ 521-K-1-8/98:AI3-04/1/0866/88 
(S1) and 55.8867/-4/93 (greenhouse)]. 
II.2.1 Hybridoma culture and purification of mouse mAb P7278 
II.2.1.1 Subcloning of the hybridoma P7278 by limiting dilution 
The hybridoma P7278 (II.1.7.2) was grown in RPMI medium supplemented with 10% (v/v) 
fetal calf serum (FCS) at 37°C in a humidified 5% CO2 incubator. Subcloning of hybridoma 
P7278 was performed by limiting dilution. The hybridoma cells were diluted at a ratio of 
100 cells/ 10 ml medium and 100 µl per well of the diluted cell suspension was aliquoted in a 
96 well tissue culture plate. Wells with single colonies were identified and the secretion of 
mouse mAb P7278 was confirmed by direct LHRH ELISA (II.2.3.5).  
II.2.1.2 Purification of mouse mAb P7278 from the hybridoma supernatant 
The hybridoma P7278 was grown in 500 ml tissue culture flasks. The culture supernatant was 
harvested when the medium became acidic. The culture supernatant was collected over a 
period of 2 weeks. The storage bottle for collection of the cell supernatant was always 
handled in sterile conditions to avoid any contamination. 
The mouse mAb P7278 was purified from the hybridoma supernatant via Protein A 
chromatography. 1.6 ml of Protein A matrix was packed in a column and equilibrated with 
5 column volumes (CV) of PBS (pH 7.4). The hybridoma supernatant was centrifuged 
(10000 rpm/10 min/4°C) and filtered through Whatman 3M paper before applying it onto the 
column. The supernatant was passed through the column at a flow rate of 5 ml/min. Non-
specifically bound proteins were washed away with PBS containing 100 mM NaCl (pH 7.4) 
till the online UV detector showed zero absorbance at 280nm. The bound antibody was eluted 
from the column with 4 ml of elution buffer (100 mM glycine, pH 3) under gravity flow. The 
pH of the eluate was immediately equilibrated to pH 7 by adding unbuffered 1 M Tris pH 11.  
0.01% (w/v) of sodium azide and 10% glycerol (v/v) were added to the eluate. The eluate was 
aliquoted and frozen at –20°C. The Protein A matrix was regenerated by washing the column 
with 2 column volumes of 1.5 M HCl and stored in 20% (v/v) ethanol at 4°C. 1-10 microlitres 
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of the eluate were used for ELISA (II.2.3.5), Western blot (II.2.3.2) and SDS-PAGE analysis 
(II.2.3.1). 
II.2.2 Recombinant DNA techniques 
General recombinant DNA techniques including DNA precipitation, restriction enzyme 
digestion, DNA ligation, and DNA agarose gel electrophoresis were performed according to 
the standard protocols described by Sambrook et al., (1989) or according to the manufacturers 
protocol when using a kit. 
II.2.2.1 Isolation of plasmid DNA from E. coli  
Plasmid DNA was purified using Qiagen plasmid DNA mini prep and midi prep kits 
according to the manufacturers instructions. Quality and quantity of plasmid DNA was 
confirmed by spectrophotometric analysis (II.2.2.4) and analytical agarose gel electrophoresis 
(II.2.2.2). Isolated plasmid samples were stored at –20°C. 
II.2.2.2 Analytical agarose gel electrophoresis 
Undigested plasmid DNA (II.2.2.1), restriction enzyme digested plasmid DNA and PCR 
fragments (II.2.2.8) were electrophoretically separated on 0.8-1.2% agarose gels prepared in 
TBE buffer containing 0.1 µg/ml ethidium bromide.  
Known amounts of DNA molecular marker such as 1 kb ladder, 100 bp ladder, and PstI 
digested lambda DNA was used for evaluation of sample size, integrity and determination of 
DNA concentration. The DNA was visualised on a UV transilluminator at 302 nm and 
documented by a black and white E.A.S.Y 429K camera (Herolab). 
II.2.2.3 Preparative gel electrophoresis 
Preparative gel electrophoresis was used for the isolation of PCR amplified DNA (II.2.2.8) or 
DNA fragments after digestion with restriction enzymes prior to cloning in the appropriate 
vectors. After electrophoresis the desired DNA fragment was excised from the gel on an UV 
transilluminator. “QIAquick gel extraction kit” (Qiagen) was used to extract DNA from the 
agarose gel according to the manufacturers’ instructions. The concentration of the recovered 
DNA was measured spectrophotometerically (II.2.2.4) or determined by agarose gel 
electrophoresis (II.2.2.2).  
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II.2.2.4 Quantification of nucleic acids 
The amount of RNA or DNA in a sample was estimated by measuring the OD260nm. The 
OD260nm of one corresponds to ~50 µg/ml of double stranded DNA, ~40 µg/ml of single 
stranded DNA and RNA and ~20 µg/ml of single stranded oligonucleotides. Purity of the 
nucleic acid was ascertained by the OD260/OD280 ratio of the measured optical density, which 
is 1.8 for pure DNA and 2.0 for pure RNA. 
II.2.2.5 Growth and maintenance of bacterial strains  
E. coli bacterial cells were grown at 37°C o/n either in liquid LB medium in a shaker 
incubator or plated on solidified LB-agar (1.5% agar w/v) plates. The LB medium was 
supplemented with appropriate antibiotics and 2% (w/v) glucose for the growth of 
recombinant bacteria. The plates were stored at 4°C for not more than 2 weeks. For long-term 
storage of the bacterial strains, glycerol was added to a final concentration of 20% (v/v) to the liquid 
culture, and frozen at –80°C. 
Agrobacterium tumefaciens cells were cultivated in YEB Rif-Km medium at 28°C with 
vigorous shaking at 250 rpm. Glycerol stocks were made for long-term storage. The cells 
were resuspended in 1:1 volume of YEB Rif-Km medium and glycerol stock media (GSM). 
The suspension was aliquoted (100 µl) and stored at –80°C for future experiments. 
YEB Rif-Km media: nutrient broth 0.5% (w/v); yeast extract 0.1% (w/v); tryptone 0.1% 
(w/v); sucrose 0.1% (w/v); 2 mM MgSO4, 50 µg/ml rifampicin, 25 µg/ml kanamycin were 
added to the media after autoclaving and cooling below 50°C. 
Glycerol stock media (GSM): glycerol 50% (w/v); MgSO4 100 mM; Tris, pH 7.4 25 mM. 
II.2.2.6 Bacterial transformation 
II.2.2.6.1 Preparation of competent E. coli cells for heat-shock transformation 
E. coli competent cells were prepared for CaCl2-mediated heat-shock transformation as 
described by Hanahan (1985). A single bacterial colony was inoculated in 5 ml of LB broth 
and cultured at 37°C o/n. 0.5 ml of the o/n culture was transferred into 50 ml of LB broth 
containing 20 mM MgSO4 and 10 mM KCl. The cells were cultured at 37°C for 3-4 h until 
the OD600nm reached 0.4-0.5 and then transferred to an ice-cold tube. After cooling on ice for 
10 min, the cells were recovered by centrifugation (2,000 g/4°C/10 min). The pellet was 
resuspended in 15 ml ice-cold TfB-I solution by gentle vortexing and stored on ice for 
10 min. The cells were sedimented down by centrifugation as described above and 
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resuspended in 2 ml ice-cold TfB-II. 200 µl-aliquots of the suspension were dispensed into 
prechilled Eppendorf tubes, frozen immediately in liquid nitrogen and stored at -80°C. 
TfB-I (pH 5.8): potassium acetate 30 mM; MnCl2 50 mM; CaCl2 10 mM; glycerol 15% (v/v). 
TfB-II (pH 5.8): MOPS 30 mM; CaCl2 75 mM; RbCl 10 mM; glycerol l5% (v/v) 
II.2.2.6.2 Transformation of E. coli by heat-shock 
The competent cells (II.2.2.6.1) were thawed on ice; plasmid DNA (~ 100 ng) or ligation 
products (SAMBROOK et al., 1989) were mixed gently with the competent cells then placed 
on ice for 30 min. The cells were placed at 42°C for 90 seconds then cooled on ice for 
two min. 800 µl of LB medium was added to the tubes and transformed cells were incubated 
at 37°C for 45 min. 200 µl of cells were plated onto a LB-agar plate supplemented with 
appropriate antibiotics and incubated at 37°C overnight. 
II.2.2.6.3 Preparation of electrocompetent E. coli cells  
Electrocompetent E. coli cells were prepared for DNA transformation as described by Dower 
et al., (1988). A single colony was cultured in LB-broth at 37°C until the mid-log phase 
(OD600nm = 0.5-0.8). The cells were placed on ice for 30 minutes prior to centrifugation 
(3,000g/4°C/10 min). The harvested cells were subsequently washed thrice with sterile water 
and resuspended in ice-cold 10% (v/v) glycerol resulting in a 300-fold concentration of the 
original culture volume (at >1010 cells/ml). 40 µl aliquots were frozen in liquid nitrogen and 
stored at -80°C. 
II.2.2.6.4 Transformation of E. coli by electroporation 
Aliquoted electrocompetent cells (II.2.2.6.3) were thawed on ice and the cells were mixed 
with 1 pg to 300ng of DNA in sterile dH2O. The cell and DNA mixture was transferred into a 
pre-chilled electroporation cuvette (0.2 cm) (BioRad) and assembled into the safety chamber 
of the electroporation appratus. After application of the pulse (25 µF, 2.5 kV, 200 Ω), the 
cells were diluted in 800µl of SOC medium and incubated at 37°C with shaking for 45 min. 
200 µl of the cells were plated onto LB-agar containing appropriate antibiotics and in-
cubated at 37°C o/n. 
II.2.2.6.5 Preparation of electrocompetent Agrobacterium cells  
A single colony of A. tumefaciens GV3031 grown on a YEB-agar plate containing 100µg/ml 
rifampicin (rif) and 25 µg/ml kanamycin (kan) (YEB-Rif-Kan) was inoculated in 5 ml of 
YEB-Rif/Kan medium in a 100 ml Erlenmeyer flask and incubated at 28°C for 36-48 hrs with 
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shaking (250 rpm). 1 ml of the culture was used for inoculation of 100 ml of YEB-Rif-Kan 
medium and cultivated at 28°C for 15-20 h with shaking (250 rpm) or until the OD660 nm 
reached 1-1.5. The cells were chilled on ice for 15 min and peletted by centrifugation 
(4,000 g/4°C/5 min). The culture medium was decanted and the cells were washed three times 
with 10 ml of dH2O and finally resuspended in 500 µl of sterile 10% (v/v) glycerol. 45 µl-
aliquots of the suspension were dispensed into prechilled Eppendorf tubes, frozen 
immediately in liquid nitrogen and stored at -80°C. 
II.2.2.6.6 Transformation of Agrobacterium by electroporation 
0.2-1.0 µg of plasmid DNA (II.2.2.1) in sterile dH2O was added to a thawed aliquot of A. 
tumefaciens electrocompetent cells (II.2.2.6.5) and incubated on ice for 3 min. The mixture 
was transferred into a prechilled electroporation cuvette (0.2 cm) and assembled into a safety 
chamber. After application of the pulse (25 µF, 2.5 kV, 200 Ω), the cells were diluted in 1 ml 
of SOC medium and incubated at 28°C with shaking (250 rpm) for 1 h. Finally, 1-10 µl of the 
cells were plated on YEB-agar containing 100 µg/ml rifampicin (rif), 25 µg/ml kanamycin 
(Kan) and 100 µg/ml carbenicillin (carb) (YEB-Rif-Kan-Carb) and incubated at 28°C 
for 2-3 days.  
II.2.2.6.7 Determination of transformation efficiency of competent cells 
Efficiency of tranformation of each new batch of competent cells was determined by test 
transformation with known concentration of supercoiled plasmid pUC18 for E.coli and pSSH1 
for A. tumefaciens cells. The following transformation rates were obtained: Heat shock 
competent E. coli >107/µg pUC18; Electrocompetent E. coli >108/µg pUC18; 
Electrocompetent A. tumefaciens >103/µg pSSH1. 
II.2.2.7 RNA Isolation and synthesis of first strand cDNA 
II.2.2.7.1 Total RNA extraction and mRNA preparation  
Trizol reagent (Invitrogen) was used for extraction of total RNA according to the 
manufacturers protocol. Briefly, 5-10⋅106 cells of P7278 hybridoma were lysed by 
resuspension in 1 ml of Trizol reagent followed by incubation of these homogenized cells at 
15-20˚C for 5 min. 0.2 ml of chloroform (Merck) was added per ml of Trizol used, followed 
by 15 seconds of vigorous shaking by hand and subsequent incubation for 2-3 min at 15-20˚C. 
The samples were centrifuged for 15 min at 12,000 g at 2-8˚C. The colourless aqueous phase 
containing the RNA was transferred to fresh tube and RNA precipitated by incubation with 
0.5 ml of Isopropanol (Gibco BRL) per ml of Trizol followed by incubation at 15-20˚C for 
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10 min and centrifugation (12,000 g/10 min/ 2-3˚C). The RNA pellet was washed once with 
75% Ethanol (Merck). The pellet was air dried for 5-10 min and redissolved in RNase free 
water (50-100 µl) followed by heating at 55-60˚C for 10 min. The purity and the amount of 
total RNA were estimated by spectrophotometric analysis at 280 nm and 260 nm (II.2.2.4). 
OligotexTM mRNA kit (Qiagen) was used for isolation of mRNA from the total RNA. Total 
RNA was passed through a column of oligo-dTs bound to latex particles that allow specific 
hybridisation of the poly A- tailed mRNA to the column. The procedure followed is described 
briefly. Total RNA was mixed with 250 µl of the provided 2X-binding buffer, 15µl of 
Oligotex suspension and the volume made to 515 µl with Diethyl pyrocarbonate (DEPC) 
treated water. The mix was heated at 65˚C for 3 min, and then kept at 23-25˚C for 10 min 
followed by centrifugation (14,000 g/2 min). The pellet was resupended in 400 µl of the 
provided wash buffer and applied to the column provided, followed by centrifugation as 
before. The wash step was repeated and mRNA eluted with 50 µl of preheated (70˚C) 
elution buffer. 
II.2.2.7.2 cDNA synthesis 
First-strand cDNA was synthesized using the “SuperScript preamplification system” kit. 
Separate reactions for cDNA synthesis of the heavy and the light chain were carried out. 
100 ng of mRNA (II.2.2.7.1) was used for each reaction. The cDNA primers, COH32 and 
MuPD31 (II.1.8.1) that specifically anneal to the CH1 region of the IgG2a/2b and CL1 region 
of kappa light chain respectively were used for cDNA synthesis. The primers were added at a 
concentration of 30 pmol per reaction. The reaction was performed at 42°C for 30 min. The 
heavy and light antibody variable domains were amplified by PCR from the synthesised 
cDNA (II.2.2.8.3). 
II.2.2.8 PCR amplification 
II.2.2.8.1 PCR amplification of DNA fragments 
Polymerase chain reaction (PCR), a procedure for rapid in-vitro enzymatic amplification of a 
specific segment of DNA, was used for the amplification of the genes of interest (SAIKI 
et al., 1988). The reactions were performed in 0.2 ml PCR reaction tubes (Biozym Diagnostik 
GmbH, Oldendorf), using a DNA thermal cycler (MWG Biotech). PCR reactions were carried 
out in a total volume of 50 µl as described in the following table. 
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Components Volume Final Conct. 
10x PCR buffer 5 µl 1x 
50 mM MgCl2 1.5 µl 1.5 mM 
10 mM dNTP mixture 1 µl 0.2 mM each 
10 pmol forward Primer  0.5-1 µl 5-10 pmol  
10 pmol backward primer  0.5-1 µl 5-10 pmol  
template DNA 0.5-5 µl 10-100 ng 
Taq DNA polymerase (5U/µl) 0.25 µl 1.25 units 
distilled H2O  added to 50 µl  
Amplification was carried out under the following conditions: 
                        94°C            5 min                  initial denaturation  
                        94°C  30 sec                 denaturation 
  35x         Tp               30 sec                 primer annealing 
                        72°C             45 sec                 primer extension 
                        72°C             7 min                  final extension 
The optimal annealing temperature (Tp) of the primers was experimentally optimised or 
calculated by the empirical formula (WU et al., 1991):  
( ) ( )[ ]{ }TACGX246.122Tp ++++=  
PCR products were resolved on a 1-1.2% (w/v) agarose gel (II.2.2.2) with appropriate DNA 
markers to confirm the amplification and integrity of the amplified product.  
II.2.2.8.2 PCR based analysis of recombinant bacterial clones 
Bacterial clones harbouring plasmids containing the gene of interest were identified by PCR 
as described by Jesnowski et al. (1995). Single colonies were picked with sterile toothpicks. 
The bacteria laden toothpick was first used for inoculating a ”master plate” and then dipped in 
a PCR tube containing 10 µl of sterile water. 15 µl of the PCR mix (II.2.2.8.1) was added to 
the 10 µl bacterial suspension to give a final reaction volume of 25 µl. Specific primers 
annealing to the 5´ and 3´ ends of the cloned gene or primers specific for the vector backbone 
were used for PCR amplification reaction (II.1.8.9).  The reaction conditions for the PCR 
were the same as II.2.2.8.1 except that the time for initial denaturation of DNA was increased 
to 10 minutes. 10 µl of the PCR product was analysed on a 1.2% (w/v) agarose gel (II.2.2.2).  
II.2.2.8.3 PCR amplification of variable domains of mouse mAb P7278 
The light chain variable domain was amplified with a set of 13 different forward primers 
(MPDVLF1-13; II.1.8.3) and a mixture of 4 back primers (MPDVLB1-4; II.1.8.2). For the 
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amplification of the heavy chain variable region a repertoire of 16 forward primers 
(MPDVHF1-16; II.1.8.4) were used with a mixture of 5 different backward primers 
(MPDVHB1-5; II.1.8.5). PCR reactions were carried out in a total volume of 50 µl to which 
10 pmol of each primer and one-fifth of the first strand cDNA reaction product  (II.2.2.7.2) 
was added. Reaction conditions: an initial denaturation for 5 min at 94°C followed by 30 
cycles at 94°C for 1 min, 55°C for VL/53°C for VH for 1 min, 72°C for 2 min and a final extension 
at 72°C for 10 min. 10 µl of the PCR product was analysed on a 1.2% (w/v) agarose gel (II.2.2.2). 
II.2.2.8.4 Splice overlap extension PCR  
Splice overlap extension (SOE) PCR is a modified PCR method in which the primers are 
designed in a way that the coding region of the 3´ end of one primer is complementary to the 
5´ region of the next primer (HORTON et al., 1989).  
The chimeric heavy and light antibody chain fragments were constructed by SOE PCR. The 
variable light (VL) and heavy (VH) regions of mouse mAb P7278 and the human IgG1 and 
kappa constant regions were amplified as four separate reactions with specific primers 
(II.1.8.7) using 0.2 units Expand™ high fidelity Taq DNA polymerase under the following 
conditions: an initial denaturation for 5 min at 94°C followed by 30 cycles at 94°C for 1 min, 
55°C for constant region/53°C for variable regions for 1 min, 72°C for 2 min and a “fill in” at 
72°C for 10 min. 
SOE PCR was carried out with equimolar amounts of the two overlapping PCR fragments, VH 
with human IgG1 constant region and VL with human kappa constant region under the 
following conditions: 5 cycles at 94°C for 5 min, 37°C for 1 min and at 72°C for 2 min. 10µl 
of the SOE-PCR product was used for amplification of the spliced fragment using the end 
primers of the joined chains. The PCR conditions used were: an initial denaturation for 5 min 
at 94°C followed by 30 cycles at 94°C for 1 min, 52°C for 1 min, 72°C for 2 min and a 
extension step of 72°C for 10 min. The product of the SOE PCR was analysed on a 1.2% 
(w/v) agarose gel (II.2.2.2). 
II.2.2.9 DNA sequencing and sequence analysis 
DNA sequencing reactions were based on the dideoxy chain termination method described by 
Sanger et al. (1977). Fluoresceins labelled oligonucleotides (II.1.8.6) were used for 
sequencing of the genes of interest using the “Thermosequenase fluorescence labelled cycle 
sequencing kit” and a LICOR 4200 IR2 automated DNA sequencer (MWG-Biotech). The 
  
 
II Materials and Methods 39
sequencing reaction mix was resolved on a denaturing (6 M urea) polyacrylamide gel 
(4.6 - 6.0%, w/v).  
Chromas software package was used for displaying the chromatogram files from the LI-COR 
automated DNA sequencer. The sequences were exported to the DNAsis and GCG software 
packages for evaluation of sequencing data. After the consensus sequence was derived the 
antibody variable domains of the mAb P7278 were further analysed by the various antibody 
analysis tools available on the World Wide Web (III.3.1.3). 
II.2.2.10 Construction of anti-LHRH antibody fragments 
II.2.2.10.1 Construction of scFv P7278 
The antibody variable domains of mouse mAb P7278 were amplified (II.2.2.8.3) with specific 
primers listed in section II.1.8. VH and VL chain antibody fragments were gel purified using 
“QIAquick gel extraction kit” (Qiagen) (II.2.2.3) and digested with SfiI and BstEII, or AscI 
and NotI enzymes, respectively. pHEN4II phagemid DNA was digested with SfiI and BstEII 
or AscI and NotI and gel purified. 200 ng of purified vector was ligated with a five fold molar 
excess of purified fragments. Ligation products were electroporated into competent E. coli 
DH5α cells to create the sublibraries. The scFv mini library was constructed by excising the 
VL antibody fragments with AscI and NotI enzymes and ligating them into the linearised 
pHEN4II vector containing VH antibody fragments.  
II.2.2.10.2 Construction of diabody P7278 
The scFv P7278 cloned into pHEN4II (II.2.2.10.1) was reamplified with M13 universe primer 
(II.1.8.9) that binds to the vector backbone near the 5´end of the single chain fragment and the 
RN8 primer (II.1.8.8) complementary to the first first eight amino acid residues of the 
Whitlow 218 linker. The reamplified VH fragment was digested with SfiI and AscI enzymes 
and ligated with similarly digested pHEN4II vector containing the scFv P7278 resulting in the 
VH and the VL fragments spaced by a shortened linker constituted of eight amino 
acids residues.  
II.2.2.10.3 Construction of chimeric rAb P7278 
The VH and the VL antibody fragments of scFv P7278 and the human IgG1 and kappa constant 
domains from the plasmids chiB72.3L and chiB72.3H (PRIMUS et al., 1990) were amplified 
by PCR with specific primers (II.1.8.7). The amplified fragments were spliced together by 
SOE-PCR (II.2.2.8.4). The chimeric light and heavy antibody fragments were digested with 
NcoI and SalI restriction enzymes and cloned into pGEM-3zf vector (II.1.6.2). After 
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confirmation of the sequence the antibody fragments were excised from the pGEM-3zf with 
EcoR1 and SalI enzymes and cloned into similarly digested plant expression vector pSSH1 
(II.1.6.2). 
II.2.3 Methods for protein analysis 
II.2.3.1 SDS-PAGE and Coomassie brilliant blue staining 
Discontinuous SDS-polyacrylamide gel electrophoreis (for the stacking gel: T = 4%, C = 
2.6%, pH 6.8; for the separating gel: T = 12%, C = 2.6%, pH 8.8) (AUSUBEL et al., 1994) 
was used for the separation of protein samples. The protein samples to be analysed were 
denatured by boiling in 1X SDS sample buffer for 5 minutes. The proteins were separated by 
electrophoresis by applying 20V/cm for 1 h. Separated proteins were revealed by staining the 
gel with Coomassie brilliant blue or transferred onto nitrocellulose membrane for Western 
blot analysis (II.2.3.2). 
10x SDS-PAGE sample buffer: Tris-HCl 35 mM; DTT 600 mM; SDS 10.3% (w/v) 
bromophenolblue 0.05% (v/v); glycerol 36% (v/v).          
Coomassie staining solution: coomassie brillant blue G-250 0.25% (w/v); methanol 50% 
(v/v); glacial acetic acid 9% (v/v). 
Coomassie destaining solution: methanol 10% (v/v); glacial acetic acid 10% (v/v).                                    
II.2.3.2 Western blot analysis 
Electrophoretically separated proteins (II.2.3.1) were transferred from a SDS-PAA (II.2.3.1) 
gel to a HybondTM-C nitrocellulose membrane (0.45 µm) at 50 Amperes and 4°C for 1 h 
according to manufacturers protocol. The membranes were blocked with PBS buffer 
containing 4% (w/v) skimmed milk (MPBS) and blotted proteins probed with a primary 
antibody that reacted specifically with antigenic epitopes displayed by the target protein 
attached to the membrane. The bound antibody was detected by alkaline phosphatase (AP) 
labelled secondary polyclonal antibodies. Both primary and secondary antibodies were diluted 
in PBS-Tween (0.05%. v/v). Between each step the blot was washed three times for 5 min 
each in PBS-Tween (0.05%, v/v). The blot was incubated with each antibody for 1 h on a 
shaker at room temperature or at 4°C o/n. The target protein was finally revealed by 
colorimetric reaction of AP with the substrate NBT/BCIP (BioRad). 
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PBS buffer (pH 7.4): NaCl 137 mM; KCl 2.7 mM; Na2HPO4.2H2O 8.1 mM; KH2PO4 
1.5 mM. 
II.2.3.3 Dot blot analysis  
The transgenic plants were screened for identification of the best expressing lines by spotting 
10 µl of leaf extract diluted 1:10 in PBS on dry HybondTM-C nitrocellulose membrane 
(0.45 µm) with a pipette. After the spotted protein dots had dried the membrane was blocked 
in 4% (w/v) skimmed milk (MPBS). The heavy and the light chain of the chimeric rAb P7278 
were detected with the AP conjugated GAH-Fc and GAH-F(ab´)2 antibodies respectively 
(II.1.5). The target protein was revealed by colorimetric reaction of bound AP by addition of 
NBT/BCIP substrate (BioRad).  
II.2.3.4 Protein quantification 
BCA protein assay was used for determination of protein concentrations. This is a detergent-
compatible formulation based on bicinchoninic acid (BCA) for the colorimetric detection and 
quantification of total proteins (SMITH et al., 1985). This method combines reduction of Cu+2 
to Cu+1 by protein in an alkaline medium with the highly sensitive and selective colorimetric 
detection of the cuprous cation (Cu+1) using a reagent containing bicinchoninic acid. 
The purified proteins were diluted in the buffer used for solubilization of the protein of 
interest and a known concentration of BSA was serially diluted in the same buffer. Ten µl of 
each dilution was transferred into the wells of a low-protein-binding 96-well microtiter plate 
(Greiner) with 10 µl of the buffer as a control. 200 µl of BCA colour reagent was 
subsequently added to each well, mixed with the proteins and incubated at RT for 10 min 
followed by the measurement of colour development at 595nm. For each dilution, 
measurements were performed in duplicate and the average was taken for the calculation of 
the protein concentration.   
II.2.3.5 Enzyme-linked immunosorbent assay 
Direct LHRH ELISA was used for the detection of functional mAb P7278 in hybridoma 
supernatant, scFv P7278 and diabody P7278 in bacterial supernatant and plant extract, and 
chimeric P7278 in the plant extract. The same set up was also used for analysis of all the 
antibody variants after purification. ELISA was carried out in 96-well microtitre plates 
(M129B, Greiner). Conditions used for the direct LHRH ELISA were as follows:  
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 Steps             Concentration Vol. (µl/well) Time (min) Temp. (°C) 
Coating (Ag) 1µg/ml LHRH in CB 100 120 37 
Blocking 1% (w/v) BSA in PBS 300 60 37 
Sample Recombinant Ab in PBS 100 60 37 
Primary Ab 1:5000 in PBS-T 100 60 37 
AP-labelled Ab 1:5000 in PBS 100 60 37 
Substrate 1mg/ml PNPP in SB 100 15-30 RT 
CB – carbonate buffer: 15 mM Na2CO3, 35 mM NaHCO3; pH9.6.   
PBS-T - 1xPBS; 0.05% Tween-20 (w/v).  
Primary Ab and AP-labelled Ab – Refer to section II.1.5 for the detection antibodies used.  
PNPP - p-Nitrophenyl Phosphate.   
SB - 0.1M Sodium Citrate buffer, pH9.8.  
Between each incubation step the plates were washed three times with PBS-T. 
Capture ELISA was used for detection of the plant expressed heavy and light chains of the 
chimeric antibody. GAH-Fc and GAH-F(ab´)2  polyclonal antibodies, at a concentration of 
1 µg/ml, were coated on the ELISA plates for capturing the heavy and light chain 
respectively. Antibodies used for detection of the captured immunoglobulin for this assay are 
given in section II.1.5. 
II.2.3.6 Size exclusion chromatography 
A Superose 12 HR 10/30 column (Amersham Pharmacia Biotech) was equilibrated with PBS. 
Affinity purified scFv P7278 and diabody P7278 were loaded and run at 1 ml/min. Cytochrome 
C, carbonic anhydrase, BSA, ß-amylase and Dextran Blue were run as molecular weight 
standards. The eluates were monitored by UV 260 nm and 280 nm and Dextran Blue by 610 nm.  
II.2.4 Bacterial expression and purification of scFv P7278 and diabody P7278  
II.2.4.1 Small-scale expression of scFv P7278 and diabody P7278   
A single recombinant colony of E. coli strain HB2151 harbouring the pHEN4II phagemid 
containing the scFv P7278 and diabody P7278 antibody gene fragments was inoculated in 2 ml 
of 2YT medium containing 100 µg/ml ampicillin and 0.1% (w/v) glucose and cultivated at 
37°C for 3-4 h with shaking at 180 rmp until the OD600nm reached 0.4-0.6. The bacterial 
culture was induced 0.5 mM IPTG for 16 h at 30°C. The cells were removed by centrifugation 
(4,000 g/4°C/10 min) and the supernatant was used for Western blot analysis (II.2.3.2) and 
ELISA (II.2.3.5). 
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II.2.4.2 Upscaled expression of scFv P7278 and diabody P7278 
For upscaled periplasmic expression and purification of soluble antibody fragments, the 
cDNAs of the scFv and diabody P7278 were subcloned into the prokaryotic expression vector 
pSyn1 and transformed into E.coli strain HB2151. 
A single recombinant colony was inoculated in 5 ml of 2YT medium containing 1% (w/v) 
glucose and 100 µg/ml ampicillin and cultivated at 37°C o/n with shaking (200 rpm). Two ml 
of the o/n culture was transferred into 200 ml of 2YT medium containing 0.1% (w/v) of 
glucose and 100µg/ml ampicillin and cultivated at 37°C until the OD600nm of the culture 
reached 0.7-0.8. Following induction with 0.5 mM IPTG and additional cultivation at 30°C 
for 3-4 h, the cells were harvested by centrifugation (4,000g/4°C/20 min). The cell pellet was 
resuspended in 20 ml of PTS (30mM Tris, sucrose 20% (w/v), pH 8.0). EDTA was added to 
the cell suspension to a final concentration of 1 mM and the suspension kept on ice for 10-
15 min with gentle agitation followed by centrifugation (8,000 g/4°C/20 min). The 
supernatant (sample 1) was removed and kept on ice. The pellet was resuspended in 20 ml of 
5 mM MgSO4 and EDTA added to the suspension to a final concentration of 1 mM. The 
suspension was incubated on ice for 10-15 min followed by centrifugation (8,000g/4°C/20 
min). The resulting supernatant was mixed with the sample 1 and dialyzed against PBS. The 
dialyzed periplasmic extract was subjected to affinity purification by IMAC (II.2.4.3).  
II.2.4.3 Purification of the recombinant proteins by IMAC 
The bacterially expressed scFv P7278 and diabody P7278 tagged with His-6 motif were affinity 
purified by IMAC. The dialysed osmotic shock fluid was adjusted to pH 8.0. A 0.5 cm 
(diameter) x 20 cm (length) column was packed with 1 ml of ProSep Chelating matrix, 
charged with 5 column volumes (CV) of 50 mM NiSO4 and equilibrated with 10 CV of 
binding buffer (PBS pH 8.0). The osmotic shock fluid was applied to the column at a flow 
rate of 2 ml/min. After sample application, the column was washed with 5 CV of binding 
buffer. Non-specifically bound proteins were removed with binding buffer containing 25 mM 
imidazole. Ni-NTA bound his-6 tagged scFv and diabody were recovered using 2 CV of 
binding buffer containing 125 mM imidazole by competitive elution. The collected fractions 
were immediately dialyzed against PBS (pH 7.4) to remove imidazole and salt. The purified 
scFv and diabody preparations were used for further characterization by SDS-PAGE 
(II.2.3.1), Western blot (II.2.3.2) and ELISA (II.2.3.5). 
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II.2.5 Plant expression and purification of LHRH specific antibodies  
II.2.5.1 Growth of N. tabacum cv. Petit Havana SR1   
Nicotiana tabacum cv. SR1 plants were grown in a greenhouse in DE73 standard soil at 24°C 
under supplementary illumination (4000 Lux, 16 hr photoperiod). Of the other plant species 
listed in section II.1.7, the ones grown in Aachen, Germany were all cultivated under the same 
greenhouse conditions as SR1. The plant species tested in Delhi, India were grown in an open 
garden under no special condition for care and maintenance. 
II.2.5.2 Small-scale transient expression of LHRH specific antibodies 
Growth of recombinant Agrobacterium and vacuum infiltration of tobacco leaves was 
performed as described by KAPILA et al., (1997) and VAQUERO et al., (1999). 
Agrobacterium clones positive for the presence of the scFv, diabody and the heavy and light 
chains of the chimeric antibody were identified by colony PCR (II.2.2.8.2). A single colony 
was inoculated into 10 ml of YEB-Kan/Rif/Carb medium and cultivated at 28°C for 2-3 days 
with shaking at 250 rpm. One ml of each was transferred into 100 ml of YEB-Kan/Rif/Carb 
medium and cultivated at 28°C o/n with shaking at 250 rpm. The remaining culture was used 
for making glycerol stocks (II.2.2.8), which were aliquoted in volumes of 200µl and stored at 
-80°C. The cells were peletted by centrifugation (4000 g/4°C/20 min), resuspended in 250 ml 
of induction medium and cultivated at 28°C o/n with shaking at 250 rpm. The cells were 
again harvested by centrifugation (4,000 g/15-25°C/15 min) and each pellet resuspended in 
50 ml of MMA solution to which 200µM acetosyringone was added. The cell suspension was 
kept at RT for 2 hr.  
For agroinfiltration of the scFv and the diabody the recombinant bacterial cell suspension was 
diluted to an OD600 of one. For agroinfiltration of both the chimeric chains separately, the cell 
suspension was diluted to an OD600 of one. For co-expression of the two chimeric chains, 
equal volumes of both the chimeric light and heavy chain agrobacterium cultures having an 
OD600nm of two were mixed resulting in a final OD600 of one for each chimeric antibody chain.  
Tobacco leaves (four leaves for each construct) were placed in 100 ml of agrobacteria 
suspension in a “Weck” glass that was placed in a glass dessicator attached to a vacuum 
pump. A continuous vacuum (60-80 mbar) was applied for 15-20 min. The applied vacuum 
was released rapidly; the leaves were briefly rinsed in tap water and kept on a wet Whatman 
3M paper with adaxial side up in sealed trays (23°C/16 hr photoperiod/60 hrs). After 60 hrs of 
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incubation, the central vein of the leaves was removed, leaves were weighed, frozen in liquid 
nitrogen and stored at -80°C until analysis. 
For the extraction of transiently expressed recombinant proteins from vacuum infiltrated 
tobacco leaves, frozen leaves were ground in liquid nitrogen to a fine powder with a mortar 
and pestle. Total soluble proteins were extracted using 2 ml of extraction buffer per gram leaf 
material. Cell debris was removed by two rounds of centrifugation (16,000g/4°C/30 min) and 
the supernatant was used for analysis by Western blot (II.2.3.2) and ELISA (II.2.3.5).  
Induction medium (pH 5.6) YEB medium; MES 10 mM; 2 mM MgSO4, 25 µg/ml 
kanamycin, 100 µg/ml rifampicin, 100 µg/ml carbenicillin, 20 µM acetosyringone were added 
after autoclaving and cooling. 
MMA buffer (pH 5.6): MS-salts 0.43% (w/v); MES 10 mM (w/v); sucrose 2% (w/v). 
200 µM acetosyringone was added after autoclaving and cooling.  
Extraction buffer (pH 6): PBS 1x; ascorbic acid 50 mM; ß-mercaptoethanol 7 mM, 
EDTA 5 mM. 
II.2.5.3 Purification of LHRH specific antibodies from tobacco leaves 
The Agrobacterial glycerol stocks of the chimeric heavy and light chain clones (II.2.5.1) were 
used for initiating the cultures. The method used for culturing the Agrobacteria was the same 
as for the small-scale infiltration experiment (II.2.5.2) except that the quantity of culture was 
scaled up to 2-3 litres. Tobacco plants having not more than 4 to 5 leaves each were used for 
vacuum assisted infiltration of recombinant agrobacterium culture. Plant material amounting 
to more than 500 grams was used for each experiment. The leaves from each plant were 
harvested and immersed in the Agrobacterium suspension culture. The rest of the procedure 
was the same as for the small-scale infiltration experiment (II.2.5.2) except that the leaves 
were not rinsed with water before placing on the Whatman paper prior to incubation. Sixty 
hours post incubation the leaves were weighed without excising the central vein and stored at 
–80°C without flash freezing in liquid nitrogen. 
For total soluble protein extraction from large number of leaves (more than 500 gms), the 
infiltrated leaves were ground in 2 ml of cold extraction buffer per gram of leaf material. The 
extract was filtered through Mira cloth (Calbiotech). The flow through was collected and 
centrifuged (10,000 rpm/4°C/30 min). The supernatant obtained after centrifugation was 
sequentially passed through Mira cloth and Whatman 3M paper. The pH of the plant extract 
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was increased to 8 and the extract was placed on ice for 30 min. The extract was centrifuged 
(1000 rpm/4°C/30 min) and filtered through Whatman 3M paper and applied to the affinity 
column for antibody purification. 
For purification of chimeric rAb P7278 one ml of Protein A matrix was packed in a Bio Rad 
column. The matrix was equilibrated with three column volumes of PBS, pH 8 before 
application of the plant extract. The plant extract was passed through the column at a flow rate 
of 3 ml/min. The column was washed with PBS containing 100 mM NaCl (pH 8) till the 
online UV detector showed zero absorbance at 280 nm. The antibody was eluted from the 
column with 100 mM glycine (pH 2) under gravity flow. The first elution was of 500 µl 
followed by 4 batches of 2 ml fractions. The elution fractions were neutralized to pH 7.5 with 
1 M unbuffered Tris solution and checked for the presence of the purified protein by SDS-
PAGE analysis (II.2.3.1). The relevant fractions were subsequently dialyzed o/n against PBS 
(pH 7.4). 
The scFv and the diabody were purified using Ni-NTA matrix. The procedure followed was 
the same as for the purification of bacterially expressed antibodies (II.2.4.3). Samples at each 
step of purification were collected for Western blot analysis (II.2.3.2) and SDS-PAGE 
(II.2.3.1). 
II.2.6 Generation of transgenic tobacco plants expressing chimeric 
rAb P7278 
II.2.6.1 Agrobacterium-mediated stable transformation of tobacco plants 
Stable transformation of N. tabacum was performed with the help of Dr. F. Schuster (RWTH 
Aachen, Institut für Biology VII). Transgenic N. tabacum cv. Petite Havana SR1 plants were 
generated by leaf disc transformation using recombinant Agrobacteria transformed with 
pSSH1 plasmid carrying the light and heavy antibody chains of the chimeric rAb P7278 targeted 
for expression in the ER (III.6.2). Transgenic T0 plants were regenerated from transformed 
callus (FRALEY et al., 1983; HORSCH et al., 1985). Briefly, wild type plants were grown on 
MS medium in “Weck” glasses and the youngest leaves (length up to 4 cm) were used for 
transformation. The agrobacteria suspension was prepared as described (II.2.5.2) and the 
OD600nm was adjusted to at least 1.0 after dilution in MMA buffer. The leaves were cut into 8-
10 pieces and transferred into “Weck” glasses containing 50-100 ml of agrobacteria 
suspension and incubated at RT for 30 min. The leaf pieces were then transferred onto sterile 
pre-wet Whatman 3M filters in petri dishes, closed with saran wrap and incubated at 26-28°C 
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in the dark for two days. Following washing with distilled water containing 100 µg/ml 
kanamycin, 200 µg/ml claforan and 200 µg/ml Betabactyl (Ticarcillin/Clavulanic acid, 25:1), 
leaf pieces were transferred onto MS II-plates and incubated at 25°C in the dark for one week 
and with a 16 h photoperiod for 2-3 weeks. Upon shoot formation, the shoots were removed 
and transferred onto MS-III-plates and incubated at 25°C with a 16 h photoperiod for 10-
14 days until roots developed. The small plants were transferred into Weck glasses containing 
MS-III medium and incubated at 25°C in 16 h light rhythm for 2 weeks until transferred into 
soil. Leaves from regenerated transgenic plants were used for ELISA (II.2.3.4) and dot blot 
analysis (II.2.3.3) of expressed antibody chains.  
MS medium: MS-salts 0.43% (w/v); Myo-inosite (SERVA) 0.1% (w/v); sucrose 2% (w/v); 
Thiamin-HCl 0.4 mg/l; bidistilled water added to 1000 ml. The pH was adjusted to 5.8 with 
1 N NaOH. For preparation of solid MS-plates, 0.8% (w/v) agar was added. 500 µl of vitamin 
solution I was added after autoclaving and cooling below 50°C. 
MS-II medium: MS medium supplemented with BAP (in DMSO, from Sigma) 1 mg/l; NAA 
(from Sigma) 0.1 mg/l; kanamycin 100 mg/l; claforan 200 mg/l; betabactyl 200 mg/l. 
MS-III medium: MS medium supplemented with kanamycin 100 mg/l; claforan 200-
250 mg/l; betabactyl 200-250 mg/l. 
Vitamin solution I: glycin 0.4% (w/v); nicotinic acid 0.1% (w/v); pyridoxin 0.1% (w/v); 
filter sterilized and stored at 4°C. 
II.2.6.2 Generation of non-segregated transgenic tobacco lines  
The T0 generation of the transgenic plants expressing the heavy and light chains of the 
chimeric rAb P7278 were screened for identification of the best expressing lines by dot blot 
analysis of the leaf extract (II.2.3.3). Plants that were identified as the best expressers were 
selected and backcrossed for generation of the T1 generation. The seeds obtained were planted 
on MS-III plates and incubated at 25°C in 16 h light rhythm after which the small plantlets 
were transferred into soil in the greenhouse. The T1 generation plants were tested for 
expression levels by dot blot analysis of leaf extracts (II.2.3.3). The seeds obtained by 
backcrossing of TI generation were sown on MS-III plates and the ratio of the regenerated 
plants to the non-regenerated ones was determined for each selected line. Heavy and light 
antibody chain expressing plant lines whose seeds showed 100% viability were selected, 
grown and crossed with each other. The seeds obtained were planted and the resulting plants 
were analysed for the expression of the full-length chimeric antibody.  
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II.2.7 Characterisation of LHRH specific antibodies using BIAcore  
II.2.7.1 Immobilisation of D-Lys6-LHRH on the sensor chip surface 
The antigen, D-Lys6-LHRH was immobilised on the carboxymethly-dextran surface (CM5) 
sensor chip (Pharmacia). A continuous flow of HBS buffer pH 7.4 over the sensor surface at 
5µl/min was maintained. Equal volumes of NHS and EDC were first mixed and then 25µl of 
this solution was pumped across the chip to activate the carboxylated dextran surface. 30µl of 
D-Lys6-LHRH (50µg/ml) in 50mM acetate buffer pH5.6 was injected over the activated 
surface followed by 35µl of ethanolamine to block the remaining activated NHS-ester groups 
on the sensor chip. 
HBS Buffer (pH 7.4): Hepes 10 mM; NaCl 0.15 M; EDTA 4 mM; surfactant 20 0.05% (v/v). 
II.2.7.2 Sample measurement and surface regeneration 
Each binding cycle was performed with a constant flow of degassed HBS buffer at 5 or 
10 µl/min. Samples of antibody prepared in HBS were injected across the sensor chip surface 
via the sample loop contained within the fluidic cartridge of the system. Typically the sample 
volume injected was 30 µl at a flow rate of 5 µl/min. The surface was regenerated by injection 
of 100mM HCl followed by 100mM glycine, 0.03% (v/v) Triton-X-100 (pH 12) at the rate of 
30 µl/min. The contact time for each regeneration buffer was 1 min.   
II.2.8 In vivo bioassays 
II.2.8.1 Animal care and maintenance  
Wistar rats were maintained in groups of 4 per cage while Swiss/CD1 mice were kept in 
groups of 6 animals per cage. The animals were kept in an air-conditioned animal house 
illuminated daily from 0500-1900 hrs in a constant temperature of 21°C. The animals had free 
access to tap water and food. The animal studies were consistent with the principles of 
laboratory animal care issued by the National Institute of Immunology, New Delhi, India. 
II.2.8.2 Cyclicity disruption 
Female outbred Wistar rats and CD1/Swiss mice, 6-8 week old, were used for in vivo 
bioassays that involved estrous cyclicity disruption. Vaginal smear from the animals were 
taken at a fixed time everyday. The smear was taken by saline lavage of the vaginal tract. The 
smear was spotted on a glass slide and observed under the microscope. Animals that showed 
three consecutive estrous cycles of four days were chosen for the experiment. The antibody 
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used for the study was diluted in PBS. The antibody was administered to the 
animals intraperitoneally.  
II.2.8.3 In vivo pharmacokinetics of anti-LHRH mAb 
Six CD1 male mice were used for determining the serum clearance of the anti-LHRH murine 
mAb. 200 µgs of the antibody in 200 µl of PBS was administered intraperitoneally to each 
animal. Blood samples were collected by retro-orbital plexus puncture at a fixed time each 
day for six consecutive days. Serum was separated by centrifugation and stored at –20°C. 
II.2.9 Peptide display for isolation of anti-LHRH antibody mimotope 
The Ph.D.-12 phage display peptide library kit (NEB) was used for isolation of the anti-
LHRH antibody mimotope. The protocols and procedures followed were as described by the 
manufacturers, a brief description of which is stated below.  
II.2.9.1 Panning procedure 
The phage displayed Ph.D.-12 peptide library was panned in multititer well plates. LHRH was 
coated in 150 µl carbonate coating buffer at a concentration of 5 µg/ml. After 2 h incubation 
at room temperature the solution was removed by pipetting. No washing step was performed. 
Wells were blocked overnight at room temperature with 300 µl 4% (w/v) skimmed milk 
dissolved in TBS. Blocking solution was removed and the plate was washed once with TBS 
containing 0.01% (v/v) Tween (TBST). Phages were diluted in TBST containing 0.5 % (w/v) 
skim milk and 100 µl were transferred to the wells. Phages were incubated with the antigen 
for at least 2 h. The plate was extensively washed 5 times with TBST containing 0.5 % (w/v) 
skim milk and another 5 times with TBST. For each wash the plate was incubated with the 
wash buffer for two minutes. Then soluble LHRH was added as competitor at a concentration 
of 50 µg/ml for 1 h. Supernatant containing the antigen-eluted phages was collected and kept 
on ice. Remaining phages were eluted with 100-200 mM glycine pH 2.2 for 5 minutes and 
immediately neutralized by addition of 1 M unbuffered Tris solution containing 1 mg/ml 
BSA. Antigen and glycine eluted phages were added to the bacterial cultures for 
phage amplification. 
II.2.9.2 Phage amplification 
An o/n culture of ER2738 (II.1.7.1) was diluted 1:100 in LB in a 50 ml plastic Falcon tube. 
The bacterial culture was inoculated with phages eluted after panning (II.2.9.1) or from phage 
plaques obtained from petri dishes after phage titration (II.2.9.4) and incubated at 37°C with 
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shaking for no longer than 4.5 h. The bacterial culture was then centrifuged and the 
supernatant containing the phages used for DNA preparation (II.2.9.5) or for preparing phages 
(II.2.9.3).  
II.2.9.3 Phage preparation 
To the phage containing bacterial culture supernatant (II.2.9.2), 1/6 volume of PEG/NaCl was 
added and the solution kept at 4°C for at least 1 h or o/n. The precipitated phages were 
separated from the supernatant by centrifugation and the obtained pellet resuspended in 1 ml 
TBS. The phage suspension was re-centrifuged for five minutes to remove any residual cell or 
other particulate matter. The obtained supernatant containing phages was reprecipitated with 
5x PEG/NaCl and resuspended in 50 µl of TBS. 
II.2.9.4 Phage titration 
From the phages eluted after panning (II.2.9.1) 10 µl were used to make dilutions. The diluted 
phages were mixed with 200 µl of ER2738 culture and 3 ml Top-agar and spread on LB 
plates containing IPTG/X-gal. On the next day blue phage plaques were counted for 
estimation of the titres of recombinant phages obtained after panning. The blue colour of the 
phage plaques results from the LacZα gene present on the cloning vector M13mp19 from 
which the phage are derived. The blue colour helped to distinguish between the white plaques 
that result due to the wild type filamentous phages.   
II.2.9.5 Preparation of phage DNA for sequencing 
Plaque amplification was carried out as described in section II.2.9.2. 500 µl of bacterial 
supernatant carrying phages were transferred to a fresh microfuge tube to which 200 µl of 
PEG/NaCl was added and the solution incubated at RT for 10 min. After ten minutes the 
precipitated phages were centrifuged and the supernatant discarded. The pellet containing 
phages was resuspended in 100 µl iodide buffer and 250 µl ethanol and incubated at RT for 
another ten minutes and then centrifuged for ten minutes. The supernatant was discarded and 
the DNA pellet was washed in 70% ethanol, dried and dissolved in 30 µl TE buffer. 5 µl of 
DNA was used for sequencing reaction (II.2.2.9). 
5 x PEG/NaCl: polyethylene glycol-8000 20 % (w/v); NaCl 2.5 M. 
Iodide buffer: Tris-HCl, pH 8.0 10 mM; EDTA 1 mM; NaI 4 M.  
 
  
 
  
III Results 
The work presented in this thesis had the objective of producing antibodies reactive with 
LHRH by recombinant DNA technology. A highly specific and bioeffective monoclonal 
antibody P7278 having high affinity was selected for cloning the variable antibody domains for 
subsequent generation of recombinant antibody fragments. Briefly, the procedure included the 
isolation of the variable heavy and light chain domains of the mouse mAb P7278 from mRNA 
of hybridoma cells, followed by cloning, sequencing and characterization of the scFv; 
construction of the diabody fragment and the chimeric antibody; expression of recombinant 
antibodies in plants; characterization and bioefficacy testing of plant expressed rAbs. The in 
vitro characterization of the antibodies included basic protein analysis methods (SDS-PAGE, 
ELISA, immunoblots and gel filtration techniques), affinity determination by surface plasmon 
resonance for comparison with that of the parent antibody. The bioeffect of the neutralizing 
chimeric rAb P7278 was demonstrated by estrus cycle disruption of regularly cycling mice. A 
detailed characterization of the antibody-antigen interaction for delineation of the residues in 
LHRH that constitute the binding motif was also carried out. The methods chosen comprised 
of the analyses of the binding interaction of the rAb P7278 with LHRH variants and analogues 
and the characterization of antibody binding peptides from a phage displayed random 12mer 
peptide library. 
III.1 Characterisation of mouse mAb P7278 
III.1.1 Sub-seeding and culturing of the hybridoma P7278 
The anti-LHRH antibody secreting hybridoma cell line P7278 was subcloned as described in 
section II.2.1.1. Wells with single colonies were identified under the microscope. The 
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supernatant from these wells was applied to LHRH coated microtiter plate to confirm the 
binding of the secreted antibody to the antigen by ELISA (II.2.3.5). Antibody binding was 
observed for all clones tested (data not shown). Moreover all the clones showed similar levels 
of antibody secreted into the supernatant demonstrating the homogeneity of the cell line. One 
such clone was selected and propagated for further work (III.1.2, III.2.2). 
III.1.2 Purification and analysis of mouse mAb P7278  
The freshly sub-cloned P7278 hybridoma cell line was propagated in tissue culture flasks and 
the culture supernatant was collected for the purification of the secreted mouse mAb P7278. 
The hybridoma culture supernatant was centrifuged to remove the cells and cell debris before 
applying it to the equilibrated Protein A matrix (II.2.1.2). The amount of purified antibody 
obtained was determined by BCA (II.2.3.4) to be 9 mg per litre of hybridoma culture 
supernatant. The SDS-PAGE analysis of the purified mouse mAb P7278 showed two major 
bands of approximately 53 and 26 kDa corresponding to the mouse mAb P7278 heavy and 
light chains respectively (Fig. III-1.a). The integrity of the Protein A purified antibody was 
further confirmed by Western blot analysis (Fig. III-1.b). Direct LHRH ELISA (II.2.3.5) with 
the purified antibody demonstrated binding activity of the antibody to the antigen (Fig. III-2). 
 
KDa         M            1      KDa           M        1       2 
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(a)                                                                    (b) 
Fig. III-1: SDS-PAGE and immunoblot analysis of the affinity purified mouse 
mAb P7278.  
(a) The mouse mAb P7278 purified from the hybridoma culture supernatant (II.2.1.2) was separated 
on a 12% (w/v) SDS-PAGE gel and stained with Coomassie brilliant blue (II.2.3.1). M: Molecular 
weight standard (Mark 12); 1: 5 µg of Protein A purified mouse mAb P7278; 2: 15 µg  
(b) The Protein A purified mouse mAb P7278 was separated on a 12% (w/v) SDS-PAGE gel and 
blotted onto Immobilon-P membrane (II.2.3.2). AP labelled GAM - (H+L) antibody (0.12µg/ml) 
was used for detection followed by staining with NBT/BCIP.  M: Prestained molecular weight 
standard; 1: 2 µg of purified mouse mAb P7278. 
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Fig. III-2: Binding activity of the purified mouse mAb P7278 to LHRH in an ELISA. 
Two fold serial dilutions starting from 1400 ng/ml of the Protein A purified antibody was applied 
to ELISA plate coated with 1µg/ml LHRH peptide. Bound antibody was detected with AP 
conjugated GAM-Fc antibody (0.12µg/ml). Reactivity was colourimetrically measured at 405 nm 
after addition of 1mg/ml p-nitophenly phosphate substrate for 30 minutes at 37°C.   
III.1.3 Optimisation of ELISA conditions for the detection of antibody 
binding to LHRH 
The optimal conditions for coating and blocking in a direct ELISA set up for antibody binding 
to LHRH had to be determined. The three variables tested were: Coating buffer - carbonate-
bicarbonate buffer (15mM Na2CO3, 35mM NaHCO3; pH9.6), or PBS (pH7.4); temperature 
used for coating LHRH - 37°C for 2 hrs or 4°C overnight; blocking solution - 1% (w/v) BSA 
in PBS or 2% (w/v) milk powder (Marvel, England) in PBS. All eight combinations were 
tested by ELISA. The difference between the incubation temperatures and the coating buffers 
while keeping the other two parameters constant was not significant although coating at 37°C 
with carbonate buffer worked better. A significant difference was observed between the two 
blocking solutions; 1% (w/v) BSA in PBS or 2% (w/v) milk powder (Marvel, England) in 
PBS. When the blocking was performed with BSA the OD values were two fold higher as 
compared to the wells blocked with milk (Fig. III-3). In all cases the background due to non-
specific binding was low. 
The conditions for the direct LHRH ELISA were optimal when LHRH was coated at a 
concentration of 100ng/well in PBS, pH7.4 at 37°C for 2 h and blocking performed with 1% 
(w/v) BSA in PBS for one hour. 
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Fig. III-3:  Optimisation of direct LHRH ELISA. 
The optimal conditions for direct LHRH ELISA were established by varying the coating buffers, 
coating temperature and the blocking buffers. (a) Serial dilutions of the protein A purified mouse 
mAb P7278  (II.2.1.2) starting from 2.5µg/ml were applied to the LHRH coated plate. The mouse 
mAb P7278 was detected by the AP labelled GAM-Fc antibody (0.12µg/ml). CB – Carbonate 
Buffer, pH9.6; PBS – Phosphate Buffer Saline, pH7.4; BSA – Bovine Serum Albumin, 1% (w/v) 
in PBS; Milk- Marvel, 2% (w/v) in PBS. (b) The linear fit of each curve in graph-a was 
normalised with respect to the maximum value obtained and plotted as relative reactivity. 
III.2 Amplification and cloning of the variable domains of mouse 
mAb P7278 
III.2.1 Cloning strategy 
The variable region of the heavy (VH) and the light (VL) chains of the mouse mAb P7278 were 
amplified from mRNA isolated from the P7278 hybridoma cell line and cloned in the pHEN4II 
vector for the generation of a mini-scFv library as depicted in Fig. III-4. 
III.2.2 mRNA isolation and cDNA synthesis  
The freshly subcloned hybridoma cell line (III.1.1) was propagated and the cells were used for 
RNA isolation (II.2.2.7.1). The amount of total RNA isolated from 5⋅106 hybridoma cells 
ranged between 75 to 95 µgs. Total RNA amounting to 175 µg was used for mRNA isolation 
(II.2.2.7.1). Approximately 1500 ng of mRNA was obtained. The isolated mRNA was reverse 
transcribed into cDNA (II.2.2.7.2). The primers used for first strand cDNA synthesis, COH32 
and MuPD31, were specific for the murine IgG2a/2b and the kappa antibody 
chains respectively.  
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Fig. III-4: Schematic representation of the strategy used for cloning a mini-scFv 
library constituted of the light and heavy variable domains of the mouse mAb P7278.   
VH: variable domain of antibody heavy chain; VL: variable domain of antibody light chain; 
pHEN4II vector: phagemid vector used for cloning the variable antibody domains; mini-VH and 
mini-VL libraries: Pooled PCR amplification products were cloned in pHEN4II; MPDVHF and 
MPDVLF: forward primers for murine heavy and light chain amplification respectively; 
MPDVHB and MPDVHL: back primers for amplification of murine heavy and light chains 
respectively; COH32 and MuPD31: primers for cDNA synthesis of murine IgG2a/2b heavy and 
kappa light chains respectively. For primer sequences see section II.1.8. 
  
 
III Results 56
III.2.3 Amplification and cloning of variable domains of mouse mAb P7278 
The VH and VL fragments of the mouse mAb P7278 were amplified by PCR using the first 
strand cDNA as template (II.2.2.7.2). Sixteen degenerate forward primers (MPDVHF1-16) 
were used individually with a mix of 5 back primers (MPDVHF1-5) for PCR amplification of 
the VH fragment (II.2.2.8.3). Of the 16 individual PCRs for the heavy chain, an amplified 
product of the expected size (380 bp) was obtained with primers MPDVHF2, 4, 5, 6, 7, 9, 10 
and 15  (Fig. III-5).   
 
1   2    3    4    5    6   7   8   M   9  10  11 12 13  14  15  16 17  
 
~ 380 bp 
 
Fig. III-5: PCR amplification of the VH fragment of mouse mAb P7278.  
VH antibody domain was amplified by PCR (II.2.2.8.3) and separated on a 1.2% (w/v) agarose gel 
(II.2.2.3). 5 µl of the PCR products were loaded in each well. A ~ 380 bp long PCR product 
corresponding to the variable region of the heavy chain can be seen in lanes 2, 4, 5, 6, 7, 9, 10 and 
15; Lane 17: PCR mix without DNA (negative control); M: λ DNA marker digested with Pst I. 
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                         ~ 350 bp
 
       
 
Fig. III-6: PCR amplification of the VL fragment of mouse mAb P7278.  
VL antibody domain was amplified by PCR (II.2.2.8.3) and separated on a 1.2% (w/v) agarose gel 
(II.2.2.3). 5 µl of the PCR products were loaded in each well. A ~ 350 bp long PCR product 
corresponding to the variable region of the light chain can be seen in lanes 1, 5, 6, 8, 9, 12 and 13; 
Lane 14: PCR mix without DNA (negative control); M: λ DNA marker digested with Pst I. 
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For the amplification of the VL antibody fragment the cDNA was amplified with each of the 
13 light chain specific forward primers (MPDVLF1-13) with a mix of the 4 backward primers 
(MPDVLB1-4) (II.2.2.8.3). PCR products of the expected size (~350 base pairs) were 
obtained with the forward primers MPDVLF-1, 5, 6, 8, 9, 12, and 13 (Fig. III-6). PCR with 
the primers MPDVLF3 and MPDVLF10 resulted in smaller amplification products (~300bp), 
which could be a result of a PCR artefact or because of an internal binding site in the VL 
sequence and were not included for the cloning procedure. 
The amplified products obtained for both the VH and the VL antibody fragments were pooled 
and purified from an agarsoe gel (II.2.2.3). The gel-purified VH antibody fragments were 
digested with SfiI and BstEII while the VL antibody fragments with AscI and NotI restriction 
enzymes. The digested variable gene fragments were cloned into pHEN4II phagemid vector 
and transformed into electrocompetent DH5α cells. To verify the presence of the insert, 
plasmid mini-preparations were performed followed by restriction analysis of 10 randomly 
selected ampicillin resistant E. coli DH5α colonies for both VH and VL. All the clones tested 
carried recombinant plasmids with inserts of the expected size ~350 bp for the VL and ~ 380 
bp the VH fragment (data not shown). The colonies obtained on transformation of the ligation 
product were pooled together to generate mini-VL and mini-VH libraries.  
III.3 Generation of LHRH specific scFv and diabody anti-
body fragments 
III.3.1 Cloning and characterisation of scFv P7278  
III.3.1.1 Cloning of the scFv P7278 
The mini-VH and -VL libraries cloned in the pHEN4II vector (III.2.3) were used to generate a 
mini-scFv library (II.2.2.10.1).  Plasmid DNA isolated from the two libraries was subjected to 
restriction digestion with AscI and NotI restriction enzymes. The vector from the mini-VH 
library and the VL fragments from the mini-VL library were purified from the gel and ligated. 
The ligation reaction resulted in the cloning of the scFv with N´ terminal VH and the C´ 
terminal VL fragment separated by the Whitlow 218 linker (see cloning strategy in Fig. III-4). 
The presence of the scFv fragment was verified by restriction analysis of 10 randomly picked 
clones. A fragment of approximately 800 bps was recovered on restriction of plasmid DNA 
with NcoI and NotI from 8 of the 10 clones analysed (data not shown). The size of the library 
was estimated to be 2⋅103. 
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III.3.1.2 Screening of functional scFv fragments derived from the hybridoma 
A small-scale expression in E. coli strain HB2151 of the eight clones (numbered, 1/scFv to 
8/scFv) that were verified to be positive for the presence of the scFv fragment by restriction 
analysis (III.3.1.1) was carried out as described in section II.2.4.1.  
The scFv was cloned in pHEN4II such that it was in translational fusion with the gene III, the 
minor coat protein of M13 phage, for phage display. However, the phagemid is engineered in 
a way that an amber stop codon is inserted between the cloned antibody fragment and the 
gene III. This format enables switching between expression of gene III anchored fusion 
proteins and soluble antibody fragments simply by changing the expression host to a non-
suppressor strain such as HB2151. Therefore the eight clones that were identified by 
restriction analysis to be carrying an scFv were transformed into HB2151 cells. The scFv that 
was secreted into the supernatant was detected by Western blot analysis (II.2.3.2) and the 
reactivity analysed by ELISA (II.2.3.5). 
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(a)                                                                               (b) 
Fig. III-7a: Direct LHRH ELISA of soluble scFvs.   
100 µl of the bacterial culture supernatant from the clones induced by 1mM IPTG for expression 
of soluble scFv (II.2.4.1) were applied on a LHRH coated ELISA plate (II.2.3.5). Bound scFvs 
were revealed by anti-c-myc tag monoclonal antibody (9E10) (0.3 µg/ml) and polyclonal goat anti 
mouse antibody conjugated to alkaline phosphatase (0.12 µg/ml). Reactivity at 410 nm was 
measured after colour development at 37°C for 30 min in the presence of 1 mg/ml p-nitophenyl 
phosphate substrate in 0.1M sodium citrate buffer, pH9.8. Numbers 1-8: the eight scFv clones 
tested. Number 9: clone carrying only the bacterial expression vector (negative control). 
Fig. III-7b: Immunoblot analysis of bacterially expressed soluble scFvs. 
15 µl of the bacterial culture supernatant containing soluble scFv (II.2.4.1) from each clone was 
separated on a 12% (w/v) SDS-PAGE gel (II.2.3.1) and blotted onto nitrocellulose membrane 
(II.2.3.2).  Blotted scFvs were revealed by anti-c-myc tag monoclonal antibody (9E10) (0.3 µg/ml) 
and goat anti mouse polyclonal antibody conjugated to alkaline phosphatase (0.12 µg/ml) followed 
by staining with NBT/BCIP. Lane 1: unrelated scFv (positive control); Lanes 2-4: scFv clones 1-3; 
Lanes 5-9: scFv clones 4-8; M: Molecular weight standard/ pre-stained protein marker. 
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Direct LHRH ELISA of the culture supernatants containing the secreted scFv revealed that six 
of the eight clones tested, expressed scFv fragments that bound to the LHRH peptide (Fig. III-
7a). Western blot analysis of the culture supernatant confirmed the presence of a band of 
~30kDa, the expected size for an scFv, for those six clones that also demonstrated binding 
activity in ELISA (Fig. III-7b). The two clones that did not show reactivity to LHRH in 
ELISA were also found to be negative for the expression of the c-myc tagged protein as 
determined by Western blot analysis.   
III.3.1.3 Sequence analysis of scFv P7278 
The six scFv clones that showed binding to LHRH peptide (III.3.1.2), were sequenced. The 
nucleotide sequences of all the six clones were identical except for micro heterogeneity at the 
5´ primer-binding region that spans the first eight amino acid residues of the sequence (data 
not shown). One of the six clones, clone 6/scFv that gave the highest binding signal in direct 
LHRH ELISA (Fig. III-7a) was selected and used for all subsequent experiments.  
The sequence of scFv P7278 was analysed with the help of the numerous computational 
analysis tools available online through the World Wide Web for antibody sequences. The 
standard Kabat numbering for the scFv sequence was assigned by submitting the sequence to 
http://www.bioinf.org.uk/abs/seqtest.html. This tool provides an automated alignment facility 
with the consensus sequence. Once the Kabat numbering was assigned to scFv P7278 sequence 
the complementary determining regions (CDRs) and the framework regions were easily 
identified by comparison with the Kabat protein database. An additional facility provided at 
http://www.bioinf.org.uk/abs/seqtest.html, analysed for the presence of any unusual features 
introduced in the sequence due to cloning artefacts or PCR errors. The method employed for 
the analysis being that after the Kabat numbering is assigned to the sequence, the KabatMan 
database is used to identify amino acid residues occurring in less than 1% of the data in the 
database. The scFv P7278 sequence was found to be devoid of any such unusual residues.  
The sequence family and sub-group were assigned to the variable antibody regions of scFv 
P7278 by http://immuno.bme.nwu.edu/famgroup.html and http://immuno.bme.nwu.edu/subgroup.html 
respectively (Table III.1). The scFv sequence was submitted to 
http://www.rubic.rdg.ac.uk/cgi-bin/AndrewMartin for allocation of canonical classes to the 
CDRs. The results based on the strictest templates i.e. the ones derived solely from available 
crystal structures are given in Table III.1. 
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            Primer binding region          10    
   VH-P7278: Amino Acid -    Q   V   K   L   K   E   S   G   P   G   I   L   K   P    
   VH-P7278: Nucleotide -   CAG GTG AAG CTG AAG GAA TCT GGC CCT GGG ATA TTG AAG CCC   
   U23020: Nucleotide  -   --- --T -CT --- --A --G --- --- --- --- --- --- C-- --- 
   U23020: Amino Acid  -    .   .   T   .   .   .   .   .   .   .   .   .   Q   .    
  
 
 
   15                   20                 25                  30     CDR1 
    S   Q   T   L   S   L   T   C   S   F   S   G   F   S   L   S   T   T   N   M    
   TCA CAG ACC CTC AGT CTG ACT TGT TCT TTC TCT GGG TTT TCA CTG AGC ACT ACT AAT ATG 
   --C --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- T-- --- --- 
    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   S   .   .    
 
 
 
   35                  40                   45                  50 
    G   V   G   W   I   R   Q   P   S   G   K   G   L   E   W   L   A   H   I   W    
   GGT GTA GGC TGG ATT CGT CAG CCT TCA GGG AAG GGT CTG GAG TGG CTG GCA CAC ATT TGG 
   --- A-- --- --- --- --- --- --- --C --- --- --- --- --- --- --- --- --- --- --- 
    .   I   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .    
 
 
 
   55     CDR2         60                  65                  70 
    W   D   D   V   K   Y   Y   N   P   S   L   R   S   R   L   T   I   S   K   D    
   TGG GAT GAT GTT AAG TAC TAT AAC CCA TCC CTG AGG AGC CGG CTA ACA ATC TCC AAG GAT 
   --- --- --- -A- --- --- --- --- --- --- --- -A- --- --- --C --- --- --- --- --- 
    .   .   .   D   .   .   .   .   .   .   .   K   .   .   .   .   .   .   .   .    
 
                         
          
   75                  80                   85                  90                  
    T   S   R   N   Q   V   F   L   K   I   T   S   V   D   T   A   D   T   A   T    
   ACC TCC AGA AAC CAG GTA TTC CTC AAG ATC ACC AGT GTG GAC ACT GCA GAT ACT GCC ACT 
   --- --- -AC --- --- --- --- --- --- --- --- -C- --- --- --- --- --- --- --- --A 
    .   .   N   .   .   .   .   .   .   .    .  T   .   .   .   .   .   .   .   .           
 
 
 
   95                  100                 105   CDR3          110 
    Y   Y   C   V   V   R   E   S   L   L   R   P   S   F   D   V   W   G   A   G    
   TAC TAC TGT GTT GTT CGG GAG TCA TTA CTA CGG CCC TCC TTC GAT GTC TGG GGC GCC GGG 
   ---                                                                   JΗ1 
   . 
                                                                            
 
    115                  120                  
    T   T   V   T   V   S   S 
   ACC ACG GTC ACC GTC TCC TCA  
 
 
Fig. III-8: Nucleotide and deduced amino acid sequence of the VH compared with 
the most homologous germline gene. 
The V gene fragment of the heavy chain of scFv P7278 is compared with the closest germline 
sequence U23020. The complementary determining regions (CDR 1, 2, and 3) are shown in boxes. 
The forward primer binding region and the J segment with which the V region was re-
arranged are indicated. 
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            Primer binding region          10    
   VL-P7278: Amino Acid -    D   V   L   M   T   Q   A   P   F   S   L   P   V   S  
   VL-P7278: Nucleotide -   GAT GTT TTG ATG ACC CAA GCG CCA TTC TCC CTG CCT GTC AGT     
   D00081: Nucleotide  -   --- --- --- --- --- --- A-T --- C-- --- --- --- --- ---  
   D00081: Amino Acid  -    .   .   .   .   .   .   T   .   L   .   .   .   .   .    
  
 
 
    15                 20                  25                  30    CDR1 
    L   G   D   Q   A   S   I   S   C   R   S   S   Q   S   I   L   H   S   D   G    
   CTT GGA GAT CAA GCC TCC ATC TCT TGC AGA TCT AGT CAG AGC ATT CTA CAT AGT GAT GGA  
   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- G—- --- --- A-- ---  
    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   V   .   .   N   .    
 
 
 
    35                 40                   45                  50      
    N   T   Y   L   Q   W   Y   L   Q   K   P   G   Q   S   P   K   L   L   I   Y    
   AAC ACC TAT TTA CAA TGG TAC CTT CAG AAA CCA GGC CAG TCT CCA AAG CTC CTG ATC TAC    
   --- --- --- --- G-- --- --- --G --- --- --- --- --- --- --- --- --- --- --- --- 
    .   .   .   .   E   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .    
 
 
                     
    45     CDR2        50                  55                  60 
    T   V   S   N   R   F   S   G   V   P   D   R   F   S   G   S   G   S   G   T    
   ACA GTT TCC AAC CGA TTT TCT GGG GTC CCA GAC AGG TTC AGT GGC AGT GGA TCA GGG ACA 
   -A- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
    K   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .    
 
 
 
    65                  70                75                 80 
    D   F   T   L   K   I   S   R   V   E   A   E   D   L   G   V   Y   Y   C   F    
   GAT TTC ACA CTC AAG ATC AGC AGA GTG GAG GCT GAG GAT CTG GGA GTT TAT TAC TGC TTT 
   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- 
    .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .   .    
 
 
 
    85        CDR3      90                  95       
    Q   G   S   H   V   P   W   T   F   G   G   G   T   K   L   E   I   K 
   CAA GGT TCA CAT GTT CCG TGG ACG TTC GGT GGA GGC ACC AAG TTG GAG ATC AAA     
   --- --- --- --- --- --T CC-                      Jκ1 
    .   .   .   .   .   .   P 
 
 
Fig. III-9: Nucleotide and deduced amino acid sequence of the VL compared with the 
most homologous germline gene. 
The V gene fragment of the light chain of scFv P7278 is compared with the closest germline 
sequence D00081. The complementary determining regions (CDR 1, 2, and 3) are shown in boxes. 
The forward primer binding region and the J segment with which the V region was re-
arranged are indicated. 
The closest germ line gene sequence to the variable antibody regions of the scFv P7278 were 
found by aligning the DNA sequence of the variable genes to the germ line sequence library, a 
facility provided by http://imgt.cnusc.fr.  Sequence comparison showed that the VH region of 
the scFv P7278 showed the highest homology with the U23020 gene (IMGT database: The 
international ImMunoGeneTics database; Fig. III-8). The CDR3 of the heavy chain is 
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composed of the DFL16.2 gene segment and the JH1 gene segment. Moreover, the VH region 
accumulated a total of 18 somatic mutations during the time course of the immunization 
process, of which nine are silent.  
The VL antibody region of the scFv P7278 shows highest homology to the D00081 gene 
(IMGT databse; Fig. III-9). During the immunization process, the VL P7278 accumulated a 
total of twelve mutations, of which five are silent. The above stated information for both the 
heavy and the light chains of the scFv P7278 is summarized in Table III.1. 
Table III-1: Sequence analysis of the variable domains of scFv P7278. 
 
Amino acid differences     
from germline 
Canonical classes Variable 
region 
Family/ 
Subgroup 
Closest 
germline 
sequence 
Nucleotide 
differences 
from germline Primer 
region 
CDR 
region 
Frame
-work 
region 
CDR1 CDR2 CDR3 
VL IV/ II D00081 12 1 4 2 Similar to 
4/16A 
1/7A 1/9A 
VH XIX/ IB U23020 18 1 
 
4 
 
4 3/12A 
 
Similar to 
1/9A 
- 
 
Certain residues at the VL and VH domain interface make contact with each other and are 
known to be important for the stability of scFvs. These residues are also expected to influence 
the heterologous expression and folding of antibody fragments. Due to the highly conserved 
structure of the immunoglobulins, the variations observed in the residues occurring on the 
interface are also small. For each contact position a set of amino acids has been assigned 
according to the frequency of occurrence. The Table III-2 summarizes the data for mouse 
antibodies as given in http://www.cryst.bbk.ac.uk~ubcg07s/interface.html. A comparison of 
the VL and VH interface residues found in scFv P7278 with the list of conserved residues 
showed three differences at positions - L34, H35 and H95. Glutamate at L34 seems unique to 
this antibody, as it is also absent in the closest germline sequence. Residues H35 and H94 are 
the same as in the nearest germline sequence and could be ones that are not frequently 
encountered at the specified positions. 
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Table III-2: Comparison of the amino acids present at the VL/VH interface in scFv P7278 with the 
conserved residues assigned for each position.  
Residues marked with an asterix are core residues i.e. they form the core of the VL and VH inter-
face according to Chothia. Residues marked in bold are within the framework and the others are 
in the CDRs. 
Variable light chain 
Kabat 
position 
Conserved residues Residues in 
scFv P7278 
34 H678 N420 A408 Y147 E114 Q 
36 Y1653 F198 L96 Y 
38 Q1865 H47 Q 
44* P1767 V132 I40 P 
46 L1381 R374 P97 L 
87 Y1457 F448 Y 
89 Q1170 L206 F144 F 
91 W376 S364 G356 Y295 H182 G 
96* L537 Y380 W285 L 
98* F1724 F 
 
Variable heavy chain 
Kabat 
position 
Conserved residues Residues in 
scFv P7278 
35 H1001 N636 S402 E184 G 
37 V2336 I200 I 
39 Q2518 K67 Q 
45* L2636 P16 L 
47 W2518 L64 Y50 W 
91 Y2149 F479 Y 
93 A2202 T222 V102 V 
95 Y399 G375 S340 D340 R226 E 
100* F1285 M450 F 
103* W1469 W 
 
III.3.1.4 Reactivity of scFv P7278 with soluble LHRH 
Binding activity of the selected scFv P7278 with LHRH in solution was investigated by 
competition ELISA. ScFv P7278 was induced for expression (II.2.4.1) and two different 
dilutions of the bacterial supernatant containing the secreted scFv - 1:4 and 1:8 were used for 
the ELISA. Two fold serial dilutions of the peptide starting from 1µM were made while 
keeping the scFv concentration constant. The peptide scFv mixture was incubated at room 
temp for 15 minutes before applying it to an LHRH coated ELISA plate. On plotting the OD 
values at 405 nm versus the peptide concentration a typical inhibitory sigmoidal curve was 
obtained demonstrating that the scFv was able to bind the LHRH peptide in solution 
(Fig.III-10).   
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Fig. III-10: Competition ELISA with bacterial culture supernatant containing 
soluble scFv P7278.  
The clone scFv P7278 transformed into HB2151 was induced and the secreted scFv in the culture 
supernatant was tested for binding to LHRH peptide in solution. Two dilutions, 1:4 and 1:8, of the 
culture supernatant were used for the binding assay. The starting concentration of the LHRH 
peptide used for competition was 1µM. Serial dilutions of the peptide were made while keeping 
the scFv concentration constant. The bound scFv fragment was detected with 9E10 antibody that 
was in turn revealed by AP labelled GAM-Fc antibody.   
III.3.2 Cloning and characterisation of diabody P7278 
The VH domain of the scFv P7278 was reamplified with pHENII specific forward primer (M13 
Universe) and 3’ primer (RN8) designed to shorten the linker residues to 8 amino acids for 
construction of the diabody P7278 (II.2.2.10.2). The PCR amplification product was digested 
with restriction enzymes NcoI and AscI and cloned into pHEN4II vector containing 
scFv P7278, which had been digested to release the VH domain and linker sequence using the 
same enzymes. Sequence analysis of the plasmid DNA from 5 colonies confirmed the 
shortening of the linker fragment. Cloning strategy is depicted in Fig. III-11. 
The diabody P7278, secreted in the culture supernatant in a mini-scale expression study 
(II.2.4.1) showed binding to LHRH in direct ELISA (Fig. III-12). This result confirmed that 
the variable regions connected by the shortened linker could combine with another chain to 
form a functional bivalent antibody fragment.   
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Fig. III-11: Generation of the diabody P7278 construct. 
The VH domain of the scFv P7278 clone was amplified by PCR (II.2.2.10.2) using the 3´RN8 
primer and the 5´M13-Universe primer. The amplified VH fragment was digested with restriction 
enzymes NcoI and AscI and cloned into similarly digested scFv P7278 clone. The resulting diabody 
P7278 contained a shortened eight amino acid long linker between the heavy and light chain 
variable antibody domains.  
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Fig. III-12: Direct LHRH ELISA of soluble diabody P7278.  
Two-fold serial dilutions of the bacterial supernatant (II.2.4.1) were applied to ELISA plate coated 
with 1µg/ml LHRH peptide (II.2.3.5). 9E10 antibody was used as a primary antibody for detection 
of bound diabody. AP conjugated GAM-Fc antibody (0.12µg/ml) was used as the secondary 
antibody. Reactivity at 405 nm was measured after colour development at 37°C for 30 min in the 
presence of 1 mg/ml p-nitophenyl phosphate substrate in 0.1M sodium citrate buffer, pH9.8. 
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III.4 Bacterial expression of scFv P7278 and diabody P7278 
III.4.1 Cloning of scFv P7278 and diabody P7278 into the bacterial 
expression vector pSyn1 
The scFv and the diabody constructs of mAb P7278 were generated in the phagemid vector 
pHEN4II as the restriction sites incorporated by the primers used for amplification of the 
variable domain limited the choice to this vector. For further characterization of the rAbs, 
subcloning in a prokaryotic vector designed for expression and purification of soluble rAbs, 
was necessary. Therefore the scFv P7278 and diabody P7278 cDNA constructs, were subcloned 
into the prokaryotic expression vector, pSyn1 (AMERSDORFER et al., 1997) for targeted 
expression into the bacterial periplasm. The biochemical milieu in the periplasmic space of 
the E. coli promotes correct folding and formation of the intrachain disulphide bonds of the 
recombinant protein (GLOCKSHUBER et al., 1990). The targeting of the antibody to the 
periplasmic space was achieved by the amino terminal bacterial leader sequence – pelB, 
which is removed during secretion (LEI et al., 1987). The vector also had the necessary tags 
present on the carboxy terminal - His6 for IMAC purification (HOCHULI et al., 1988) and c-
myc tag as a marker for full-length expression (MARKS et al., 1991). The scFv P7278 and 
diabody P7278 cDNA fragments were isolated as NcoI and NotI fragments from pHEN4II. The 
1.2kb kanamycin gene present between the NcoI and NotI sites of pSyn1 vector was removed 
by digestion and the digested vector was ligated with similarly digested scFv P7278 and 
diabody P7278 cDNA fragments. The rAbs were cloned downstream to the pel B leader and 
upstream to the c-myc and His6 tags. The positive clones were identified by plasmid 
restriction of the transformed ligation product and named as – scFv-P7278/pSyn1 and 
diabody-P7278/pSyn1. 
III.4.2 Upscaled periplasmic expression of scFv P7278 
ScFv P7278 cloned into the pSyn1 bacterial expression vector was induced for expression in 
two E. coli strains HB2151 and TG1 (II.2.4.2) and purified by IMAC as described in II.2.4.3. 
The SDS-PAGE analysis of the purified scFv from the soluble periplasmic fraction of the 
bacterial cultures HB2151 and TG1 is shown in Fig. III-13 (a) and Fig. III-13 (b) respectively. 
The amount of scFv P7278 purified, from HB2151, was estimated to be 300µg of soluble scFv 
per litre of bacterial culture. The yields of scFv obtained from TG1 as compared to HB2151, 
keeping all the other experimental parameters constant, was at least twice as much. Analysis 
of the elution fractions by SDS-PAGE revealed a band of the expected size (~32kDa) as well 
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as other contaminating bands, the most prominent one
~28kDa in size. 
  1     kDa 1 2 M 3 4 5
 
 
 
 
 
                                         (a)                                                     
 
Fig. III-13: SDS-PAGE analysis of Ni-NTA affinity-p
The scFv P7278 cDNA cloned in pSyn1 vector was expres
induction with IPTG (II.2.4.2). The soluble scFv from the 
IMAC (II.2.4.3). Samples (10µl) from each purification step
PAGE gel and stained with Coomassie brilliant blue (II.2.3.1
induction; Lane 2: flow through of the sample applied to the 
Lane 4: second wash with PBS; Lane 5: scFv elution with PB
Molecular weight standard, 10µl Novex Mark 12. (b) Lane 
affinity column; Lane 2: flow through of the sample appli
PBS; Lane 4: scFv elution with PBS containing 250 m
standard, 10 µl Novex Mark 12. 
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(a)                                              
Fig. III-14: Stepwise elution of the scFv from the N
concentrations of imidazole. 
Periplasmic extract of the TG1 cells induced for expression
the Ni-NTA column (II.2.4.3). The column was extensively w
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A stepwise elution with increasing concentrations of imidazole (40 mM, 60 mM, 80 mM, 
100 mM and 250 mM) was performed and the fractions analysed by SDS-PAGE and Western 
blot (Fig. III-14). The elution profile was similar for all fractions. Most of the scFv eluted 
within the range of 40 – 80 mM imidazole along with the contaminating proteins. There was a 
significant enrichment of the scFv seen over the contaminants in the fraction eluted with 
80 mM imidazole, although there was a considerable loss of the protein in the earlier 
fractions. The Western blot analysis of the various elution fractions revealed a band at the 
expected size for the scFv (Fig. III-14b). None of the other proteins that co-eluted with the 
scFv were detected in the Western blot showing that the contaminants were not multimeric or 
degraded forms of the scFv but unrelated bacterial proteins. 
III.4.3 Upscaled expression and purification of diabody P7278  
The LHRH specific diabody P7278 cDNA, cloned in the bacterial expression vector pSyn1 was 
transformed in the E. coli strain TG1 and induced for expression (II.4.1). IMAC purification 
of the periplasmic fraction (III.4.3) resulted in an elution profile very similar to that seen for 
the scFv P7278. The diabody P7278 co-eluted with other contaminating proteins (Fig. III-15).  
The yield of the bacterially expressed diabody was estimated to be 500µg per litre of TG1 
bacterial culture. A step-wise elution of the diabody from the column with increasing 
concentrations of imidazole was tried in order to minimize the contaminants. But like for the 
scFv P7278 (Fig. III-14), there was not a significant improvement in the purity of the sample 
(data not shown).  
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Fig. III-15: SDS-PAGE analysis of affinity-purified diabody P7278. 
The diabody P7278 cDNA cloned in pSyn1 vector was expressed in TG1 by induction with IPTG 
(II.2.4.2). The diabody from the periplasmic fraction was purified by IMAC (II.2.4.3). Samples 
(10µl) at each purification step were separated on a 12% (w/v) SDS-PAGE gel and stained with 
Coomassie brilliant blue (II.2.3.1). Lane 1: supernatant after 3 h of induction; Lane 2: flow 
through of the sample applied to the column; Lane 3: first wash with PBS containing 10 mM 
imidazole; Lane 4, 5, 6, 7: elution fractions with PBS containing 250 mM imidazole; M: molecular 
weight standard, 10 µl Novex Mark 12. 
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III.5 Expression of scFv P7278 and diabody P7278 in plants 
III.5.1 Cloning of scFv P7278 and diabody P7278 into the plant expression 
vector pSSH1 
The scFv P7278 and diabody P7278 cDNA fragments were isolated by digestion with the 
restriction enzymes NcoI and NotI enzymes from pHEN4II and cloned into a similarly 
digested modified pGEM-3zf vector (CLh8466HP, kindly provided by Dr Carmen Vaquero). 
The pGEM-3zf vector was used to introduce the 5´untranslated region of the chalcone 
synthase (CHS) (VOSS et al., 1995) and the codon-optimised leader peptide of the heavy 
chain of the murine mAb24 (VOSS et al., 1995) to the N´ terminii of the cDNA encoding the 
scFv P7278 and diabody P7278. The scFv P7278 and diabody P7278 cDNA clones in pGEM-3zf 
were checked for the presence of correct insert and sequenced. Clones devoid of any PCR 
error were identified – scFv-P 278/pGEM and diabody-P7278/pGEM, and used for further 
cloning steps. 
7
CHS LPH scFv/ diabody His Pw
5´ 3´
Eco RI ATG Nco I Sal I Stop  Asc I
pGEM-3zf (CLh8466HP)
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pHEN4-II
Not I
5´
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Fig. III-16: Strategy for cloning the cDNA encoding the anti-LHRH scFv and 
diabody fragments into the plant expression vector pSSH1. 
LHRH-specific scFv and diabody genes were cloned in the pSSH1 vector for the expression and 
targeting of the rAbs to the plant endoplasmic reticulum. 35SS: Enhanced 35S promoter; CHS: 
5´untranslated region of the chalcone synthase; LPH: Plant codon optimised leaded sequence of 
the heavy chain of mAb24; His-6 tag: epitope for IMAC purification and detection; KDEL: ER 
retention signal peptide; Pw: 3´untranslated region from TMV; pA CaMV: Cauliflower mosaic 
virus termination signal. 
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The EcoRI/ SalI cDNA fragment containing the scFv P7278 and diabody P7278 together with 
the CHS and the LPL on the N´ terminal were excised from the scFv-P7278/pGEM and 
diabody-P7278/pGEM vectors and cloned into similarly digested pSSH1 plant expression vector 
(VOSS et. al., 1995). The fragments were inserted downstream from the enhanced 35SS 
promotor and upstream from the His6 tag, the ER retrieval signal sequence – KDEL 
(DENECKE et al., 1992), the 3´untranslated region from TMV (Pw) and the cauliflower 
mosaic virus termination region. The clones obtained by transformation of Agrobacteria were 
checked for the presence of the cDNA insert by colony PCR (II.2.2.8.2) with pSSH1 specific 
primers (II.1.8.9). Positive clones, one each for the scFv and the diabody, scFv-P7278/pSSH1 
and diabody-P7278/pSSH1, were used for the subsequent experiments. 
III.5.2 Purification of plant expressed scFv P7278 and diabody P7278 
Cultures of Agrobacteria transformed with scFv-P7278/pSSH1 and diabody-P7278/pSSH1 were 
grown and used for vacuum assisted agro-infiltration of Nicotiana tabacum leaves (II.2.5.2). 
Transient expression of scFv P7278 and diabody P7278 in tobacco leaves was confirmed by 
Western blot of total soluble leaf protein firstly in a small-scale (data not shown).  
Upscaled infiltration of tobacco leaves was performed for purification of the rAbs for further 
characterization. Upscaled expression differed from the small-scale only in the volume of 
Agrobacterial culture used and the amount of leaves infiltrated. Purification of the his6-tagged 
rAbs was performed by immobilized metal affinity chromatography (IMAC) using the Ni-
NTA matrix (II.2.5.3). SDS-PAGE of affinity purified rAbs revealed two closely spaced 
bands migrating at an apparent molecular mass of ~ 32 kDa, the expected size for correctly 
processed scFv and diabody (Fig. III-17). Yields for both scFv P7278 and diabody P7278, were 
estimated by BCA to be ~1mg per kg leaf material. 
Western blot analysis of both the plant purified scFv and the diabody was performed with 
antibodies specific to both the tags present at the 3´ terminal of the rAbs i.e. the His6 tag 
followed by the KDEL motif (Fig. III-18). Two closely spaced bands were seen when the 
anti-His6 antibody was used for detection. The lower band of the two was not detected when 
KDEL specific antibody was used for analysis. This indicates the absence of the KDEL tag in 
the lower band. The difference in mobility observed between the scFv and the diabody in the 
Western blot is due to the different linker lengths of the two rAbs. 
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Fig. III-17: SDS-PAGE analysis of Ni-NTA purified scFv P7278 and diabody P7278 
from tobacco leaves. 
Samples at each purification step of the scFv P7278 and diabody P7278 (II.2.5.3) were analysed on a 
12% SDS-PAGE gel and stained with Coomassie brilliant blue (II.2.3.1).   
(a) Purification of scFv P7278 Lane 1: 10 µl of total soluble protein extracted from the infiltrated 
tobacco leaves (II.2.5.3); Lane 2: 10 µl of flow through from the Ni NTA column to which the 
plant extract was applied; Lane 3: 10 µl of column wash samples; Lane 4: 5 µl of the 1st elution; 
Lane 5: 5 µl of the 2nd elution; M: Molecular weight standard, 10 µl Novex Mark12. 
(b) Purification of diabody P7278 Lane 1: 10 µl of total soluble protein extracted from the 
infiltrated tobacco leaves (II.2.5.3); Lane 2 and 3: 10 µl of flow through from the Ni NTA column 
to which the plant extract was applied; Lane 4: 10 µl of column wash samples; Lane 5, 6, 7: 5 µl 
of the 1st, 2nd, and 3rd elutions respectively; M: Molecular weight standard, 10 µl Novex Mark12. 
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Fig. III-18: Western blot analysis of the plant purified scFv P7278 and diabody P7278.  
The purified rAbs (II.2.5.3) were separated on a 12% SDS-PAGE gel and blotted onto 
Immobilion-P membrane for Western blot analysis (II.2.3.2). Lane 1: diabody detected by mouse 
anti-KDEL antibody; Lane2: scFv detected by mouse anti-KDEL antibody; M: pre-stained protein 
marker; Lane 3: scFv detected by mouse anti-His6 antibody; Lane 2: diabody detected by mouse 
anti-His6 antibody. AP labelled GAM-Fc antibody was used as the secondary antibody. 
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III.5.3 Size exclusion chromatography of purified scFv and diabody P7278  
Size exclusion chromatography of the plant derived and purified scFv P7278 and diabody P7278 
was performed to determine the size and the oligomerisation state of the antibody fragments 
(II.2.3.6). Proteins of known molecular weight were run as standards. A calibration curve was 
prepared by plotting the logarithms of the known molecular weights of protein standards 
versus their respective Ve/Vo values (Ve is the elution volume and Vo is the void volume). 
Molecular weight determination of the scFv P7278 and diabody P7278 were made by comparing 
their Ve/Vo ratio with the Ve/Vo of the protein standards. Elution was monitored by UV 
absorption at 280nm.  
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Fig. III-19: Size exclusion chromatography of Ni-NTA affinity purified scFv P7278 
and diabody P7278 expressed in tobacco leaves.  
ScFv and diabody P7278 was purified via IMAC (II.2.5.3) and analyzed after dialysis on a 
calibrated Superose 12 HR 10/30 column (II.2.3.6). The scFv eluted as two major peaks at 14.60 
and 16.43, corresponding to the monomeric (~27kDa) and dimeric (~54kDa) forms of the antibody 
fragment. The diabody eluted as a single peak at 14.60, corresponding to the molecular weight of 
~54kDa. The protein standards of known molecular weight that were used for preparing the 
calibration curve are also shown. The column was equilibrated in PBS, pH7.4 and the flow rate 
was maintained at 0.5 ml/min.          
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Fig. III-19 shows the gel filtration analysis of scFv and diabody P7278.  The elution profile of 
scFv P7278 showed two peaks with retention volumes of 14.60 ml and 16.43 ml corresponding 
to a molecular weight of ~54 kDa and ~27 kDa respectively. This showed that the scFv 
existed in a monomeric as well as a dimeric form. The dimeric form constituted nearly 40% of 
the scFv population as is evident from the intensity of the peaks. The protein preparation used 
for this analysis was stored at 4°C for about 6 months. 
The elution profile of the diabody P7278 showed a single peak with a retention volume of 
14.60 ml corresponding to a molecular weight of ~54kDa. The protein peak was symmetric 
indicating the uniformity and integrity of the diabody. There was a small shoulder seen with a 
retention volume between 15.5 ml and 16 ml, which could be a result of a very small 
population of degraded form of the diabody or some impurity. The protein preparation used 
for this analysis was stored at 4°C for about one year demonstrating that the diabody P7278 
remains stable under such conditions. 
III.6 Generation of LHRH specific chimeric rAb P7278 
III.6.1 Assembly of the heavy and light chains of chimeric rAb P7278 
The VL and the VH domains of the scFv P7278 were combined with the human kappa and IgG1 
constant regions respectively by SOE-PCR to form the chimeric heavy and light chain genes. 
The chimeric heavy and light chain genes were assembled by a 3-step PCR. Firstly the VL, 
VH, CH (constant region of human IgG1) and CL (constant region of human kappa chain) gene 
fragments were amplified and appropriate flanking sequences (restriction enzyme sites and 
overlapping regions) were introduced by the primers. 
The variable regions were amplified using the recombinant plasmid scFv-P7278/pHEN4II . The 
sense primer used for the PCR included an NcoI site preceding the sequence encoding the first 
residue of FR1 and an antisense SOE primer containing the first few nucleotide residues of 
the corresponding constant regions (II.1.8.7). The constant regions were amplified from the 
plasmids chiB72.3L and chiB72.3H (PRIMUS et al., 1990). The sense primer used for the 
amplification of the kappa and IgG1 constant regions contained the last few nucleotide 
residues of the VL and the VH respectively and the antisense primers contained a SalI site 
immediately following the last residue of the constant regions (II.1.8.7).   
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Fig. III-21: Schematic representation of the assembly of the chimeric light and 
heavy chains by SOE PCR. 
VH = variable domain of heavy chain; VL = variable domain of light chain; CH = constant region of 
human IgG1; CL = constant region of human kappa light chain. 
In the amplification reaction for incorporation of the splice sites in the variable and constant 
domains, Pfu high fidelity Taq DNA polymerase was used. The reason for using this enzyme 
was that the fragments when amplified with Taq DNA polymerase failed to splice in the SOE 
PCR step. Taq DNA polymerase is known to possess a terminal transferase like activity due 
to which the enzyme often adds a non-template adenosine nucleotide on the 3´end of the 
amplimers (HU, 1993). This additional adenosine nucleotide must have interfered with the 
extension step in the SOE PCR where the amplified variable and constant gene fragments 
anneal together to form the complete chimeric chain. The Pfu DNA polymerase instead has a 
3´-5´exonuclease activity that removes any non-template addition of nucleotide from the 
3´end of the sequence. The first PCR generated the products of the following sizes: VH - ~450 
bps; CH - ~1000 bps; VL – ~350 bps; CL - ~350 bps (Fig. III-22; Lanes 1, 2, 4 and 5). The size 
of the VH is bigger than expected (360 bp) as the forward primer (M13 Universe) used for the 
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amplification anneals to the vector backbone ~100 bp upstream to the start of the 
variable region.      
Secondly equimolar amounts of the amplified VH/ CH and VL/ CL fragments were mixed and 
subjected to five rounds of SOE PCR (II.2.2.10.3). Since the 3´regions of the variable 
domains and the 5´regions of the constant domains have complementary sequences due to the 
amplification by the SOE primers, annealing and subsequent extension yields one piece of 
DNA encoding the chimeric light or the heavy chains. 
Thirdly the SOE-PCR products from the second step were amplified in order to get sufficient 
product to facilitate cloning. The SOE PCR product of the VH and CH mix, the chimeric heavy 
chain, was amplified in the presence of the VH sense and CH antisense primers, while the PCR 
product of the VL and CL mix, the chimeric light chain was re-amplified using the VL sense 
and CL antisense primers. A single product was generated for each PCR. The chimeric heavy 
chain (P7CHC) was  ~ 1400 bps and the chimeric light chain (P7CLC) was ~ 700 bps long 
(Fig. III-22: Lanes 3 and 6). 
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Fig. III-22: Analysis of the assembled heavy and light chimeric chains by agarose 
gel electrophoresis. 
The variable region of the heavy chain of the mouse mAb P7278 (lane 1; ~450 bp) and the constant 
region of the human IgG1 chain (lane 2; ~ 1000 bp) were spliced to give the mouse/human 
chimeric heavy chain (lane 3; 1400 bp). Similarly the variable region of the light chain of the 
mouse mAb P7278 (lane 4; ~350 bp) and the constant region of the human kappa chain (lane 5; ~ 
320 bp) were spliced to give the mouse/human chimeric light chain (lane 6; 700 bp). M: 100 bp 
DNA marker. 
III.6.2 Cloning of the chimeric rAb P7278 into the plant expression 
vector pSSHI 
The SOE-PCR assembled chimeric heavy and light chains flanked by a 5´NcoI site and a 
3´SalI site (III.6.1) were gel-purified and subsequently digested with SalI and NcoI restriction 
enzymes. The digested DNA was gel-purified and ligated into a modified pGEM-3zf vector. 
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The pGEM-3zf vector was used to introduce the 5´untranslated region of the chalcone 
synthase (CHS) and the codon-optimised leader peptide of the light chain of the murine 
mAb24 to the N terminal of the chimeric heavy and light chains. The chimeric heavy and light 
chain clones in pGEM-3zf were checked for the presence of insert and sequenced. The clones 
devoid of any PCR error were identified and termed – CHC-P7278/pGEM and CLC-
P7278/pGEM and then used for the further cloning steps. 
The EcoRI/SalI gene fragment containing the chimeric heavy and light chains spliced with the 
CHS and the LPL on the N´ terminal was excised from the CHC-P7278/pGEM and CLC-
P7278/pGEM vectors and cloned into similarly digested pSSH1 plant expression vector. The 
fragments were inserted downstream from the enhanced 35S promotor and upstream from the 
KDEL, the ER retrieval signal sequence, the 3´untranslated region from TMV (Pw) and the 
cauliflower mosaic virus poly-adenylation and termination region (pA). The clones obtained 
by transformation of Agrobacteria were checked for the presence of the cDNA insert by 
colony PCR (II.2.2.8.2). Individual positive clones, one each for the heavy and light chains, 
CHC-P7278/pSSH1 and CLC-P7278/pSSH1, were used for the subsequent experiments. 
Chimeric heavy and light chains devoid of the KDEL tag were created by digesting the CHC-
P7278/pSSH1 and CLC-P7278/pSSH1 clones with SalI and XhoI, the restriction sites flanking the 
KDEL motif. As both enzymes are isochizomers the DNA overhangs religated and yielding 
the whole expression cassette except the KDEL motif. The transformed bacterial colonies 
housing the pSSH1 plasmid containing the chimeric heavy and light chains without the KDEL 
tag, when digested with SalI, failed to linearise confirming the removal of the KDEL tag (data 
not shown). Sequence analysis of the clones pSSH1-P7CHC∆K and pSSH1-P7CLC∆K re-
confirmed the absence of KDEL. Although digestion with SalI and XhoI restriction enzyme 
removed the linker and the KDEL tag three amino acids are added to the end of the construct, 
two from the restriction site (Val and Glu) and the third (Gly) because the stop codon doesn’t 
directly follow the XhoI site (see nucleotide sequence in Fig. III-23). 
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Fig. III-23: Strategy for cloning the chimeric heavy and light chains into the plant 
expression vector pSSH1. 
The P7CHC and P7CLC cDNAs were cloned from the (a) pGEM-3zf into the pSSH1 plant 
expression vector for targeting to the (b) ER and (c) to the apoplasm. The nucleotide sequence 
spanning the 3´cloning site and the stop codon is delineated. 35SS: enhanced 35S promoter; CHS: 
5´untranslated region of the chalcone synthase; LPL: plant codon optimised leaded sequence of 
the light chain of mAb24; KDEL: ER retention signal peptide; Pw: 3´untranslated region from 
TMV; pA CaMV: Cauliflower mosaic virus termination signal.    
III.6.3 Small scale transient expression of the chimeric rAb P7278 
A small-scale pilot study was carried out for the expression of the chimeric antibody targeted 
to the ER. Agrobacterial strains containing the chimeric heavy (CHC-P7278/pSSH1) and the 
light chains (CLC-P7278/pSSH1) were co-infiltrated as well as infiltrated separately into 
tobacco leaves (II.2.5.2). Western blot analysis (II.2.3.2) and ELISA (II.2.3.5) were 
performed with the extracts from the infiltrated tobacco leaves.  
Western blot analysis of the plant extract from leaves infiltrated with CHC-P7278/pSSH1 
cDNA construct revealed a ~53 kDa band and for the leaves infiltrated with the CLC-
P7278/pSSH1 cDNA construct a ~25 kDa band was detected.  For the co-infiltrated leaves, 
bands corresponding to both the heavy and the light chimeric chains were observed. Mouse 
anti-KDEL antibody was used as the detection antibody (data not shown). 
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The extracts from the leaves infiltrated with the chimeric heavy and light chains separately 
and from the leaves co-infiltrated with both the constructs was applied on ELISA plates 
coated with LHRH and goat anti-human antibodies against Fc and Fab fragments. The 
controls used for this experiment were polyclonal human IgG and non-infiltrated SR1 leaves 
(Fig. III-24).  
On GAH-Fc coated ELISA plates binding activity was observed with the plant extract from 
the leaves singly infiltrated with the chimeric heavy chain, leaves co-infiltrated with both the 
chains and the polyclonal human IgG antibodies. For the GAH-F(ab´)2 coated plates binding 
activity was observed for co-infiltrated leaves, polyclonal human antibodies and for the leaves 
infiltrated with the light chain. Low binding signals observed for the heavy chain infiltrated 
leaves was probably because of the cross reactivity of the GAH-F(ab´)2 antibody with the CH1 
constant domain of the antibody heavy chain. 
For the ELISA performed on LHRH coated plates, binding activity was only observed with 
the plant extract of the leaves co-infiltrated with both the chimeric heavy and light chains 
constructs, indicating the presence of functionally assembled anti-LHRH chimeric antibody. 
No binding activity was observed in leaf extracts infiltrated with the heavy or the light chain 
alone and for the polyclonal human IgG and wild type SR1.     
GAH-Fc GAH-Fab LHRH 
0
1
2
3
4
O
D
 40
5 
nm
 Heavy
 Light
 Heavy+Light
 Human IgG
 Negative
 
Fig. III-24: Analysis of total soluble proteins extracted from the infiltrated tobacco 
leaves by ELISA. 
Extracts from the infiltrated leaves (II.2.5.2) were applied to ELISA plates coated with GAH-Fc, 
GAH-Fab and LHRH (II.2.3.5) and the detection antibodies used were AP conjugated GAH-Fc, 
AP conjugated GAH-F(ab´)2 and AP conjugated GAH-Fc antibody (0.12µg/ml) respectively. 
Heavy: TSP extracted from leaves infiltrated with pSSH1-P7CHCK; Light: extracts from leaves 
infiltrated with pSSH1-P7CLCK; Heavy + Light: Extracts from leaves co-infiltrated with pSSH1-
P7CHCK and pSSH1-P7CLCK; Human IgG: purified polyclonal human antibodies; Negative: non-
infiltrated SR1. OD values of 1:50 dilution of the extract for all samples are depicted after 30 min 
p-nitrophenyl phosphate substrate development.  
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III.6.4 Comparison of expression levels of chimeric rAb P7278 directed to 
the ER and to the apoplasm 
The plant expression constructs of the chimeric heavy and light chains with and without 
KDEL were transiently expressed in tobacco leaves (II.2.5.2). Expression levels of the two 
antibody variants were compared by applying the extracts from the leaves co-infiltrated with 
chimeric heavy and light chains with and without KDEL on LHRH coated ELISA plate.  
The expression level of the chimeric antibody in the two cellular compartments - the 
endoplasmic reticulum or the apoplasm was found to be similar with no pronounced 
differences (Fig. III-25). 
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Fig. III-25: Direct ELISA of extracts from leaves expressing the chimeric heavy and 
light chains with and without KDEL motif. 
Serial dilutions of the extracts from the infiltrated leaves were applied to LHRH coated ELISA 
plates (II.2.3.5). The chimeric antibody P7278 both with and without KDEL tag were detected by 
the AP labelled GAH-Fc antibody (0.12µg/ml). (b) a plot of the normalised slopes of the linear 
range of each curve shown in (a).  
III.6.5 Purification and characterisation of ER retained chimeric rAb P7278 
Chimeric anti-LHRH antibody was purified from 1 kg of tobacco leaves infiltrated with equal 
amounts of Agrobacterium cultures carrying independently the chimeric heavy and light chain 
expression cassettes in the pSSH1 plant expression vector. Extract was prepared from the 
infiltrated leaves and used for affinity purification of the chimeric antibody on a Protein A 
column (II.2.5.3). The bound antibodies were eluted from the column with 100 mM Glycine 
buffer, pH 2.0. On neutralization of the eluted fractions with 1M Tris a cloudy precipitate was 
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observed. The precipitates were removed by centrifugation and the elution fractions were 
dilaysed overnight against PBS, pH7.4. The purified chimeric antibody was analysed by SDS-
PAGE, Western blotting and ELISA.   
SDS-PAGE analysis of the chimeric anti-LHRH antibody revealed two distinct bands of 
approximately 53 and 26 kDa corresponding to the heavy and light chimeric chains (III-13). 
An equivalent molar ratio of the light and heavy chimeric chains was estimated. The eluted 
sample had minor impurities as seen in the SDS gel (Fig. III-26).  
The white coloured precipitate observed on neutralization of the eluate was removed by 
centrifugation and analysed by SDS-PAGE. The precipitate ran as a smear (data not shown). 
Although two protein bands corresponding to the size of the heavy and light chimeric chains 
were also observed, the amounts were nominal. The precipitates could have either been 
genomic DNA, lipids, or plant polysaccharides that could not be washed away from the 
Protein A column prior to antibody elution. 
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Fig. III-26: SDS-PAGE analysis of plant purified chimeric rAb P7278.  
Samples at each Protein A purification step of the chimeric antibody (II.2.3.5) were analysed on a 
12% (w/v) SDS-PAGE gel and stained with Coomassie brilliant blue (II.2.3.1).  Lane 1: 10 µl of 
total soluble protein extracted from the infiltrated leaves; Lane 2 and 3: 10 µl of flow through from 
the Protein A column to which the plant extract was applied; Lane 4 and 5: 10 µl of column wash 
samples; Lane 6: 5 µl of the 1st elution; Lane 7: 5 µl of the 2nd elution; Lane 8: 5 µl of the 3rd 
elution; M: 10 µl Novex Mark12. 
In a separate experiment, plant extract from 700 grams of infiltrated leaf material was 
processed as described in II.2.5.3, except that at the step where the pH of the extract is 
increased to 8 and the extract incubated at 4°C for 30 min, the extract was divided into two 
halves. Keeping everything the same, to one part of the plant extract 100 mM NaCl was 
added. The two halves of the extract were then processed in a similar way. The bound 
antibodies after elution were analysed on SDS-PAGE (Fig. III-27). The amount of antibody 
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obtained from the part to which no extra salt was added was about 10 fold higher than the one 
in which the salt was added as estimated from the SDS-PAGE analysis. Thus the addition of 
extra salt to plant extract for purification is contraindicated for the anti-LHRH full-length 
chimeric antibody. Western blot analysis of the plant purified chimeric antibody was 
performed for detection of any degradation products. Two distinct bands were observed for 
the light chain when GAH antiserum was used as the detection antibody whereas only one 
band for the light chain was observed when anti-KDEL antibody was used for detection 
(Fig. III-28). 
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Fig. III-27: Influence of salt concentration (100 mM NaCl) on chimeric rAb 
P7278 yields. 
The SDS-PAGE (II.2.3.1) shows the Protein A purification profiles of two parallely-processed 
plant extract halves the only difference being in the salt content. Lanes 5, 6 and 7: elution fractions 
1, 2 and 3 from the plant extract half to which 100 mM NaCl was added before application to the 
column. Lanes 3, 2 and 1: elution fractions 1, 2 and 3 of the plant extract half in which no 
additional salt was present. M: 10 µl Novex Mark12. 
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Fig. III-28: Western blot analysis of the plant purified chimeric rAb P7278. 
The Protein A purified chimeric antibody (II.2.5.3) was separated on a 12% (w/v) SDS-PAGE gel 
and blotted onto Immobilion-P membrane for Western blot analysis (II.2.3.2). Lane 1: Chimeric 
antibody detected by mouse anti-KDEL antibody followed by AP labelled GAM-Fc antibody; 
Lane2: chimeric antibody detected by AP labelled GAH-Fc and GAH-Fab antibody; M: Pre-
stained protein marker. 
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The binding activity of the purified chimeric anti-LHRH antibody to LHRH was tested by 
direct ELISA (II.2.3.5). The purified antibody was applied to LHRH coated ELISA plate 
starting from a 1:40 dilution (Fig. III-29).  The purified chimeric antibody exhibited high 
binding activity to LHRH. 
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Fig. III-29: Binding activity of the plant purified chimeric rAb P7278 as deter-
mined by ELISA. 
Two-fold serial dilutions starting from 160 ng/ml of the purified chimeric antibody was applied on 
LHRH coated ELISA plate (II.2.3.5). The AP labelled GAH-Fc antibody was used for detection of 
the recombinant antibody. Reactivity was colourimetrically measured at 405 nm after addition of 
1mg/ml p-nitophenly phosphate substrate for 30 minutes at 37°C.   
III.6.6 Variation in the amount of purified chimeric rAb P7278 from 
batch to batch  
Three large-scale Agro-infiltration experiments were performed for purification of chimeric 
rAb P7278 . The amount of leaf material used in each experiment amounted to approximately 1 
kg. The concentration of the purified chimeric antibody for each case was determined by BCA 
(II.2.3.4). The amount of the purified antibody determined for the three purifications was - 7 
mg, 4.5 mg and 3 mg, demonstrating the variation inherent to this procedure. 
III.6.7 Expression of chimeric rAb P7278 in plant species other than 
Nicotiana tabaccum cv. Petit Havanna SR1 
The chimeric anti-LHRH antibody was transiently expressed in the leaves of a few commonly 
available plant species in Germany (spinach, lettuce, butterhead lettuce, spinach beet, green 
squash and pumpkin) and a variety of tobacco - blooming tobacco. All the plants were grown 
in the greenhouse under similar conditions as used for growing SR1 (II.2.5.1). The same 
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experiment was also performed with some plant species that commonly grow in India 
(spinach, brinjal, bittergourd, ladyfinger, beans, sunflower and a gourd).  
Four leaves from each plant species were co-infiltrated with Agrobacterium strains containing 
pSSH1-P7CHCK and pSSH1-P7CLCK vectors. Extracts from the infiltrated leaves were 
applied on LHRH coated ELISA plates. Expression of the chimeric rAb P7278 in SR1 was 
used as a standard for comparison of the expression levels obtained in the various 
plant species. 
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(a)                                                                              (b) 
Fig. III-30: Comparison of expression levels of chimeric rAb P7278 in plant species 
found in Germany. 
(a) Total leaf extracts from leaves of different plant species co-infiltrated (II.2.5.2) with heavy and 
light chain genes of chimeric rAb P7278 were applied to LHRH coated ELISA plate (II2.3.5). The 
chimeric rAb P7278 was detected by the AP labelled GAH-Fc antibody (0.15µg/ml). (b) The linear 
fit of each curve in graph-a was normalised with respect to the maximum value obtained and 
plotted as relative reactivity. 
In the experiment carried out in Aachen, Germany the expression level of the chimeric 
antibody in Green Squash (Zucchini) was comparable to the expression in SR1. Intermediate 
expression levels were observed in pumpkin, spinach beet and blooming tobacco while 
negligible expression of the chimeric antibody was seen in the salads and the variety of 
spinach used (Fig. III-30). 
In the study carried out in Delhi, India the expression of the chimeric chains in SR1 was the 
highest while the Indian varieties of bitter gourd, brinjal and spinach showed intermediate 
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levels of expression while expression levels in the other plant varieties tested was negligible 
(Fig. III-31). 
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Fig. III-31: Comparison of expression levels of chimeric rAb P7278 in plant species 
found in India.  
(a) Protein extracts from leaves of different plant species co-infiltrated (II.2.5.2) with chimeric 
heavy and light chain genes were applied to LHRH coated ELISA plates (II2.3.5). The chimeric 
antibody P7278 was detected by the AP labelled GAH-Fc antibody (0.15µg/ml). (b) The linear fit of 
each curve in graph-a was normalised with respect to the maximum value obtained and plotted as 
relative reactivity. 
III.7 Generation and screening of stable transformed tobacco plants 
expressing chimeric rAb P7278  
III.7.1 Generation of non-segregating transgenic tobacco lines 
The heavy and light chains of chimeric rAb P7278 targeted for expression in the ER, were 
stably transformed into N. tabacum cv. Petite Havana SR1 by Agrobacterium mediated gene 
transfer (II.2.6.1). Regenerated plants for each of the two constructs were screened for 
accumulation of recombinant protein by dotblot analysis of the crude extract of the total 
soluble leaf protein (II.2.3.3). Being the T0 generation, expression of the chimeric antibody 
chains was observed in almost all the lines although the expression levels varied from plant to 
plant (Fig. III-32). For each of the two chimeric antibody chains, seven high expressing 
tobacco plants (H5, H13, H16, H49, H67, H78, H92 and L2, L5, L15, L41, L,45, L47, L60) 
were selected and self-fertilized for establishment of homozygous lines (II.2.6.2). 
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Fig. III-32: Dotblot analysis of transgenic tobacco T0 lines individually expressing 
heavy and light chains of the chimeric rAb P7278.  
Expression levels of the heavy and light chains of the chimeric rAb P7278 in transgenic tobacco 
plants were analysed by spotting 10 µl of the leaf extract diluted 1:10 times in PBS on the 
nitrocellulose membrane (II.2.3.3). 93 plants transformed (II.2.6.1) with chimeric heavy chain 
(H1-H93) were analysed. The detection antibody used was AP labelled GAH-Fc. 65 lines of the 
chimeric light chain (L1-L65) were analysed. For detection of the blotted Protein AP labelled GAH-
Fab antibody was used. The plants numbered in red were selected for self-fertilisation for 
propagation of the T1 generation (II.2.6.2). 
The seeds from each of the 14 selected T0 plants were sown on MSIII plates (III.7.1). Ten 
regenerated plants from each cross were transferred to soil in the greenhouse. The plants were 
screened for accumulation of recombinant protein by dot blot analysis of the crude extract of 
the total soluble leaf protein (II.2.3.3). For some of the lines similar protein expression levels 
were seen in all ten plants. While for others expression levels varied amongst the offsprings 
with some plants demonstrating protein levels below detection limits (Fig.III-33). Further 
screening for establishment of homozygous lines is ongoing. 
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Fig. III-33: Dotblot analysis of T1 generation of transgenic tobacco lines expressing 
heavy and light chains of the chimeric rAb P7278.  
Expression levels of the heavy and light chains of the chimeric rAb P7278 in transgenic tobacco 
plants were analysed by spotting 10 µl of the leaf extract diluted 1:10 times in PBS on the 
nitrocellulose membrane (II.2.3.3). Ten plants from each of the seven lines (Fig. III-44) selected as 
the best expressers of the chimeric heavy chain (H13, H5, H16, H49, H67, H78 and H92) and light 
chain (L59, L2, L41, L47, L60, L5 and L15) were analysed. AP labelled GAH-Fc was used for the 
detection of the former while AP labelled GAH-Fab antibody was used for detection of the latter 
recombinant antibody chain.  
III.7.2 Analysis of accumulation levels of chimeric rAb P7278 in progeny 
resulting from a cross between the T0 generation plants 
Some of the T0 tobacco lines accumulating high levels of the chimeric heavy chains were 
crossed with lines accumulating high levels of the chimeric light chain. The seeds resulting 
from these crosses were germinated and the progeny analysed for the expression of both the 
genes i.e. the presence of full-length chimeric rAb P7278. As both parents for the cross were 
tested to be positive for expression of the respective chains before crossing (the plants marked 
in red in Fig. III-32), 25 % of the progeny were expected to express the full-length chimeric 
rAb P7278 assuming single integration sites for both parental lines. Twenty plants from each of 
the six crosses were analysed for expression of the chimeric rAb P7278 by direct LHRH 
ELISA (Fig. III-34). The percentage of positive plants for five of the six crosses averaged to 
21 %, while in one of the crosses (Cross B) there was only one plant positive out of the 20. 
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Fig. III-34: Analysis of the progeny of six crosses made between transgenic tobacco 
T0  plant lines expressing the heavy and light chains of chimeric rAb P7278. 
Twenty transgenic plants from each cross were analysed for the expression of full-length chimeric 
rAb P7278 by direct LHRH ELISA (II.2.3.5). Leaf extracts from each plant was diluted 1:10 in 
PBS and applied onto LHRH coated ELISA plate and detected with AP labelled 
GAH-Fc antibody.  
Sixteen plants identified to be positive for the expression of chimeric rAb P7278 by ELISA 
were also analysed for the levels of chimeric antibody expression by surface plasmon 
resonance using the BIAcore. The plant extracts were diluted (1:10) in HBS buffer and 
applied onto the BIAcore over a D-Lys6-LHRH coated sensor chip. A known amount of 
purified chimeric rAb P7278 antibody applied onto the antigen-coated chip served as the 
standard sample. The amount of functional anti-LHRH antibody present in the plant extract 
was calculated from the slopes of the binding curves and is represented in Fig. III-35. The 
average yield of antibody was determined to be 16 mg per kg of fresh leaf material, at least 
twice more than the amount of antibody obtained from transient expression (III.6.5).  
Western blot analysis of the 16 plants selected for the BIAcore analysis was also carried out. 
Anti-KDEL antibody was used for detection of the chimeric antibody chains to observe the 
difference in expression levels of the two (Fig. III-36). In most of the plants analysed the 
levels of accumulation of the heavy chain were similar. A wide difference was observed for 
the chimeric light chain accumulation levels, which ranged from negligible amounts to nearly 
similar levels as the heavy chain. The plants in which equal ratios of the two chimeric chains 
were observed are currently being used for anther culture for obtaining homozygous lines 
expressing high level of the full-length chimeric mAb P7278.      
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Fig. III-35: Estimation of accumulation levels of chimeric rAb P7278 in sixteen 
transgenic plants identified to be positive for the presence of the antibody by ELISA.  
Sixteen of the 125 plants that were tested by ELISA (II.2.3.5, Fig. III-46) for conformation of the 
presence of chimeric rAb P7278 were analysed by SPR (II.2.7.2) for protein accumulation levels. 
Plant extract diluted 1:10 in HBS was passed over a D-Lys6-LHRH coated sensor chip for 
measurement of active chimeric antibody by SPR. The corresponding ELISA result obtained on 
applying the plant extract onto LHRH coated ELISA plate and detected with AP labelled GAH-Fc 
antibody is also shown. 
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Fig. III-36: Western blot analysis of the plant
presence of the chimeric rAb P7278. 
The total plant extract of the 16 plants analysed by SPR a
12% (w/v) SDS-PAGE gel and blotted onto Immobilion
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III.8 Affinity determination of LHRH specific antibodies  
The equilibrium constants of the mouse mAb P7278 and the chimeric rAb P7278 were measured 
by means of competition experiments using BIAcore. The measurements for the competition 
assays were made on a high capacity binding surface prepared by immobilising D-Lys6-
LHRH on the carboxymethly-dextran surface. The peptide was immobilised by standard 
amine coupling procedure as described in section II.2.7.1. 
Serial dilutions starting from 5µg/ml concentration of chimeric rAb P7278 were injected over 
the chip immobilised with D-Lys6-LHRH to obtain the dose response curves. For each of the 
sensogram the binding rates and the endpoints were recorded and plotted against the antibody 
concentration. The calibration curves for both the endpoint response and the slopes showed a 
linear behaviour (Fig. III-37).  
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Fig. III-37: Calibration curve for the determination of endpoint response and slopes.  
The binding rates and the endpoint response of a series of sensograms (II.2.7.2) obtained by serial 
dilution of the chimeric rAb P7278 when plotted against the antibody concentration exhibit 
a linear response. 
The concentration of the antibody to be used for the inhibition assays was determined by the 
calibration curves, as it was important to know whether the signals generated by the antibody 
concentration used for the assay would be measurable. Inhibition experiments were set up 
with varying antibody concentrations. The antibody concentration chosen were 2µg/ml, 
0.5µg/ml and 0.125µg/ml. Inhibition studies were carried out by co-incubation of a constant 
amount of antibody with decreasing amounts of LHRH, starting from 1µM, o/n at 25°C prior 
to injection. After the o/n incubation, the equilibrium mixtures were injected over the sensor 
surface immobilised with the D-Lys6-LHRH.  The binding signals obtained were a measure of 
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the antibodies present in the equilibrium mixtures having one or both antibody binding sites 
free. The concentration measurements were performed under mass transport limitation (MTL 
= 0.86). The determined binding rates were plotted against the concentration of the added 
peptide. The inhibitory constant Ki and the concentration of the chimeric antibody were 
determined by non-linear least square fit using the Origin software and the equation:  
[ ] ( ){ }  ⋅⋅−+⋅+−+⋅+⋅⋅−⋅= 2220  822 16 11 totaltotaltotaltotalitotaltotalItotal CLLCKLCKCmm
where,  
m = observed binding rate; m0 = observed binding rate without peptide; Ctotal  = total 
antibody concentration; Ltotal  = total LHRH concentration; Ki = inhibitory constant 
The KI value of the chimeric rAb P7278 determined by inhibition in solution for all three 
competition assays using varying amounts of antibody concentration was determined to be -
 3.4⋅10-10 M-1 (Fig. III-38).   
10-10 10-9 10-8 10-7 10-6
0.0
0.2
0.4
0.6
0.8
1.0  
 Ab conct.    9.3634E-10
Kinhibition        3.238E-10
Ab conct.   1.4772E-8
Kinhibition      3.0905E-10
Ab conct.    3.8269E-9
Kinhibition       3.9705E-10
m
/m
0
LHRH concentration [M]  
 
Fig. III-38: Determination of the inhibitory constant of the chimeric rAb P7278. 
For each concentration of the chimeric rAb P7278 used, the values of the relative slopes (m/m0) of 
the sensograms (II.2.7.2) obtained from the inhibition experiments were plotted against the 
inhibitor concentration and fitted by non-linear curve fitting to obtain the value of KI.    
Two different concentrations of mouse mAb P7278 – 0.125 µg/ml and 0.25 µg/ml were used 
for setting up the competition assay for determining the KI The starting concentrations of the 
LHRH peptide for the assays for antibody concentrations 0.125 µg/ml and 0.250 µg/ml were 
10-7 M and 10-6 M respectively. After incubation of the samples overnight the free antibody at 
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each peptide dilution was measured by injecting the sample over a high capacity surface 
coated with D-Lys6-LHRH. The slope of each of the sensogram was plotted against the 
peptide concentration in that sample.  
The inhibitory constant KI and the concentration of the murine monoclonal antibody were 
determined by non-linear least square fit using equation 1. The average value of inhibitory 
constant obtained from the two measurements was determined to be - 3.5⋅10-10 M-1 (Fig. III-39). 
Within experimental limits, the KI of the plant expressed chimeric rAb P7278 (3.4⋅10-10 M-1) 
and the parental mouse mAb P7278 (3.5⋅10-10 M-1) were found to be indistinguishable. 
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Fig. III-39:  Determination of the inhibitory constant of the mouse mAb P7278. 
For each concentration of the mouse mAb P7278 used, the values of the relative slopes (m/m0) of 
the sensograms (II.2.7.2) obtained from the inhibition experiments were plotted against the 
inhibitor concentration and fitted by non-linear curve fitting to obtain the value of KI. 
III.9 Pharmacokinetics of the anti-LHRH antibody 
III.9.1 Pharmacokinetics of the mouse mAb P7278 in mice 
Six Swiss (CD-1) mice were used for studying the pharmacokinetics of the mouse mAb P7278. 
Before injecting the antibody a pre-bleed was taken from each animal. 200 µg of mAb was 
injected intra-peritoneally into all six mice. For 6 days blood samples were taken from the 
orbital sinus of the mice. The time of bleeding was fixed at 10:00 a.m. every day.  
The serum obtained from the blood samples was diluted (1:20) in HBS buffer and applied 
onto the BIAcore over a D-Lys6-LHRH coated sensor chip. A known amount of anti-LHRH 
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antibody applied onto the antigen-coated chip served as the standard sample. The amount of 
functional anti-LHRH antibody present in the serum sample was calculated from the slopes of 
the binding curves.  
The average amount of blood in a mouse weighing ~30 gm is known to be ~2ml. Therefore 
the dose of mouse mAb P7278 injected in each mouse was 100µg/ml. The amount of 
functional antibody per ml obtained from each serum sample was expressed as the percentage 
of injected dose and plotted against the time when the blood sample was taken (Fig. III-40).  
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Fig. III-40: Pharmacokinetics of mouse mAb P7278 in mice. 
Six mice were injected intra-peritoneally with 200µg of mouse mAb P7278. Mouse serum was 
assayed for the amount of functional antibody present in the sample for six consecutive days using 
the BIAcore (II.2.7). The antibody concentration was calculated by comparison with a standard 
antibody sample applied on the sensor chip. The pre-bleed from all the animals before injection 
with the mouse mAb P7278 served as the 0 hr reading. The graph shows the determined antibody 
concentration as the percent-injected dose. The last four data points are fitted to first order 
exponential decay. 
The plot obtained could be divided into two phases, the “distribution phase” that lasted for 
~75 h after which there was seen an exponential decay of the antibody till the last day of the 
bleed. This phase was called the “decay phase”. 
III.9.2 Stability of mouse and chimeric rAb P7278 in human serum at 37˚C 
The mouse mAb P7278 and the chimeric rAb P7278 antibodies incubated in human serum at 
37°C at a starting concentration of 250 µg/ml were assayed for binding activity to LHRH over 
a period of 32 days (Fig. III-41). The serum was diluted (1:10) in HBS buffer and the binding 
activity was measured on the BIAcore on D-Lys6-LHRH coated sensor chip. The active 
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concentration of the antibody was determined by comparison to the standard antibody sample 
(chimeric antibody at a concentration of 1µg/ml) at each time point. The fluctuations observed 
in the measurements are probably due to pipetting errors that get overtly accentuated for very 
small quantities. Antibody activity after 32 days at 37°C in human serum was determined to 
be 70% for chimeric rAb P7278 and 60% for mouse mAb P7278. This study demonstrates that 
both the mouse mAb and the chimeric antibody have almost indistinguishable stability in 
vitro at the physiological temperature in the human serum environment. 
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Fig. III-41: Stability of mouse and chimeric rAb P7278 in human serum at 37˚C. 
The mouse mAb P7278 (III.1.2) and the chimeric rAb P7278 (III.6.5) antibodies were incubated in 
human serum at 37°C at a concentration of 250µg/ml. Degradation of the antibodies was 
monitored by SPR for 32 days by measuring active antibody concentration on a D-Lys6-LHRH 
coated sensor chip (II.2.7.1) in serum samples diluted 1:10 in HBS. A known amount of anti-
LHRH antibody served as the standard sample for estimation of concentration. 
III.10 Bioefficacy of mouse and chimeric rAb P7278, in vivo 
The bioefficacy of mouse mAb P7278 and the chimeric rAb P7278 was tested in vivo by their 
ability to cause a dose dependent disruption of the estrus cycle in rodents. Regularly cycling 
female Swiss (CD-1) mice and Wistar rats were identified by monitoring vaginal cytology by 
saline lavage. Vaginal cytology confirmed that each animal had shown 3 consecutive regular 
estrus cycles of four-day duration. In the rats, the four-day estrus cycle consisted of the 
following stages proestrus (P), estrus (E) and two days of diestrus (D1 and D2). The 
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metaestrus (M) stage was not observed. Whereas for the mice the four-day estrus cycle 
consisted of an E, M, D1 and D2 stage while the proestrus stage was not observed (Fig. III-42). 
The histological characteristics of the cells at proestrus, estrus, metaestrus and diestrus were 
easily identifiable without staining. The proestrus stage of the cycle was marked with large 
round nucleated cells. During the estrus phase of the cycle the cells observed were cornified 
squamous epithelial cells. The metasetrus phase of the cycle showed a mixed population of 
leucocytes and cornified cells while in the diestrus phase the only cell type that was visible 
were the leucocytes (Fig. III-37). 
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Fig. III-42: Stages of estrus cycle observed in rats and mice.  
Schematic representation of estrus cycle in (a) mice and (b) rats. Slides of the vaginal smear 
(II.2.8.2) prepared at the (c) estrus stage marked by large squamous cornified epithelial cells and 
(d) diestrus stage marked by leucocytes.  
III.10.1 Mouse mAb P7278 causes dose dependent disruption of rat 
estrus cycle 
The dose response of the murine antibody for disruption of the estrus cycle was studied in 
regularly cycling rats by administering varying amounts of mouse mAb P7278 (III.1.2). For 
each experiment two rats injected with PBS formed the control group. Two different 
approaches, a single injection regimen and a multiple injection regimen, were tried. For the 
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single injection regimen the mAb was always injected on the first day of diestrus (D1) 
whereas for the multiple injection regimen another dose of the mAb was injected on one of 
the days during the time period that the cycle stayed suppressed due to the first injection on 
D1. In rats that were passively immunized with anti-LHRH antibodies the estrus cycles, 
assessed by vaginal smearing, was interrupted in a dose dependent manner. Vaginal smears of 
all rats in which the cycle was disrupted were leucocytic.  
III.10.1.1 Single dose injection regimen  
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Fig. III-43: Effect of administration of single dose of monoclonal anti-LHRH 
antibody on cyclicity of rats.  
The mouse mAb P7278 was injected intra-peritoneally on the first day of diestrus and the vaginal 
cytology was monitored daily to study the estrus cycle pattern (II.2.8.2). The injected dose and the 
number of days for which it caused estrus suppression are shown against each recorded cycle. E: 
Estrus; D: Diestrus. 
Twelve mg of mAb were given on the first day of diestrus to two rats. The estrus cycle in 
these rats was arrested in the diestrus stage for about 30 days followed by constant estrus for 
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whole of the experimental period. A single dose of 1.2 mg of the mAb disrupted the cycle for 
26 days after which the normal four-day cycle was resumed. Of these 26 days, on the first ten 
days continuous diestrus was observed followed by 16 days of constant estrus interspersed 
with proestrus stages. A 500µg dose disrupted the cycle for five days after which regular 
cyclicity was resumed. A dose of both 250 µg and 150µg of the mAb disrupted the cycle for 
only three days. The pictoral description of the results is shown in Fig. III-43. 
III.10.1.2 Multiple dose injection regimen  
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Fig. III-44: Effect of administration of two doses of monoclonal anti-LHRH 
antibody on cyclicity of rats.  
The first injection of the mouse mAb P7278 was administered intra-peritoneally on the first day of 
diestrus while the day of the second injection varied as indicated by the arrows. Vaginal cytology 
of the injected animals was monitored on a daily basis to study the estrus cycle pattern (II.2.8.2). 
The injected dose and the number of days for which it caused estrus suppression are shown against 
each recorded cycle. E: Estrus; D: Diestrus. The arrows indicate the day of injection. 
Two injections of 250µg mAb were given, one on each day of diestrus i.e. D1 and D2. The 
estrus cycle was disrupted for six days as opposed to a three-day disruption caused by a single 
250µg dose on the D1. A multiple injection of 250µg given on the first and the third day of 
diestrus did not extend the period of estrus suppression and cyclicity resumed after three days. 
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A single dose of 500µg mAb caused estrus suppression for five days (Fig. III-44). When two 
doses of 500µg antibody were given consecutively on the first and the second day of diestrus 
the rat stayed in estrus for seven days. Multiple injections on the first and the third day of 
diestrus caused a disruption for five days whereas injections on the first and the fourth day 
caused estrus suppression for eight days. 
III.10.2 Chimeric rAb P7278 causes dose dependent disruption of mouse 
estrus cycle  
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Fig. III-45: Effect of administration of chimeric anti-LHRH antibody on cyclicity of 
mice.  
The chimeric rAb P7278 antibody (III.6.5) was injected intra-peritoneally on the first day of 
diestrus and the vaginal cytology was monitored (II.2.8.2). The injected dose and the number of 
days for which it caused estrus suppression are shown against each recorded cycle. E: Estrus; 
D: Diestrus. 
Six regularly cycling mice were used for this study. Two mice were used as control and were 
kept along with the four experimental animals in the same cage. A dose of 100µg chimeric 
anti-LHRH antibody when injected intra-peritoneally into two mice on the first day of 
diestrus caused estrus suppression for four days from the day of injection in both the animals.  
An intra-peritoneal injection of 200µg of the antibody given to two other regularly cycling 
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animals on the first day of diestrus disrupted the estrus cycle for six days. Sterile PBS was 
injected into the control mice, which were found to be regularly cycling for the experimental 
period (Fig. III.45). 
III.11 Isolation of a mimotope of mAb P7278  
Anti-LHRH antibody binding peptides were selected by phage display technology using a 
random 12mer phage display library (Ph.D.–12; NEB). The randomised peptide sequences in 
the library are expressed between the leader sequence and the mature N-terminus of the minor 
coat protein pIII, resulting in an average valency of five displayed peptides per virion. In the 
linear Ph.D.-12 library, the first position of the mature displayed fusion protein is the first 
randomised position. Each displayed peptide is followed by a short spacer (Gly-Gly-Gly-Ser) 
and then the wild-type pIII sequence. The complexity of the library provided by the 
manufacturers for panning is 2.7⋅109 resulting in a concentration of 1.5⋅1013 phage particles 
per ml. Therefore in 10 µl, the amount of phages used for panning, every sequence was 
expected to be represented at least 50 times.  
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Fig. III-46: Monoclonal phage ELISA of the clones retrieved from the two rounds of 
panning using the NEB library.  
The phages eluted from the two rounds of panning were amplified and applied to chimeric rAb 
P7278 coated on ELISA plates at a concentration of 5µg/ml (II.2.9.1). The bound phages were 
detected with goat anti-M13 HRP labelled antibody.  The graph depicts clones grouped according 
to their reactivity to the coated antibody based on the OD reactivity after 30 minutes of 
substrate reaction. 
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The phages were subjected to two rounds of panning against the Protein A purified chimeric 
rAb P7278 that was coated on microtiter plates at a concentration of 5µg/ml (II.2.9.1). After 
the first round of panning, individual phage plaques were amplified and the resulting phages 
were tested for binding to the chimeric rAb P7278 in a direct ELISA set up. 12 of the 85 clones 
tested showed binding activity to the antibody (Fig. III-46). The eluted phages from the first 
round were amplified (2⋅1010 phages per ml) and subjected to a second round of panning. The 
phages from the second round were sequentially eluted with LHRH at a concentration of 
50 µg/ml followed by 200 mM glycine, pH 2.2. 
The phages eluted from the second round of panning were amplified and monoclonal phage 
ELISA was carried out on plates coated with chimeric rAb P7278. Most of the phages – 82% 
of the acid eluted phages and 66% of LHRH eluted phages showed high reactivity (OD>1) to 
the coated antibody (Fig. III-46). The reactivity of phages eluted with the peptide was 
observed to be lower than that for phages eluted with glycine (Fig. III-46). This result 
demonstrated that the elution with LHRH was not as effective as the elution with acid given 
that the time allowed for competition with the soluble antigen was short  (in this case 30 min). 
A few clones from the first and the second rounds of panning that exhibited high reactivity  
(OD>1) to the chimeric rAb P7278 were sequenced. None of the sequence was found to be 
similar or identical to the native LHRH peptide, indicating that the phage displayed peptide 
sequences represented mimotopes of the native epitope (Table III-3).  
There was a conserved motif, S/T-R-S/T, observed in all the sequenced clones preceded by 
F/Y-E in 17 of the 21 clones. As a control four phage clones that showed no reactivity for the 
chimeric antibody in the direct ELISA were sequenced. The conserved sequence present in all 
the reactive clones was absent in these clones indicating the importance of the conserved 
motif for binding to the antibody. 
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Table III-3: Sequence analysis of the phage clones reactive to chimeric rAb P7278 and the 
deduced consensus sequence. 
Three clones from the first round of panning were sequenced (1/1, 1/2, 1/3). The rest of the sequences 
are from the phages eluted after second round of panning. All the phages sequenced were eluted with 
glycine. The third column shows whether the phage clone was reactive in phage ELISA. A residue is 
considered a representative in the consensus sequence if it occurs in 50% or more of the sequences. Ψ 
indicates preference for an amino acid type at that position. X indicates a position that cannot be 
represented by any one amino acid type. Clones marked with an asterix were chosen for further 
binding analysis. 
     = hydrophobic amino acid       = polar amino acid      = acidic amino acid      = basic amino acid 
 
LHRH: pGlu E H W S Y G L R P GNH2 
Peptide Sequence ELISA
1/1             F  F  T  R  T  V  L  P  L  Q  P  L   + 
1/2          T  S  F  S  R  T  A  E  L  P  G  L      + 
1/3 H  H  S  Y  F  P  S  R  S  A  F  I + 
2/1             F  E  T  R  T  Q  V  L  S  A  K  A + 
2/2             F  E  T  R  S  V  S  R  I  F  E  L + 
2/3          S  F  E  S  R  T  -  W  P  S  Q  H + 
2/4          S  F  P  S  R  T  A  F  P  I  L  P + 
2/5             Y  E  T  R  S  P  A  V  F  F  H  A + 
2/6             F  E  T  R  T  F  S  M  N  H  P  W + 
2/7             F  E  S  R  T  L  Q  S  Y  N  V  F + 
2/8             F  E  T  R  T  P  V  N  T  D  G  H + 
2/9             F  E  T  R  H  A  A  P  Y  I  G  S + 
2/10             Y  E  T  R  S  A  V  R  I  D  Y  K + 
2/11             F  E  S  R  S  P  H  R  L  N  F  A + 
2/12 T  Y  T  H  Y  E  S  R  S  P  V  L + 
2/13             T  E  S  R  T  A  Q  P  P  P  V  G + 
2/14                   T  R  T  L  I  P  L  S  N  S  N  S + 
2/15             F  Q  S  R  S  M  S  D  S  W  T  W   + 
2/16*             F  E  T  R  T  Q  V  L  S  A  K  A + 
2/17*             F  E  T  R  S  P  F  N  W  P  N  T + 
2/18* T  Y  T  H  Y  E  S  R  S  P  V  I + 
2/19*             Y  E  T  R  T  L  I  P  L  S  N  S + 
2/20*             Y  E  T  R  T  A  S  W  S  E  N  F + 
2/21*             F  E  S  R  T  L  Q  S  Y  N  V  F + 
 
Consensus Sequence:      F/Y E T/S R T/S Ψ  Ψ Ψ  X  X  X  X 
 
2/22*             I  P  Y  M  T  A  S  V  G  N  A  P   - 
2/23*             W  V  G  P  L  G  K  H  A  E  H  S - 
2/24             S  I  A  V  P  L  N  M  S  V  V  I - 
2/25             S  I  Y  Q  L  F  T  P  L  D  I  N - 
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Three peptides, 12, 6 and 3 amino acids long, spanning the whole peptide length to the three 
amino acids (S/T-R-S/T) that were found to be conserved in all the sequenced clones 
were synthesized.  
  Pep12  - FETRTPVNTDGHNH2 
  Pep5   – FETRTNH2  
  Pep3   - Ac-TRTNH2 
The sequence of the 12-mer peptide (Pep12) was randomly chosen from amongst the 21 
sequenced clones (clone number 2/8, Table III-3). The 5-mer peptide (Pep5) constituted the 
first five amino acid residues of pep12 while the 3-mer (Pep3) was made of the three amino 
acid motif - TRT. The C´ terminal of all the three peptides were blocked with the amide 
residue so that the charge introduced by the free amino terminal is absent mimicking the 
condition wherein the peptide is fused to the pIII protein of the M13 phage. 
The binding of the three synthesized peptides to the chimeric rAb P7278 was tested by direct 
and competition experiments both by SPR and ELISA. The pep12, pep5, pep3 and the D-
Lys6-LHRH were coupled to a CM5 type sensor chip by standard EDC/NHS chemistry 
utilizing the free primary amine. The chimeric rAb P7278 (1µg/ml) was passed over the coated 
surface. No antibody binding was observed to pep12, pep5 and the pep3 while typical binding 
rates were obtained on the D-Lys6-LHRH surface. 
To negate the possibility of sub optimal coating of the peptides on the sensor chip, 
competition BIAcore was performed. Chimeric rAb P7278 was mixed with the free peptides 
and injected over the D-Lys6-LHRH surface. High concentration of soluble D-Lys6-LHRH 
completely inhibited the binding of the antibody to the surface while no inhibition was 
observed for any of the three synthetic peptides. Similar results were obtained with direct and 
competition ELISA experiments (data not shown).  
Therefore, the peptide mimotopes when present in fusion with the minor coat protein pIII and 
displayed on the M13 phage bound to the chimeric rAb P7278 with sufficient affinity to be 
readily detected in ELISA and Western blotting but failed to bind to the antibody as 
free peptides.  
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III.12 Fine mapping the epitope of mAb P7278  
In an attempt to identify the residues in the LHRH peptide involved in binding to the mAb 
P7278, six peptide variants were tested. LHRH isoforms differing in one or two amino acids 
(Chicken I, Chicken II and Salmon III), two LHRH fragment (LHRH (1-6) amide and 
Formyl-LHRH (2-10)) and a commonly used LHRH agonist (Fertirelin) constituted the panel 
of peptide variants tested (Fig. III-48). 
 
LHRH              pGlu H W S Y G L R P G-NH2 
Fertirelin        pGlu H W S Y G L R P NHCH2CH3 
Formyl 2-10       For  H W S Y G L R P G-NH2 
Chicken I         pGlu H W S Y G L Q P G-NH2 
Chicken II        pGlu H W S H G W Y P G-NH2 
Salmon III        pGlu H W S Y G W L P G-NH2 
LHRH(1-6)amide    pGlu H W S Y G-NH2 
 
 
 
Fig. III-48: Amino acid sequence of peptide variants of LHRH tested for binding 
activity to chimeric rAb P7278. 
The binding of the peptides to the mAb P7278 was tested by competition experiments using the 
BIAcore system. The chimeric rAb P7278 at a concentration of 1µg/ml was mixed with a high 
concentration (~40µM) of the peptides, resulting in a 1000 fold excess of the peptide over the 
antibody in order to obtain complete inhibition. After incubation for 30 min, the peptide 
antibody mix was injected over a sensor chip surface immobilized with D-6(Lys)-LHRH 
(II.2.6.1). The endpoint response for all the binding curves has been graphically represented in 
Fig. III-49. While the maximum endpoint response obtainable was estimated from the 
antibody sample without any peptide, competition with LHRH and D-6(Lys)-LHRH gave the 
maximum possible inhibition. Almost complete inhibition of antibody binding was observed 
for 4 of the 6 peptides (fertirelin, formyl2-10, chicken II and Salmon III). Partial inhibition of 
antibody binding was seen with Chicken I peptide while LHRH 1-6 peptide did not bind to 
the antibody at all.  
This experiment showed that the importance of the amino- and carboxy-terminal ends of 
LHRH for recognition by the monoclonal antibody is that they are uncharged and not related 
to the structure. The pyroglutamate at the N´ terminal was found to be non-essential for 
binding because its deletion did not abolish binding activity. Neither was the C-terminal 
glycine-amide (NHCHCONH2) essential as it could be replaced by an ethylene-group 
(NHCH2CH3) (Fertirelin; Fig. III-43) without affecting the chimeric rAb P7278 
binding activity.  
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Fig. III-49: Endpoint response of the binding curves obtained from competition of 
the six selected LHRH variants with chimeric rAb P7278 using surface plasmon 
resonance. 
The six LHRH peptide variants  (Fig. III-43) were mixed in a 1000 fold excess with chimeric rAb 
P7278, incubated for 30 minutes before injecting on the D-6(Lys)-LHRH coated chip (II.2.7.1). 
Competition with LHRH and D-6(Lys)-LHRH were included as control.   
The LHRH (1-6) amide did not show binding to the mAb P7278 indicating the importance of 
the four missing C-terminal amino acid residues – LRPG-NH2. However, the antibody 
binding to peptides in which the arginine was replaced by leucine (Salmon III) or tyrosine 
(Chicken II) was not affected demonstrating that the arginine residue may not be 
indispensable for binding of the mAb. The partial binding activity of the Chicken I isoform to 
the mAb P7278 where the arginine is replaced by a glutamine residue could be a result of the 
steric hindrance caused by the bulky side chain of glutamine. Leucine could be replaced by 
tryptophan without any effect on antibody binding. Both are hydrophobic residues and may 
contribute to binding by entropic changes. The side chain of Trp is aromatic and larger than 
that of Leu indicating some amount of inherent flexibility at this position. Therefore one may 
expect other substitutions to be tolerated and still others to be rejected e.g. hydrophilic or 
charged residues. Change of tyrosine to histidine at the fifth position was also tolerated. 
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Table III-4:  Amino acid sequence and binding property of six LHRH peptide variants.  
The amino acid differences from the native LHRH sequence are marked in bold. The third column 
shows the percent inhibition of chimeric rAb P7278 binding to the D-6(Lys)-LHRH coated sensor chip 
due to the addition of the corresponding peptide as determined by SPR (Fig. III-44). 
 
Peptide         Sequence % Inhibition 
Formyl-LHRH(2-10) ForHWSYGLRPG-NH2             99 
LHRH  pEHWSYGLRPG-NH2            100 
D-6(Lys)LHRH       pEHWSYKLRPG-NH2            100 
Chicken I  pEHWSYGLQPG-NH2              62 
Salmon III   pEHWSYGWLPG-NH2            99 
Chicken II         pEHWSHGWYPG-NH     2        98 
Fertirelin    pEHWSYGLRP-NHCH2CH3         98 
LHRH (1-6) amide  pEHWSYG-NH2                  0 
 
 
 
 
As only a few of the many possible LHRH peptide variants have so far been tested it is 
difficult to conclude which residues are important for binding and the nature of contact 
between the paratope and the epitope. Residues that were not investigated are His2, Trp3, 
Ser4 and Pro9. It would be interesting to investigate the role these residues play by analysing 
binding of appropriate LHRH variants to the antibody. Additionally the results of this 
experiment show that the mAb P7278 can bind to chicken II and salmon III, the two variants 
that have been shown to be present in humans in addition to the hypothalamic LHRH (see 
section I.3). 
 
 
  
 
 IV Discussion 
The concept of passive immunization with pre-made, bio-effective antibodies is one of the 
oldest in immunology. Low immunogenicity and mass production of the antibody at a low 
cost, the two factors that greatly limited the therapeutic potential of this approach, have now 
been overcome. Recombinant DNA technology has made possible the generation of 
antibodies to avoid complications like immunogenicity and “foreignness” which arise due to 
administration of mouse monoclonal antibodies. Numerous antibodies have recently been 
granted approval by the FDA for human use and many more are under development. 
Mammalian cell culture, although the most established expression system for production of 
full-length antibodies, is not cost effective and is prone to contamination with oncogenic 
sequences or viruses. Plant molecular farming of recombinant antibodies is an attractive 
alternative as it allows the production of functional mammalian proteins, devoid of 
contamination with mammalian viruses or oncogenic sequences, and most importantly in a 
cost effective manner.   
Described in this thesis is the generation of an scFv, diabody and chimeric antibody derived 
from a LHRH specific mouse monoclonal antibody P7278. LHRH immunoneutralisation 
results in castrate levels of sex steroids, a condition that can be achieved both by active 
vaccination against LHRH or by passive administration of polyclonal or monoclonal anti-
LHRH antibodies. Active immunisation procedures have been hampered by problems like 
patient-to-patient variation in antibody titres and the lag period in the build-up of these titres. 
The recombinant anti-LHRH antibodies were constructed to provide a ready source of bio-
effective antibody in the required amounts for passive immunisation against LHRH. As a 
considerable part of the immunogenic response in humans is directed to the constant region of 
the mouse antibodies, a mouse/human chimeric full-length antibody was engineered, in which 
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the human constant regions were spliced with the variable mouse antibody domains. All three 
antibody formats – scFv, diabody and the chimeric full size antibody - were expressed in plant 
leaves by vacuum assisted agro-infiltration, purified and characterised. The affinity and 
bioefficacy of the chimeric antibody was confirmed to be similar to the parent antibody. This 
is the first report that describes the engineering of anti-LHRH antibodies by recombinant 
DNA technology and their production in plant based expression systems.  
IV.1 Purification and characterisation of the mouse mAb P7278 
Mutations can accumulate in hybridoma cells over long periods of culturing and passaging 
resulting in a heterogenous cell population containing a set of highly homologous antibody 
genes or the entire loss of antigen binding property (BREITLING et al., 2001). These 
mutations are not evident from functional analysis of the culture supernatant as long as a 
sufficient fraction of the cells produce the correct antibody chains. Preparation of cDNA for 
cloning the variable domains from a freshly sub-cloned cell population helps to minimise the 
carryover of such mutations. For this reason, the hybridoma P7278 was sub-cloned and the 
sub-clones were checked for binding activity to LHRH before isolation of the RNA from the 
hybridoma cells. The homogeneity of the cell line and the absence of any mutation in the 
antibody genes that could have abolished antigen-binding activity were confirmed. All sub-
clones secreted antibody that showed binding activity to LHRH in ELISA (III.1). 
The typical amount of antibody that can be obtained by purification of culture supernatant 
collected from tissue culture flasks ranges from 1 to 100 µg/ml. The yield of mouse 
mAb P7278 from the hybridoma P7278 supernatant after purification via protein A affinity 
chromatography amounted to ~9 mg per litre of culture supernatant. The purified murine 
mouse mAb P7278 served as a reference for all experiments. 
IV.2 Cloning and identification of the variable domains of mAb P7278 
The variable domains of the heavy and the light chains of the mouse mAb P7278 were 
amplified using an extensive set of primers normally used for the construction of mouse 
phage display libraries (II.1.8). The forward primers for both the light and the heavy chain 
amplification were designed to bind to the first framework region while the back primers 
annealed to the fourth framework region of the variable domains of the antibody. Priming in 
the specified framework regions takes advantage of the sequence conservation in these 
regions. All the primers contained degeneracies at certain positions to enable the amplification 
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of most of the mRNA of the mouse immunoglobulin repertoire. The primers had restriction 
sites in the overhang regions that were incorporated in the amplified product for cloning into 
the phagemid vector pHEN4II.  The eight bp long AscI and NotI restriction sites were used for 
cloning the VL while BstEII and SfiI sites were used for cloning the VH antibody domain. 
These restriction sites are not regularly found in the mouse variable antibody domains. 
Although the annealing temperature used for the PCR was moderately high (55°C) to avoid 
any non-specific amplification, VL and VH fragments of the mouse mAb P7278 were amplified 
by more than one primer combination (III.2.3). The most probable reason for gene 
amplification by multiple primer combination was the degeneracy present at certain positions 
of the primers or base pair mismatches during PCR priming. Although, in some rare cases, 
entirely different variable region gene sequences derived from aberrant mRNAs, which are 
transcribed from rearranged, but non-functional, heavy and light chain genes in the hybridoma 
have been reported to be amplified (CARROL et al., 1988; KALUZA et al., 1992; 
OSTERMEIER et al., 1996). Therefore it was vital to demonstrate the binding specificity of 
the scFv to LHRH. 
One way to determine the correct V gene sequence would have been to pick, clone and 
sequence 5-10 clones of each amplification product. On identification of more than one kind 
of sequence, cloning each amplification product separately and then making all the possible 
combinations of the VH and the VL fragments, would have proved very tedious. The same 
answer was derived more rapidly by performing a test for antigen binding function with the 
mini-scFv library generated from the pooled amplimers of both the VH and the VL fragments 
of mouse mAb P7278 (III.3.1.1). The cloning of the variable antibody domains in the 
phagemid pHEN4II provided the possibility of phage display of the mini-scFv library in case 
of sequence heterogeneity in the amplified variable antibody domains to find the best binder. 
In the cases where the parental hybridoma cell line does not produce large amounts of 
contaminating, non-functional light or heavy chain, about one third of the screened colonies 
contain the sequence information of the scFv fragments (KREBBER et al., 1997). Therefore, 
it was decided to test the binding activity of ten randomly selected scFv clones from the mini-
scFv library. Of the ten clones, eight were found to contain an scFv fragment as revealed by 
plasmid restriction analysis (III.3.1.2). For soluble antibody expression, the eight scFv clones 
were transformed into E. coli strain HB2151. Six of the eight scFv clones showed binding 
activity for LHRH in direct ELISA. Western blot analysis of the clones confirmed the 
presence of a ~30 kDa scFv protein for the six clones that bound to LHRH in ELISA 
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(III.3.1.2). The two clones that showed no antigen binding activity in ELSIA were also found 
to be negative for the presence of a c-myc tagged protein in the Western blot.  
The need for phage display of the scFv library to identify binders by panning was thus 
obviated as almost 60% of the cloned scFv fragments demonstrated binding. The two clones 
that did not show expression were probably representative of a population of non-expressing 
clones due to primer mismatch or PCR errors leading to the formation of truncated anti-
body fragments.    
Sequence analysis of the six scFv clones that bound to LHRH in direct ELISA revealed 
identical sequences except for differences observed in the primer-binding region (data not 
shown). This result further confirmed that the amplification products of the VH and VL genes 
by more than one PCR primer combination (III.2.3) was indeed due to degeneracies present in 
the primer sequences or primer mismatch.  
Mutation in the N-terminal part of the framework 1 (FR1) of the VH domain introduced by 
PCR cloning using degenerate primers have been shown to result in severe impairment of 
production yields, stability and antigen binding in some cases (KIPRIYANOV et al., 1997; 
LANGEDIJK et al., 1998). Detailed studies of the FR1 have shown that residues at the 
position 6, 7 and 10 (H6, H7 and H10 (Kabat 9)) lead to a particular framework conformation, 
independent of the global sequence context (HONNEGER and PLÜCKTHUN et al., 2001; 
JUNG et al., 2001). Murine VH domains have been grouped into four distinct structural 
subtypes based on the amino acid combinations present in these positions – 6E7S10P (type I), 
6E7S10G (type II), 6Q7S10A (type III) and 6Q7P10A (type IV). The H6 amino acid residue is 
either a gluatamate or a glutamine residue in almost all VH sequences. Several researchers 
have observed drastic effects of mutation, which cause a change from glutamine to glutamate 
or vice versa at residue H6, on antibody function and stability (LANGEDIJK et al., 1998; 
de HAARD et al., 1998). 
These findings necessitated the careful selection of the anti-LHRH scFv clones. The sequence 
analysis of the primer-binding region (first eight amino acids of the sequence) of VH of the six 
LHRH-binding scFv clones showed that the positions H2, H4, H6, H7 and H8 were conserved 
while variations were observed in the positions H1, H3 and H5. The H6 and the H7 residues 
in all the sequences were glutamate and serine respectively. The residue H10, which was the 
part of the amplified sequence and not the primer, was proline in all clones. This makes the 
anti-LHRH antibody a member of type 1 group (6E7S10P). For the light chain the analysis of 
 
IV Discussion  110
the primer binding region (first eight amino acids of the sequence) of the six scFv clones 
showed that the amino acids at positions L1, L2, L5, L6 and L8 were conserved. The amino 
acids at positions L3 and L4 were either isoleucine or valine. The seventh position of the light 
chain was equally represented by arginine and threonine. All the clones checked were positive 
in direct LHRH ELISA. This suggested that the amino acid differences amongst the clones 
did not have a substantial effect on the antibody secretion or binding activity of the clones.  
Alignment of the variable domains of the selected scFv clone with the closest germ line 
sequences showed one difference each in the primer-binding regions for the heavy and the 
light chains (Fig. III-8 and III-9). The position H3 of the scFv P7278 is a lysine, while aspartic 
acid is present in the germline sequence. In the light chain, at position L7 of the scFv P7278 an 
arginine residue is present as opposed to a threonine in the germline gene sequence. These 
amino acid residue differences can be a result of primer mismatch or an acquired mutation 
during affinity maturation. The change in these residues did not affect the binding of the 
antibody to LHRH as was confirmed by affinity measurements of the chimeric antibody by 
surface plasmon resonance analysis (III.7). However, whether the expression levels of the 
antibody fragments also remain unaffected by the mutation is not known, as the residues were 
not back mutated to the ones present in the closest germline sequence for comparison. 
Priming in the first framework region of the variable domains for amplification, like in the set 
of primers used in the present work, takes advantage of the conserved nature of these 
sequences. Thus, a few degenerate primers prove sufficient to clone the majority of the 
variable regions, which is of great practical advantage (ORLANDI et al., 1989; 
GAVILONDO-COWLEY et al., 1990; LeBOEUF et al., 1989). However, the disadvantage of 
this approach is that it may introduce amino acid substitutions into the framework region that 
may affect antibody affinity. Forward primers have been designed to prime in the relatively 
conserved leader sequence to avoid such mutations (GAVILONDO-COWLEY et al., 1990; 
LARRICK et al., 1989a; LARRICK et al., 1989b). Priming in the leader sequence avoids any 
deleterious effects since the leader is removed from the mature antibody sequence. Similarly, 
the 3´primer can be designed to bind to the constant region of the antibody. 
Other than the differences in the primer binding regions, the cloned V genes of the mouse 
mAb P7278 differed from their closest germline gene by 6 and 8 amino acids respectively. 
Errors during PCR amplification and assembly process were ruled out because the amino acid 
differences were a conserved feature present in all the six scFv clones that were sequenced. A 
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new cDNA preparation from the RNA isolated from the hybridoma cells and the subsequent 
amplification and sequencing of the variable region sequence yielded the same sequence.  
The differences from the closest germline sequence are likely to have arisen because of 
somatic mutations of the V genes in the B cell. Since somatic hypermutation of antibody 
genes is triggered only after antigen-induced B-cell proliferation, the isolation of scFv 
fragments encoded by somatically mutated V gene indicates that the V gene have been 
derived from lymphocytes that have been stimulated by antigen during the immune-
ization procedure.  
IV.3 Heterologous expression of scFv P7278 and diabody P7278  
The oligomerisation state of a single-chain Fv fragment can be controlled by the linker length. 
A linker, at least 12 amino acids long, is required between the VH and VL domains of an 
antibody to bridge the approximate 3.5 nm distance between the carboxy terminus of one 
domain and the amino terminus of the other for the formation of a monomeric scFv (KORTT 
et al., 1994). Linker lengths of 3-10 residues lead to the formation of diabody fragments 
(HUDSON & KORTT 1999). The scFv P7278 was engineered by connecting the VH and the 
VL domains of the mouse mAb P7278 by an 18 amino acid long linker, the Whitlow 218 linker, 
while the diabody P7278 was constructed by reducing the length of the Whitlow 218 linker 
from 18 to the first 8 amino acids. 
The periplasmic expression level of scFv P7278 and diabody P7278 in bacteria was found to be 
below 1 mg per litre from shake flasks. The choice of bacterial strain used for expression of 
the recombinant antibody fragments made at least a two-fold difference in antibody 
accumulation levels (III.4.2). The TG1 strain of E. coli outperformed the HB2151 E. coli 
strain in the protein accumulation levels. A consistent feature of the IMAC purification of the 
bacterially expressed scFv P7278 and diabody P7278 was the co-elution of contaminating 
proteins with the protein of interest (Fig. III-13 and III-14). The major contaminants were 
approximately 30, 50 and 70 kDa as judged from he SDS-PAGE gels. These sizes correspond 
to that of bacterial chaperonins that are involved in the proper folding of nascent proteins in E. 
coli (GOTTESMAN et al., 2000). For instance the 70 kDa protein, often co-purified with 
recombinant protein, is a protein product of the E coli gene dnaK and is known to be involved 
in the degradation of “abnormal” proteins in E. coli.  
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The antibody fragments scFv P7278 and diabody P7278 were also expressed transiently in 
tobacco leaves by agro-infiltration (III.5). The antibody fragments were retained within the 
lumen of the ER by addition of a C terminal KDEL motif, as it is known to increase the 
accumulation levels of recombinant antibodies. The reason for this is allocated to the presence 
of the enzymatic catalysts present in the ER lumen that allow proteins to fold and mature, 
resulting in increased stability and accumulation levels (DENECKE 1996). The expression 
levels of the scFv P7278 and the diabody P7278 in the plant system did not differ from what was 
obtained in the bacteria amounting to 1 mg per kg leaf material. The purified antibody 
fragments were analysed for the oligomerisation state of the molecules by size-exclusion 
chromatography. The plant-purified scFv fragments emerged in two peaks corresponding in 
size to that of monomers and dimers (Fig. III-19). The presence of the two distinct peaks 
indicates that the monomers and dimers do not interconvert rapidly. Presumably the dimers 
are scFv fragments interlocked through the flexible linker joining the heavy and the light 
chains, or with the heavy chain of one scFv molecule associated with the light chain of 
another. The scFv dimers run as monomers on SDS-PAGE gels and are therefore not linked 
covalently. Several groups have reported the formation of scFv dimers, with the extent of 
dimerisation depending on the linker length and the particular antibody sequence (ESSIG et 
al., 1993; HOLLIGER et al., 1993). The plant purified diabody fragment eluted as a single 
peak in gel filtration that corresponded to the predicted size of ~ 56 kDa (Fig. III-20). A 
corollary of the experiment was the stability of the antibody fragments as elution fractions 
kept at 4°C for six months and one year of the scFv and the diabody respectively were used 
for the gel filtration assay.  
The expression levels of scFv obtained from bacteria are seen to vary widely the average 
value being ~1mg per litre in a shake flask (HUDSON & KORTT 1999). While the use of 
expression vectors that utilise leaky promoters like the lac promotor have been implicated for 
low expression levels of the antibody fragments, it is known that the primary sequence of the 
variable domains is the main factor responsible. The primary sequence of the antibody 
influences the folding efficiency of scFv fragments. Mis-folding of the protein in turn causes 
insoluble protein aggregates which may prove toxic to the bacterial host leading to low 
accumulation levels. Modifying the conditions of bacterial growth has been shown to 
marginally increase the proportion of correctly folded soluble antibody fragments for example 
lower temperatures and the addition of non metabolised additives that induce osmotic stress.   
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The reason that expression of the two anti-LHRH antibody fragments was also tried in the 
plants was because in some cases, expression in plants has resulted in antibody expression 
levels manifold higher than what was observed in bacteria (KATHURIA et al., 2002). 
Although there have been several impressive reports on the production levels of functional 
antibodies and antibody fragments in different plant cell compartments, a generalisation 
cannot be made. For instance, a research group working with scFv antibodies has reported 
that only about one in four scFv accumulates to detectable levels even if the scFvs are 
targeted to different subcellular targets including the ER (WHITELAM et al., 1994). As the 
antibodies that do not accumulate to detectable levels or are poorly expressed are never 
reported the literature shows a lopsided view.  
Possible bottleneck for the high expression levels of active protein include transcription, 
translation, translocation across the inner cell membrane and protein folding. Whether the 
reason for low accumulation levels of the P7278 antibody fragments are at the transcription or 
the translational level can be found out by perfuming a Northern Blot. The folding of the 
expressed scFvs maybe improved by modulating the primary sequence, especially of the 
framework regions, for instance by error prone PCR or by molecular evolution. 
Compared to full-sized antibodies, scFv fragments possess equivalent binding specificity but 
reduced problems in folding and assembly since both variable domains are present in a single 
polypeptide. Therefore, scFv antibodies have been regarded as the most practical solution to 
engineering a stable minimal antigen-binding domain. ScFv and other antibody fragments 
comprised of just the variable antibody domains are not effective if the constant region of the 
antibody is required for effector functions. The working principle of the anti-LHRH antibody 
is simply based on the neutralisation of LHRH. Moreover, due to monovalent binding of the 
antigen, antibody-antigen-complexes will not be formed which is a prerequisite for bringing 
about the effector function conferred by the constant region. Therefore, the action of scFv and 
diabody molecules is expected to be qualitatively similar to the full-length anti-LHRH 
antibody. A comparison of the bio-effect of scFv, diabody and chimeric antibody fragment 
based on the diffusion and clearance rates of the molecules was the intention. Due to the poor 
yields of the scFv P7278 and diabody P7278 fragments obtained from the plant and bacteria, in 
vivo assays with these proteins were not performed.  
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IV.4 Transient expression and purification of chimeric rAb P7278 
The therapeutic potential of murine monoclonal antibodies is limited due to reasons like 
anaphylaxis, clinical manifestations of immune complex formation and HAMA response. It 
has been demonstrated that a single administration of murine mAb can result in the 
appearance of HAMA in about half of the patients whereas multiple administrations (three or 
more) of some of the mAbs have resulted in an HAMA response in greater than 90% of the 
patients (SECCAMANI et al., 1989; REYNOLDS et al., 1989). Only a fraction of the anti-
mouse immune response is known to be directed to the variable region of the rodent 
immunoglobulins while most of the immunogenic portion of antibodies are the species 
conserved constant regions (BRUGGEMANN et al., 1989; LARRICK et al., 1991; 
LoBUGLIO et al., 1989). For this reason several laboratories have used recombinant DNA 
technology to construct chimeric mouse human mAbs by attaching the human constant 
regions to the rodent variable regions (MORRISON et al., 1987; BOULIANNE et al., 1984). 
As the antibody-combining site resides within the variable regions, these molecules maintain 
their affinity for the antigen and acquire the function of the substituted constant region 
(BRUGGEMANN et al., 1987; STEPLEWSKI et al., 1988). Therefore, to make the anti-
LHRH mouse monoclonal antibody more conducive to therapy, a mouse-human antibody 
chimera was constructed. 
The IgG human constant domain was chosen for the construction of the anti-LHRH chimeric 
antibody because it is the principal isotype in the blood and the extracellular fluid. The ability 
of the IgG antibodies to diffuse easily throughout the extracellular fluid makes these the ideal 
choice. Of the four IgG subclasses - IgG1, IgG2, IgG3 and IgG4- most investigators for 
therapeutic purposes have used IgG1 constant region domain to generate chimeric antibodies 
because of its serum half-life and capacity to fix complement and bind to Fc receptors 
(LoBUGLIO et al., 1989). In the case of the chimeric anti-LHRH antibody the final goal 
being the immunoneutralisation of LHRH by passive administration, for increased therapeutic 
action of the antibody, a longer serum-half life was desirable although the effector functions, 
as discussed in section IV.3, were not essential for the neutralisation action of the antibody.  
IV.4.1 Expression and purification of ER targeted chimeric rAb P7278 
The chimeric rAb P7278 was transiently expressed in tobacco leaves by vacuum assisted agro-
infiltration (III.6). The transient expression system by agro-infiltration (KAPILA et al., 1997) 
allowed quick analysis of the anti-LHRH chimeric antibody. The heavy and light chains of the 
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chimeric antibody were cloned separately in plant expression vectors and targeted to the 
secretory pathway. It has been shown that for proper assembly of the antibodies in plant cells 
it is essential that the proteins be targeted to the ER as in a mammalian system (HEIN et al., 
1991). The passage through the ER is particularly essential for the expression of full-length 
antibody because the four chains of the antibody are folded in discrete domains that are 
stabilised by intramolecular disulphide bonds. Furthermore, the chains are linked with each 
other by intermolecular disulphide bonds. Plant homologues of mammalian protein disulphide 
isomerases, involved in disulphide bond formation, and the molecular chaperones which 
mediate the correct folding of the disulphide bonded proteins have been shown to be located 
in the ER (DENECKE 1996). Passage through the ER is also important for the glycosylation 
of the protein. All full-length antibodies have a conserved N-glycosylation site (Asn297) 
present on the CH2 domain of the heavy chain that constitutes the Fc region (Rademacher et al. 
1986). N-glycosylation of the Fc is known to contribute to the structural stability of the 
immunoglobulin (Parekh et al. 1985).  
The co-translational translocation of the recombinant antibody into the ER requires the 
presence of a signal sequence fused to the genes encoding the mature H and L chains (HIATT 
et al., 1989). The origin of the required signal sequence is not critical since sequences from 
plant, mouse and yeast have been successfully used (DÜRING et al., 1990; HEIN et al., 
1991). In the case of the chimeric rAb P7278, the leader sequence derived from the light chain 
of a murine mAb was fused to the genes encoding the chimeric heavy and light chains for 
targeting to the secretory pathway.  
The expression of the full-length antibody was achieved by vacuum assisted co-infiltration of 
the two Agrobacterium cultures containing the chimeric heavy and the light chains into intact 
tobacco leaves. Simultaneous expression of the heavy and the light chains in the same cell due 
to multiple transformation events resulted in the assembly and accumulation of the full-sized 
chimeric antibody. The presence of the intact chimeric rAb P7278 and its binding activity to 
LHRH was confirmed by ELISA, SDS-PAGE and Western blot analysis.  
The only form of degradation that was observed in the purified chimeric rAb P7278 was the 
appearance of two closely placed bands both for the heavy and for the light chains as seen 
from the Western blot analysis performed with the AP labelled GAH-Fc and GAH-Fab 
antibodies (Fig.III.28). The two bands were clearly visible for the light chain. Double bands 
for the heavy chain were not easily distinguishable because of the poor separation due to the 
large size of the heavy chain and due to the glycosylation of the heavy chain that itself leads 
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to the appearance of multiple bands. Detection of the chimeric rAb P7278 with antiserum to 
KDEL, the C´ terminal tag fused to each antibody chain for ER retention, revealed only one 
band, which corresponded to the upper band of the two observed with the GAH antibodies. 
This shows the absence of the KDEL tag in the lower band of the pair. 3´ terminal sequencing 
of protein extracted from each of the two protein bands from an SDS-PAGE gel or mass 
spectrometric analysis would provide a definite answer to this anomaly. A similar antibody 
detection pattern with the anti-tag antibodies was also observed for the anti-hCG and the anti-
CEA chimeric antibodies transiently expressed in tobacco leaves in our laboratory. Such a 
cleavage of the C terminal c-myc tag of an scFv expressed in bacteria has been reported 
elsewhere, resulting in the characteristic closely spaced double band caused due to proteolytic 
cleavage (BRUYNS et al., 1996).  
CEA and hCG specific chimeric antibodies are the other two antibodies that have been 
expressed and purified from tobacco leaves by vacuum assisted agro-infiltration (VAQUERO 
et al., 1999; KATHURIA et al., 2002). A direct comparison between the three antibodies can 
be made as all the three antibodies were targeted to the ER and the constant regions of both 
the heavy and the light chain are identical. The only difference amongst the three antibodies is 
in the 5´UTR and the leader peptides used. However, this difference can be disregarded as a 
study about the expression of an scFv fused to different leader peptides and 5´UTR, including 
the ones used for the three chimeric antibodies, has shown that protein expression is only 
slightly (less than two fold) affected by the change in these elements (TORRES et al., 1999). 
A comparison of the chimeric antibody yields showed that the expression levels of chimeric 
rAb P7278 was as much as eight times higher as compared to the anti-CEA chimeric antibody 
(VAQUERO et al., 1999), while the expression levels of anti-hCG chimeric antibody were as 
high as 20 mg of antibody per kg of fresh weight leaf material i.e. 2.5 times higher than 
chimeric rAb P7278 (KATHURIA et al., 2002). The differences in expression levels of the 
three antibodies can be extrapolated to the differences in the sequence of the variable regions 
given that all other elements of the expression cassette make little or no difference. 
Comparative analysis of mRNA levels by Northern blotting would help to shed light on 
whether the difference in levels of protein accumulation is attributable to unstable RNA 
transcripts or to the instability of the translated polypeptides. 
IV.4.2 Comparison between the ER and the apoplast targeted chimeric rAb P7278  
Expression levels of recombinant antibodies in plants can be enhanced by exploiting the 
innate protein sorting and targeting mechanisms that plant cells use to target host proteins to 
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organelles. It has been experimentally confirmed that antibodies that are directed to the 
secretory pathway, following assembly and post-translational processing, are secreted by 
plant cells into the apoplastic space (HEIN et al., 1991; DeWILDE et al., 1998). Targeting 
proteins for secretion to the apoplast (the intra-cellular space beneath the cell wall) does lead 
to significant levels of expression but retention in the ER has shown to give 10 to 100 fold 
higher yields (Conrad et al. 1998). For a comparison in expression levels of the chimeric rAb 
P7278 the light and heavy chimeric chains were cloned separately in plant expression vectors 
for targeting to the ER compartment of the plant cells and to the apoplast (III.6.4). The leader 
peptide directs the protein to the secretory pathway and the KDEL retains the protein in the 
ER disallowing it to move further down the pathway. If the KDEL tag is not present the 
expressed protein is expected to be secreted into the apoplast. In the case of the chimeric rAb 
P7278 the expression levels of antibody targeted to the ER and the apoplast were found to be 
comparable, an observation that is contrary to what has been observed in the case of several 
other antibodies.  
IV.4.3 Alternate plant expression hosts 
The chimeric anti-LHRH antibody was transiently expressed by vacuum-assisted agro-
infiltration in a few plant species other than tobacco (III.6.7). Direct ELISA of the plant 
extract on LHRH coated plates revealed that expression level of the chimeric antibody was 
always observed to be the highest in Nicotiana tabaccum cv. Petit Havanna SR1. The plants 
that were tested in Germany were grown in the greenhouse under conditions optimised for the 
growth of tobacco. Therefore the possibility of an increase in protein accumulation levels 
under growth conditions optimal for the other plant species cannot be negated. Expression 
levels in species like the green squash and spinach beet were comparable to tobacco. 
Moderate level of expression was obtained in the variety of spinach tested in India. Spinach 
could serve as a good candidate for protein expression and purification as it can be grown 
easily, has a high biomass and more importantly is a common constituent of human diet. 
Tobacco has become one of the most popular hosts for production of heterologous proteins. 
This is because developing transgenic tobacco plants is a well-established and reliable 
process, and tobacco plants have been shown to correctly process complex human proteins. 
Tobacco as a crop plant has been optimised for biomass: a single acre of transgenic tobacco is 
able to produce 5-10 kg of bulk protein product.  A single transgenic tobacco plant can 
produce numerous seeds, thereby facilitating rapid scale-up to substantial acreage. However, 
that does not leave out the possibility of other plant species performing equally well or better 
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as compared to tobacco. The expression levels of proteins may also be host plant dependent 
for example an antibody that accumulates only to 0.04% of TSP in tobacco leaves 
accumulates up to 1-3% of TSP in leaves of Arabidopsis thaliana (DeNEVE et al., 1993).   
Vacuum assisted agro-infiltration of the recombinant proteins is well suited for such an 
interspecies plant analysis, as the protein accumulation levels can be accurately compared and 
in a short time.  This is so because transient expression by agro-infiltration is not constrained 
by aspects like the site of integration of the gene, or by the recalcitrance of some plant species 
to regeneration, the problems inherent with stable plant transformation. Once the plant species 
in which the protein is best expressed is found, transgenic plants can be generated.   
Other than optimal expression levels, plant species and varieties can be screened for various 
other features. The plant used for expression of a particular protein might vary depending on 
its ultimate use. Purification of recombinant proteins from tobacco requires extensive 
purification protocols for removal of the phenolic compounds present in the plant extract. A 
protein useful for in vitro assay will not require a high degree of purity that is a must for an 
antibody to be used in therapy for which the presence of such noxious compounds would be 
undesirable. An alternate plant host with reduced content of phenolic compounds, such as the 
various salads or other leafy vegetables used as food or feed crop could prove beneficial. 
Plant screening might also help to identify edible plant varieties for oral delivery of the 
recombinant protein in food for humans or feed for animals. Growth of any particular species 
of transgenic plants in fields would be season dependent; selection of alternate plant hosts can 
be based on varieties available in different seasons to provide a perennial source of the 
protein. Moreover, this would also overcome climatic constraints for the growth of a 
particular plant species if the seeds were to be distributed in the various countries around 
the world.  
IV.5 Generation of transgenic tobacco plants expressing chimeric 
rAb P7278 
For the initial characterisation, the LHRH specific antibody fragments were transiently 
expressed in up to 1 kg of tobacco leaves by vacuum assisted agro-infiltration and 
subsequently purified by affinity chromatography. While this protein expression method 
allowed the quick preliminary analysis of the antibody, transgenic plants once made would 
provide an easy and perineal source of the same. From the transient expression assay it was 
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demonstrated that the scFv and diabody accumulated to very low levels in the tobacco leaves. 
Therefore, transgenic plants were generated for expression of the chimeric rAb P7278 only.  
The method of choice for antibody expression in plants has been the generation of stably 
transformed plants expressing the individual chains that are eventually crossed sexually to 
assemble the full size antibody (HIATT et al., 1989; MA et al., 1994). Although yields 
ranging from 1–5% of total plant protein are achieved by this technique, the need for cross-
pollination to generate an antibody-producing plant requires two generations of plants. 
Double transformation techniques to introduce both the heavy and light chain genes into the 
same plant cell simultaneously (DeNEVE et al., 1993) or the introduction of the two genes on 
a single T-DNA (DÜRING et al., 1990; vanENGELEN et al., 1994) have been tried.  
Although the time required to acquire the antibody producing plant is reduced by these 
methods there is a trade-off in the expression levels and the simplicity of the procedure. The 
former strategy that requires the generation of stable lines expressing the individual chains 
followed by their sexual crossing was adopted for the generation of transgenic plants 
expressing chimeric rAb P7278.  
The regenerating transformed cells were selectively cultured which was achieved through co-
transformation of a selectable marker gene coding kanamycin resistance with the gene of 
interest. Cells that incorporate the selectable marker gene and in turn the gene of interest 
multiplied and regenerated to plantlets under selection pressure in tissue culture and then were 
transferred to soil to develop into mature plants. The plantlets were evaluated early in their 
development to ensure that they contained the transgene of interest. The selected plants were 
self-crossed twice in order to develop a transgenic plant line to ensure that the transgene is not 
lost through segregation in subsequent generations. The T0 and the T1 generations of 
transgenic plant lines expressing the chimeric light and heavy antibody chain have been tested 
and the best expressing lines have been identified (III.7.1). Currently seeds from the T1 
generation have been sown on kanamycin containing tissue culture media plates. The plant 
lines that will exhibit 100% resistance will be grown and sexually crossed with the plants 
expressing the complementary antibody chain for generation of transgenic plants expressing 
the full-length chimeric rAb P7278.    
Another method to make homozygous plant lines expressing both the antibody chains is the 
tissue culture of the anthers resulting from a cross of the T0 generation plants identified to be 
positive for expression of the two antibody chains. This method is quick and the need for the 
numerous self-crosses that are required in the previous method are averted. For this reason 
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some of the T0 generation plants identified as the best antibody chain expressers were crossed 
and are presently being developed. 
The T0 generation crosses also provided the opportunity to analyse the antibody accumulation 
levels in a transgenic plants. SPR analysis of the crude extract of the crossed plants revealed a 
two fold higher amount of the antibody accumulation level (16 mg per kg fresh leaf material) 
when compared to transient expression in tobacco leaves (III.7.2).     
As the active chimeric rAb P7278 concentrations in crude plant extract can be precisely 
determined by SPR, the transgenic plants can be used for measuring the antibody amounts in 
differing plant growth condition or growth stage with ease and rapidity.  
IV.6 Antibody affinity measurements  
The mouse mAb P7278 is a high affinity antibody with a dissociation constant of 3.9⋅10-10 M-1. 
The KD of the mouse mAb P7278 had been determined by competitive radioimmunoassay 
(RIA) using iodinated LHRH and the obtained values were fitted by Scatchard plot 
(TALWAR et al., 1985). The equilibrium constant of the chimeric rAb P7278 was instead 
determined by surface plasmon resonance (SPR) using the Biacore (III.8). For a reliable 
comparison between the chimeric and the mouse monoclonal antibody, the equilibrium 
constant of the mouse mAb P7278 was remeasured using SPR.   
The equilibrium constants have often been derived from the kinetic constants that are 
determined by measuring the interaction between the antibody and the surface bound antigen 
on the Biacore (FÄGERSTAM et al., 1990; KARLSSON et al., 1991). However, deriving the 
equilibrium constant from the kinetic rate constants determined by Biacore experiments can 
be prone to many errors and artefacts. The standard treatment for measuring the kinetic 
constants of the Ab-Ag interaction is only applicable for a pseudo-first order interaction 
model . For more complex reactions, for instance between a full-size antibody 
having two or more binding sites for the ligand, this method doesn’t always give reliable 
measurements. The other aspect that leads to a deviation from the actual measurements of the 
kinetic constants is the heterogeneity of the system, that is the antigen is immobilised and the 
analyte is in solution. The immobilisation of the antigen can lead to a change in its 
conformation causing a resulting change in its interaction with the antibody. Furthermore, the 
antibody can form higher order complexes with the immobilised antigen distorting the actual 
ABBA ⇔+
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values of the rate constants that drive the Ag-Ab reaction. These effects can lead to deviations 
from solution equilibrium constants by several orders of magnitude.  
However, it has been shown that with Biacore true solution affinities can be determined using 
competition experiments (NIEBA et al., 1996). Such experiments rely on the measurement of 
the concentration of free analyte in a solution containing ligand and analyte that has reached 
equilibrium. Because the contact time is very short (~0.6 sec) the equilibrium is not distorted 
even for fast reactions.  
In the case of the mAb P7278, native LHRH was used for establishing solution equilibrium, 
while a derivative of the antigen, D-Lys6-LHRH, was immobilised on the sensor surface for 
the measurement of the free antibody. This derivative was used, as LHRH does not have any 
free primary amine groups for immobilisation on the chip surface by amine coupling. The 
choice of D-Lys6-LHRH was ideal as the mouse mAb P7278, from which the chimeric 
antibody was derived, was raised by immunization with D-Lys6-LHRH conjugated to 
diphtheria toxin (DT) on the sixth amino acid while the mouse mAb P7278 was selected on 
native LHRH antigen. By correlation, it becomes clear that the sixth amino acid of the 
decapeptide does not constitute the epitope to which the antibody binds which was further 
confirmed by reactivity of the antibody to coated D-Lys6-LHRH in an ELISA set-up. 
The binding signal observed on injection of the antibody and antigen equilibrium mix on the 
ligand coated sensor chip is a measure of the concentration of the antibody with free binding 
sites. For an antibody that has only one binding site for the antigen, the observed binding rate 
is proportional to the free antibody concentrations. However, an antibody with two binding 
sites can bind zero, one or two antigens. Hence, the observed binding rate is no longer simply 
proportional to free antibody concentration; and instead is the measure of the concentration of 
antibody molecules bound to none or one antigen molecule. Therefore, in the case of the anti-
LHRH antibodies the bivalency of the antibody had to be taken into account for fitting the 
curve obtained on plotting the observed binding rates against the concentration of LHRH 
added to that sample. The resulting binding curve from the competition Biacore experiment 
was fitted by non-linear least square fit using an equation corrected for the bivalency of the 
antibody to obtain the value of the inhibitory constant KI. 
The underlying assumption made in this experiment was that the two binding sites of the anti-
LHRH antibodies were independent of each other. As the LHRH is a small peptide and the 
binding sites are far enough from each other it was assumed that both the binding sites have 
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the same affinity for the peptide and the binding of LHRH to one site does not effect the 
binding to the second site.  
Simulation experiments performed for calculation of the dissociation constants with varying 
concentrations of antibody P7278 demonstrated its importance in deriving accurate values of 
equilibrium constants. When higher concentrations of antibody were used, the non-linear 
curve fitted to the obtained curve was more accurate for the values of concentration of the 
antibody used in the experiment. With lower antibody concentrations the derived dissociation 
constants were more accurately. Therefore, affinity measurements were made using very low 
concentrations of the antibody.  
The KI value obtained for the chimeric rAb P7278 (3.4⋅10-10 M-1) was indistinguishable from 
that of the mouse mAb P7278 (3.5⋅10-10 M-1) within experimental errors.  Moreover the values 
of the dissociation constant obtained for the mouse mAb P7278 by competition BIAcore was 
comparable to the value derived by RIA using iodinated LHRH where the observed values 
were fitted by Scatchard plot (3.9⋅10-10 M-1) demonstrating the reliability of the 
obtained measurements.  
The prime requirement for affinity measurement in solution is the measurement of 
concentrations of free and saturated sites at equilibrium and analysis of the binding curve. The 
experimental difficulty mainly resides in distinguishing the free and bound states of either the 
mAb or the Ag. The methods that have been used are equilibrium dialysis, RIA using 
precipitation, filtration, fluorescence measurements, or ELISA based methods (OHANIANCE 
et al., 1997; SAUNAL et al., 1997). These methods are beset with problems like labelling of 
the measured molecules or measurement in heterogeneous systems. The Biacore system on 
the other hand does not require the preliminary separation of the free from bound antibody, 
which is the prerequisite for all the other methods by which equilibrium constants can be 
measured (reviewed by SAUNAL et al., 1997). The species at equilibrium in solution are not 
labelled, which ensures that the observed affinity is characteristic of the native mAb and 
antigen. Moreover, the interaction between the Ag with the Ab takes place in a homogenous 
environment resulting in accurate affinity measurements. Other advantage that measurement 
on the Biacore has over others is that it is rapid and permits the screening of a variety of 
conditions such as varying temperature.  
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IV.7 Immunoneutralisation of LHRH in vivo 
The bioefficacy of the anti-LHRH mouse and chimeric antibodies was tested by their ability 
to block the estrus cycle of regularly cycling rodents (III.10). The first experiments of estrus 
cycle disruption were demonstrated in regularly cycling rats using the mouse mAb P7278. This 
was essential because the murine antibody has not been tested for bio-efficacy independently 
in any experiment. The only experiment that proved the bio-efficacy of the mouse mAb P7278 
was the one that described estrus cycle disruption in dogs using a mixture of ascitis of two 
anti-LHRH antibodies – P81662 and P7278 (TALWAR et al., 1984). Although the authors did 
point out the possibility of the clones being derived from one original clone, this was never 
proved and therefore experimental evidence for the bio-efficacy was essential. The 
availability of ample amounts of mouse mAb P7278 also allowed the study of dose dependent 
disruption of estrus cycle in rats.  
The antibody was always injected intraperitoneally on the first day of diestrus. The choice of 
the day of injection was based on the extensive studies done that elucidate the changes in 
pituitary LHRH receptors during the rat estrus cycle. It is known that in normal cycling rats, 
the pituitary LHRH receptors begin to rise on the first day of diestrus, reaching maximal 
levels during the morning of proestrus, after which the numbers fall to a nadir at estrus 
(SAVOY-MOORE et al., 1980; CLAYTON et al., 1980). The primary driving force for the 
rise in pituitary LHRH receptors at pro-estrus in the rat is LHRH itself because treatment with 
an anti-LHRH antiserum is known to completely abolish this rise (POPKIN and FRASER et 
al., 1983). Consequently the LHRH concentration also rises from the first day of diestrus till 
the morning of proestrus. Based on these observations the anti-LHRH antibody was injected 
on the first day of diestrus (D1) to inhibit the rise in the LHRH receptor number on the 
pituitary by immunoneutralisation of the rising LHRH concentration.   
The cyclicity of the animals was monitored by examination of vaginal smears. It is well 
known that the vaginal epithelium is responsive to sex steroids, particularly estrogen 
(SHIRLEY et al., 1968), and undergoes predictable changes throughout the estrus cycle in 
response to changes in blood concentration of ovarian hormones. Rising levels of estrogen 
causes the vaginal epithelium to become "cornified" – the surface cells become large and 
flattened, with small or absent nuclei as seen in the estrus stage of the cycle (EVERETT, 
1961). The cytological profile changes as the cycle proceeds. In essence, vaginal cytology is a 
type of endocrine assay and tracking changes in the morphology of desquamated vaginal 
epithelial cells provides convenient means of assaying changes in estrogen levels. 
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Administration of varying amounts of mouse mAb P7278 caused a dose dependent suppression 
of the estrus cycle (III.10.1). While cornification of the vaginal cells was observed in control 
rats (PBS injection), the vaginal smears of the antibody treated rats did not contain cornified 
cells, the characteristic feature of the estrus phase. The arrest of the cycle in diestrus stage in 
the antibody treated rats was attributed to the inhibition of estrogen activity in the animals due 
to the disruption of the reproductive hormone cascade. The experiments further demonstrated 
that the duration of the diestrus was related to the amount of anti-LHRH antibody injected, 
proving that the observed effect was due to the anti-LHRH antibodies.  
Another corollary of this experiment was that the duration for which the cycle was disrupted 
was related to how quickly the reproductive axis recovered from the suppressive effect of the 
anti-LHRH antibody and normal cycle was resumed. This is evident from the observation that 
animals in which the estrus cycle was arrested at the diestrus stage for ~30 days did not return 
to normal cycling for the whole duration of the experiment (~60 days), instead these animals 
went into a phase of constant estrus. A dose of 1.2 mg of the antibody caused the estrus cycle 
to arrest at diestrus stage for 10 days followed by irregular cyclicity for another ten days after 
which regular estrus cycle of 4 days was resumed. This phenomenon of irregular cyclicity was 
not observed when animals were given doses of 500µg and 250 µg of the antibody that caused 
an arrest in the diestrus stage for 5 and 3 days respectively after which normal cycle was 
resumed. A similar observation, where the mice went into a persistent estrus phase after a an 
initial prolonged disetrus due to passive immunization with anti-LHRH mouse monoclonal 
antibodies has been reported before (CARSON et al., 1996). In contrast, similar studies 
carried out by the investigators who generated a panel of LHRH specific monoclonal 
antibodies including the mouse mAb P7278 (GUPTA et al., 1985), revealed that the duration of 
diestrus in the immunized mice was extended for 28-30 days after which normal cyclicity 
was resumed.      
The phenomenon of constant estrus has been reported in the population of rats actively 
immunized with LHRH that produced low titers of antibodies to LHRH. The ovaries of these 
rats showed cystic follicles, which are presumed to be stimulated by low basal levels of 
gonadotropin secretion occurring with an absence of pre-ovulatory surge (FRASER and 
BAKER 1978). Another study has shown that rats with persistent pattern of constant estrus 
exhibited alterations in basal and pulsatile LH and FSH concentrations, changes in pituitary 
response to LHRH, degenerative changes in the hypothalamus and high estrogen levels 
(BARRIA et al., 1993). These observations can be applied to the present case. The first 30 
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days of constant diestrus can be explained by complete inhibition of the hypothalamo-
pituitary-gonadal axis due to high anti-LHRH antibody titers. With time, a reduction in the 
antibody titer due to serum clearance could have resulted in cystic follicles secreting estrogen 
resulting in constant estrus.  
Due to the limited amounts of the chimeric anti-LHRH antibody available mice instead of rats 
were used for testing the bio-efficacy of the antibody (III.10.3). This was because the smaller 
body mass of the mouse would require a lesser amount of the antibody to show the desired 
effect as in the rat. From the estrus cycle disruption experiments in rats, minimum doses of 
250µg of the monoclonal antibody was required to extend the diestrus period by one day. Two 
different doses, 100µg and 200µg of the chimeric antibody caused a disruption of the estrus 
cycle of 4 and 7 days respectively. These experiments showed that the arrest in estrus cycle 
was related to the dose of the chimeric antibody injected in the mice and the rate at which the 
antibody activity disappears from the circulation.  
The changes in estrogen levels during the estrus cycle are known to be a cause of complex 
interactions between the ovarian steroid hormones and hypothalamic LHRH and pituitary LH. 
For most of the length of the ovarian cycle, pituitary LH secretion is suppressed through 
negative feedback action of estrogen on the hypothalamus and on the pituitary gonadotrophs. 
At midcycle or proestrus, however, estrogen exerts positive feedback action on hypothalamus 
by generating a surge of LHRH from the median eminence (ARIMURA et al., 1971). The 
surge in LHRH causes a surge of LH from the pituitary. The LH surge induces ovulation by 
binding to the membrane receptors on the mature follicles thereby changing the biochemistry 
of the follicle walls, which ultimately results in the rupture of the follicle wall and extrusion 
of the ovum. This mid cycle surge of LH is called the “preovulatory LH surge”. The release of 
the egg marks the estrus stage, the cytological manifestation of which is the change in cellular 
profile of the vaginal smear to cornified squamous cells. 
This assay system thus works on the principal that if anti-LHRH antibodies were administered 
to regularly cycling animals, the LHRH released from the hypothalamus by the action of 
estrogen would be neutralized leading to the inhibition of the LH surge (ARIMURA et al., 
1974). With the LH surge inhibited there would be no ovulation, and the animal would 
continue to stay in the diestrus stage of the cycle thus providing an easy system to monitor the 
bio-efficacy of the anti-LHRH antibodies.  
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The LHRH peptide and its effect on the pituitary in releasing the LH and FSH is conserved in 
both the male and female systems, therefore the in vivo experiments carried out in this study 
have bearing and utility for further studies in a male model system. The information in these 
experiments can be used as a foundation for other experiments as the data provides 
knowledge of the response of the reproductive hormonal system to a certain dose of the 
antibody. A useful experiment to prove the utility of the antibody for prostate or breast cancer 
therapy would be the ability of the anti-LHRH antibody to cause tumour regression in an 
animal model. These kinds of studies would require large amounts of purified antibody. 
Transgenic constructs of the chimeric antibody will facilitate purification of the desired 
amount of the antibody, as large amounts of plant material would be easily available as 
opposed to the transient expression system. 
Passive immunization with anti-LHRH antibodies will overcome the limitations of the active 
immunization method that includes variation in the antibody titers amongst the immunized 
patients due to which all patients fail to show clinical benefit and the lag period in the build-
up of bio-effective antibody titre. Passive immunization of the antibody would ensure the 
desired effect without any delay and would allow administration of the antibody as per the 
requirement of the individual. The murine anti-LHRH mAb would have been inadmissible for 
this approach, as mouse antibodies when administered to humans have been shown to invoke 
a HAMA response. But the plant expressed chimeric anti-LHRH antibody can prove useful 
for passive immunization. The initial experiments have shown that the engineered antibody 
purified from plants is bio-effective and functional.  
Although chimeric antibodies are less immunogenic than their murine counterparts, their 
frequent administration has been shown to cause an immune response against the murine 
variable regions. Therefore instead of using the anti-LHRH chimeric antibody for long-term 
therapy a combined regimen of passive and active immunization approach can be envisaged. 
This kind of regime would entail active immunization of the patient supplemented with the 
administration of chimeric antibody during the lag phase that is required for build-up of the 
antibody titer.  
The plant derived anti-LHRH chimeric antibody may provide a cheap mad safe alternative to 
the present mode of sex-hormone dependent cancer therapy that utilizes expensive LHRH 
agonists and antagonists. The antibody may also find use in other therapies in which LHRH 
analogues are used e.g. endometriosis, premature puberty or in vitro fertilisation. 
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IV.8 Ligand analysis of the mAb P7278 
The search for the residues in LHRH indispensable for binding of the mAb P7278 led to the 
investigation of antibody binding activity to some natural variants and analogues of LHRH, 
differing from the native peptide by one or more amino acids. Phage display of a 12-mer 
peptide library was also carried out, the rationale being that this library should contain 
peptides similar to LHRH that would be recognized by the anti-LHRH antibody providing a 
further input to the nature of the antibody epitope.   
It was known that the sixth amino acid of the LHRH is irrelevant for mAb P7278 binding as 
the Ab was raised against the modified LHRH containing (D-Lys6) and screened against the 
native LHRH. Therefore, it can be postulated that the antibody may also bind to LHRH 
analogs that have other residues at sixth position provided no steric or electrostatic hindrance 
occurs. The native LHRH molecule is modified on both ends having a pyroglutamate on the N 
terminal and an amide group at the C terminal. It was observed that the mAb P7278 was unable 
to recognise LHRH when fused by its N terminus to GST (data not shown). On fusion with 
the N terminus the glutamine residue doesn’t cyclise to form the pyroglutamate. This raises 
the following possibilities – the modified ends of the hormone are structurally essential for 
antibody binding, or the neutral charge resulting due to the modification are the factor 
responsible or both. Having known these features the minimal binding motif of the antibody 
was further elucidated by the following studies.   
IV.8.1 Binding activity of mAb P7278 to some LHRH variants 
Although the classical alanine scan or a total set of all 10 x 20 single point mutations would 
have provided essential and complete information about the contribution of individual 
residues it was decided to test a few LHRH analogues. The reason for this was twofold, firstly 
it helped in generation of a preliminary data set on the basis of which further investigations 
can be based and secondly there were important implications of the binding activity of the 
mAb P7278 with some of the chosen LHRH analogues.  
As the aim of this experiment was merely to test the antibody binding to the LHRH variants, 
therefore the peptides were mixed in great molar excess to the antibody concentration for the 
Biacore competition experiment. The affinity of the antibody to these variants may differ and 
has not yet been determined. Although the present data is preliminary there is substantial 
indication that the mAb recognizes almost all the LHRH variants that were tested (III.12). Out 
of the 10 amino acids that constitute LHRH, six replacements were made. All the 
 
IV Discussion  128
replacements were tolerated and antibody binding was maintained. This shows that at the 
positions tested a considerable degree of freedom was acceptable although a more detailed 
analysis will provide more concrete information. Moreover the importance of the amino- and 
carboxy-terminal ends of LHRH for recognition by the monoclonal antibody did not lie in the 
structure but rather on the neutral charge conferred by the modified ends. More detailed 
analysis about the contribution of an amino acid to the binding to the antibody can be 
estimated after the affinity determination for each of the variant. 
The ability of the mAb P7278 to recognize the LHRH isoforms shown to be present in 
mammals is very intriguing. While the existence of the GnRH-II has been unambiguously 
shown in the human brain the GnRH-III has two contenders (see section I.3 of the 
Introduction). The issue of the nature of the third GnRH isoform stands unresolved. The 
conflict partly arises due to the nature of the antibodies used for immunodetection. The 
antibodies are mostly polyclonal and given that the isoforms have high sequence homology 
the possibility of cross-reactivity lends to the ambiguity in the results. Initial binding 
experiments have demonstrated binding activity of the anti-LHRH antibody with salmon-
LHRH (the probable mammalian LHRH-III) and mammalian LHRH-II in addition to the 
hypothalamic LHRH. Using protein engineering it may be possible to create antibodies that 
exclusively recognize each isoform. Such antibodies can then be used to selectively detect and 
neutralise an LHRH isoform to study the localisation and biological effects.  
Some researchers have expressed concern for the unintentional immunoneutralisation of all 
the LHRH isoforms due to their close resemblance (FERRO et al., 2001). They argue that, as 
the biological functions of the isoforms are still not unambiguously stated, the implications 
that their immunoneutralisation can cause are not known. On the other hand the few reports 
that are present on the function of the LHRH isoforms show that these peptides can cause the 
release of the gonadotropins although they could be also involved in other varied functions 
(YAHOLAM et al., 1999; YU et al., 1997). If this is true then for complete hormone 
blockage it may become essential to neutralize all the isoforms, something that the mAb P7278 
can presently do. 
IV.8.2 LHRH mimotope   
To further characterize the role of each individual antigenic residue in binding to the antibody, 
peptide display using a random 12-mer library was carried out (III.11). The rationale being 
that this library should contain peptides similar to LHRH, which would be recognized by the 
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anti-LHRH antibody. Two rounds of panning with the Ph.D–12 library were sufficient for 
retrieval of phage clones that exhibited binding to the chimeric rAb P7278. Interestingly all the 
sequences were unrelated to the native LHRH sequence indicating that the phage sequences 
represented mimotopes of the neurohormone. Two observations ruled out artefacts such as 
binding of phage to the blocking reagent or to plastic. First, the mAb P7278 reactive phage 
were recognised by the antibody when bound to nitrocellulose membrane on western blot, 
exceeding any background detectable with negative control phage (Fig. III-47). Second, other 
antibodies, including IgG1, used to screen the same library with the same procedures did not 
result in similar peptide sequences (data not shown).  
Sequences identical to the native peptide were not isolated. Reasons for this could be that the 
affinities of the phage-displayed sequences in the context of the gpIII coat protein were higher 
than that of the native epitope, the native sequence when expressed was toxic for the bacterial 
host cell and therefore selected against, or the complexity of the library was not sufficient to 
isolate the identical sequence.  
None of the peptide sequences were fully identical to another although there was a preferred 
motif (F-E-T/S-R-S/T) present in many of the peptides. Other than this five-residue motif, the 
other seven amino acids that constituted the peptide, did not exhibit any visible pattern (Table 
III-3). Arginine residues have been shown to interfere with secretion of pIII and phage 
infectivity leading to counter selection of peptides containing that residue (Ph.d.-12 Phage 
display peptide library kit, Instruction Manual, NEB). Therefore, the presence of an arginine 
residue in the binding motif of the mimotope indicates its indispensable nature for 
antibody binding. 
Surprisingly a synthetic peptide representing one of the mimotopes did not show any binding 
activity on the Biacore or in an ELISA both in a direct or soluble competition set-up. A reason 
could be that the interaction between the antibody and the phage-displayed peptide might 
have depended on the peptide’s microenvironment that is provided by the phage particle 
during the affinity selection. In such a case the free peptide would lose the conformation that 
can be recognised by the Ab when displayed on phage particles. For this reason the C 
terminus of the peptide was blocked so that there is no charge present as is found when the 
peptide is fused to the pIII of the M13 phage. There is a low possibility of the amino acid 
residues immediately following the C terminal of the peptide to contribute to the binding 
epitope, as the consensus sequence that was determined was mostly present in the first half of 
the 12mer peptide (Table III-3).  
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The resulting mimotopes could mimic the epitope present in the native protein either due to 
similarity in the amino acid sequence or in the conformation adopted by the peptide. The 
increased length of the displayed peptide in the Ph.D-12 library allows folding into small 
structural elements (short helices, α-turns, etc.) that may be necessary for target binding. The 
LHRH peptide is known to adopt a preferred conformation in solution due to a type II β-turn 
involving residues 5 to 8 of the decapeptide (MORRISON et al., 1987). Therefore the 
monoclonal antibodies to LHRH can potentially accommodate certain degree of flexibility in 
interaction with an antigen provided that their recognition motifs are conformational or 
topological mimics of the native epitope. 
Identification of epitopes for an antibody by overlapping peptide synthesis has been well 
recognized as a useful tool to characterize interacting motifs. Random peptide libraries in 
which peptides are displayed as fusion protein with the minor coat protein pIII has increased 
the repertoire that can be searched for reacting domains (LANE et al., 1993) and widened the 
scope of identification of structurally similar motifs adopted by dissimilar sequences. In many 
cases identification of binding motifs by phage display has allowed the identification of 
epitope sequences not identical to that present in the protein antigen, thereby describing 
sequences that mimic the native epitope (PACHOLCZYK et al., 1997). Phage display also 
provides information on the critical amino acids that are required for interaction with a 
specific antibody, and as a corollary, identifies amino acid replacements in the epitope that 
can be tolerated by the paratope of the monoclonal antibody in question (STEPHEN 
et al., 1995).  
Further characterisation of the mimotope needs to be carried out. The primary question that 
arises is that whether the two peptides, despite having different primary structures, fold into 
similar tertiary structures with the isolated peptide being a true mimotope. And if indeed the 
mimotope would resemble the molecular image of LHRH it would be interesting to find out 
whether it would also bind to the LHRH receptor and exhibit agonistic or antagonistic 
biological effects. Thus the isolated peptide might be a valuable structural lead for developing 
new LHRH analogues. In vitro binding assays of the mimotope can be performed with LHRH 
receptor expressed on cell lines, while testosterone suppression in rats can be studied for the 
biological activity in vivo (BECKERS et al., 2001).     
The mimotopes if recognized by the anti-LHRH antibody in the context of a fusion protein 
would enable the affinity purification of the recombinant LHRH antibody making addition of 
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tags unnecessary. The mimotopes can also be assessed for their ability to raise an immune 
response cross reactive to LHRH. This ability of the mimotope would make it an effective 
vaccine. The mimotope being a non-self molecule may be more immunogenic as compared to 
the native hormone. Conventionally, immunization against LHRH is carried out by chemical 
conjugation of the hormone to a carrier protein to render it immunogenic. Chemical 
conjugation of proteins suffers from inconsistency from batch to batch requiring extensive 
characterization of each batch for therapy. A recombinant vaccine consisting of the LHRH 
mimotope could provide an easy and effective alternative.  
 
 
 V Summary 
This thesis reports the construction of a single chain variable fragment (scFv P7278), diabody 
(diabody P7278) and a mouse/human full-length chimeric antibody (chimeric rAb P7278) by 
recombinant DNA technology. The variable domains that constituted these antibody 
fragments were derived from the high affinity anti-LHRH mouse mAb P7278. The variable 
domains of the heavy and light chains of the monoclonal antibody were amplified from first 
strand cDNA synthesised from mRNA isolated from the hybridoma P7278. The variable 
regions were assembled together to generate a mini-library of single chain fragments. The 
mini-scFv library was screened for functional binders by expression of a few randomly 
selected scFv clones in E. coli. Following conformation of binding activity of the scFv by 
direct ELISA the variable heavy and light chain antibody domains were cloned as a diabody 
by linking them with an eight amino acid long linker. The chimeric rAb P7278 heavy and light 
chains were constructed by genetic fusion of the variable antibody gene fragments of mouse 
mAb P7278 to the human IgG1 and kappa constant domains respectively. 
The antibodies thus made were transiently expressed in tobacco leaves by vacuum-assisted 
agro-infiltration and purified by affinity chromatography. While the chimeric rAb P7278 was 
expressed at moderately high levels in tobacco leaves the expression levels of the scFv P7278 
and diabody P7278 fragments was found to be low. Similar expression levels of the scFv and 
diabody were also obtained in bacteria, the reason why their bio efficacy could not be tested.  
The specific reactivity of the recombinant antibodies to LHRH was analysed by direct ELISA 
while the SDS-PAGE and western blot analysis revealed the purity and intactness of the 
purified antibody. Gel filtration analysis of the plant-purified scFv P7278 indicated that when 
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in solution the scFv had the propensity to exist in both monomeric and dimeric forms as 
opposed to the diabody P7278 that was present in only one form corresponding to 
the expected size.  
A comparison of the expression levels of chimeric rAb P7278 targeted to the apoplast and the 
ER by direct LHRH ELISA of the infiltrated tobacco leaves revealed nearly similar antibody 
levels in both cellular compartments. A few plant species were screened as alternate plant 
expression host for the chimeric rAb P7278 by agro-infiltration. Although the antibody 
accumulation levels were found to be the highest in Nicotiana tabaccum cv. Petit Havanna 
SR1, moderate amounts of antibody was found in a few other plant species. Non-segregating 
lines expressing the heavy and light chains of the chimeric rAb P7278 have been generated and 
will be subsequently crossed to yield transgenic plants expressing the full-length antibody. In 
a preliminary experiment the T0 generation of plants transformed with the heavy and the light 
chimeric chains were crossed and the progeny co-expressing the two chains were identified. 
The levels of antibody expression in these plants as determined by quantitative SPR analysis 
of the crude extract was found to be nearly twice the amount of the levels obtained in 
transient expression.  
The equilibrium constants of the plant expressed chimeric rAb P7278 and the parental 
murine P7278, as measured by SPR using BIAcore, were found to be indistinguishable. 
Incubation of chimeric rAb P7278 and the mouse mAb P7278 in human serum in vitro revealed 
high stability of both the mouse mAb and the chimeric antibody at the physiological 
temperature in the human serum environment. Antibody activity after 32 days at 37°C in 
human serum was determined to be 70% for chimeric rAb P7278 and 60% for mouse 
mAb P7278. Both the anti-LHRH mAb and the plant derived chimeric antibody were shown to 
be bio-effective. The antibodies caused an arrest in the estrus cycle of regularly cycling 
rodents. The duration of the estrus cycle disruption was found to be related to the dose of the 
antibody administered.  
Finally a set of related peptide motifs were isolated from a phage displayed random 12-mer 
peptide library that unambiguously bound to the mAb P7728. The isolated peptides are 
mimotopes, as they do not show any similarity with LHRH at the primary structural level. 
Furthermore, binding analysis of a few LHRH variants with the mAb P7278 revealed that the 
antibody also recognizes two other isoforms of LHRH reported to be found in humans.
  
 
 Appendix 
List of abbreviations 
°C degree Celsius 
$ US Dollar 
% percentage 
λ wavelength 
A adenine 
aa amino acid(s) 
Ab antibody 
Amp ampicillin 
ampr ampicillin resistance 
Asn asparagines 
AP  alkaline phosphatase 
A. tumefaciens Agrobacterium tumefaciens 
BCIP  5-bromo-4-chloro-3-indolyl phosphate 
bp  base pair 
BSA  bovine serum albumin    
C  cytosine 
CaMV  Cauliflower mosaic virus 
Cb  Carbenicillin 
CB  coating buffer 
CDR  complementarity determining region 
CEA  carcinoembryonic antigen 
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CH  constant region of heavy chain 
CL  constant region of light chain 
CHS  chalcone synthase 
cv.  cultivar 
Da  Daltons, g/mol 
DMSO  dimethylsulfoxide 
DNA  desoxyribonucleic acid 
dNTP  deoxynucleotide triphosphate 
DT  diphtheria toxoid  
DTT  dithiothreitol 
E. coli                                     Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
ER  endoplasmic reticulum 
Fc  “Fragment crystallizable”  
FDA  Food and Drug Administration 
FSH  follicle-stimulating hormone 
G  glycine 
GAM  goat-anti-mouse (antibodies) 
GnRH  gonadotropin releasing hormone 
gm  gram  
h  hour(s) 
HAMA  human anti mouse antibody 
HBS  Hepes buffered saline 
His  histidine 
HPLC  high-pressure liquid chromatography 
Ig  immunoglobulin 
KA  equilibrium association constant 
kDa  kilodalton 
kg  kilogram 
KI  inhibitory constant 
Km  Kanamycin 
l  liter(s)  
LBA  Luria broth with ampicillin 
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LH  Luteinising hormone 
LHRH  Luteinising hormone releasing hormone 
M  molarity (mol/L) 
mAb  monoclonal antibody 
min  minute(s) 
mRNA  messenger ribonucleic acid 
MSMO  Murashige and Skoog medium with minimal organics 
MW  molecular weight 
NBT  nitro blue tetrazolium 
nm nanometer 
OD  optical density 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
PBST  phosphate buffered saline containing 0.05% (v/v) Tween20 
PCR  polymerase chain reaction 
PNPP  para-nitrophenylphosphate 
rAb  recombinant antibody 
Rif  Rifampicin 
RIA  radio immuno assay 
rpm  rotations per minute 
RT  room temperature 
scFv  “single chain Fragment variable” 
SDS  sodium dodecylsulfate 
SOE  splicing by overlap extension 
T  thymin 
Taq  Thermus aquaticus 
T-DNA  transfer DNA 
TMV                                      Tobacco mosaic virus 
Tris  trishydroxymethylaminomethane 
TT  Tetanus toxoid 
U  unit 
USA  United States of America 
UTR  untranslated region 
UV  ultraviolet 
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V  Volt 
VH  variable region of heavy chain 
VL  variable region of light chain 
v/v  volume per volume 
v/w  volume per weight 
w/v  weight per volume 
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Vector maps 
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M13 origin
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3327 bp
ampr
p lacZ
M13
origin
bla
pelB
leader
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pGEM 3zf
f1 region
Sp6
promotor
MCS
ampr
AatI
ScaI
T7
promotor
lac
EcoRI
SacI
KpnI
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SmaI
BamHI
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AccI
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HindIII
 
  
 
 
Appendix 140
List of tables 
Table I-1: Comparison of the structures of naturally occurring LHRH variants........................3 
Table I-2: Antibodies for therapeutic applications approved by the FDA. ..............................17 
Table II-1: Names and genotypes of bacterial strains used throughout the work. ...................25 
Table III-1: Sequence analysis of the variable domains of scFv P7278.....................................62 
Table III-2: Comparison of the amino acids present at the VL/VH interface in scFv P7278 with 
the conserved residues assigned for each position...........................................................63 
Table III-3: Sequence analysis of the phage clones reactive to chimeric rAb P7278 and the 
deduced consensus sequence.........................................................................................100 
Table III-4:  Amino acid sequence and binding property of six LHRH peptide variants. .....105 
 
List of figures 
Fig.  I-1: Primary structure of LHRH hormone..........................................................................2 
Fig. I-2: Spatial location of the hypothalamus and pituitary gland and the schematic outline of 
the reproductive hormonal cascade. ..................................................................................4 
Fig. I-3: The amino acid sequence of the three isoforms of LHRH found in mammals. ...........5 
Fig. I-4: LHRH manipulation .....................................................................................................7 
Fig. I-5: Schematic representation of the concept of mouse, chimeric, humanised and human 
antibodies. .......................................................................................................................13 
Fig. I-6: Recombinant antibody forms .....................................................................................16 
Fig. I-7: Pictorial depiction of the research objectives undertaken in this thesis. ....................21 
Fig. III-1: SDS-PAGE and immunoblot analysis of the affinity purified mouse mAb P7278. ..52 
Fig. III-2: Binding activity of the purified mouse mAb P7278 to LHRH in an ELISA.............53 
Fig. III-3:  Optimisation of direct LHRH ELISA.....................................................................54 
Fig. III-4: Schematic representation of the strategy used for cloning a mini-scFv library 
constituted of the light and heavy variable domains of the mouse mAb P7278. ..............55 
Fig. III-5: PCR amplification of the VH fragment of mouse mAb P7278. .................................56 
Fig. III-6: PCR amplification of the VL fragment of mouse mAb P7278. ..................................56 
Fig. III-7a: Direct LHRH ELISA of soluble scFvs. .................................................................58 
Fig. III-7b: Immunoblot analysis of bacterially expressed soluble scFvs. ...............................58 
Fig. III-8: Nucleotide and deduced amino acid sequence of the VH compared with the most 
homologous germline gene. ............................................................................................60 
Fig. III-9: Nucleotide and deduced amino acid sequence of the VL compared with the most 
homologous germline gene. ............................................................................................61 
Fig. III-10: Competition ELISA with bacterial culture supernatant containing soluble scFv P7278.
.........................................................................................................................................64 
Fig. III-11: Generation of the diabody P7278 construct. ............................................................65 
Fig. III-12: Direct LHRH ELISA of soluble diabody P7278. ....................................................65 
Fig. III-13: SDS-PAGE analysis of Ni-NTA affinity-purified scFv P7278. ..............................67 
Fig. III-14: Stepwise elution of the scFv from the Ni-NTA column using increasing 
concentrations of imidazole. ...........................................................................................67 
Fig. III-15: SDS-PAGE analysis of affinity-purified diabody P7278. .......................................68 
Fig. III-16: Strategy for cloning the cDNA encoding the anti-LHRH scFv and diabody 
fragments into the plant expression vector pSSH1. ..........................................................69 
Fig. III-17: SDS-PAGE analysis of Ni-NTA purified scFv P7278 and diabody P7278 from 
tobacco leaves. ................................................................................................................71 
  
 
 
Appendix 141
Fig. III-18: Western blot analysis of the plant purified scFv P7278 and diabody P7278.............71 
Fig. III-19: Size exclusion chromatography of Ni-NTA affinity purified scFv P7278 and 
diabody P7278 expressed in tobacco leaves. ....................................................................72 
Fig. III-21: Schematic representation of the assembly of the chimeric light and heavy chains 
by SOE PCR....................................................................................................................74 
Fig. III-22: Analysis of the assembled heavy and light chimeric chains by agarose gel 
electrophoresis.................................................................................................................75 
Fig. III-23: Strategy for cloning the chimeric heavy and light chains into the plant expression 
vector pSSH1. ...................................................................................................................77 
Fig. III-24: Analysis of total soluble proteins extracted from the infiltrated tobacco leaves by 
ELISA. ............................................................................................................................78 
Fig. III-25: Direct ELISA of extracts from leaves expressing the chimeric heavy and light 
chains with and without KDEL motif. ............................................................................79 
Fig. III-26: SDS-PAGE analysis of plant purified chimeric rAb P7278. ...................................80 
Fig. III-27: Influence of salt concentration (100 mM NaCl) on chimeric rAb P7278 yields. ....81 
Fig. III-28: Western blot analysis of the plant purified chimeric rAb P7278.............................81 
Fig. III-29: Binding activity of the plant purified chimeric rAb P7278 as determined by ELISA.
.........................................................................................................................................82 
Fig. III-30: Comparison of expression levels of chimeric rAb P7278 in plant species found in 
Germany. .........................................................................................................................83 
Fig. III-31: Comparison of expression levels of chimeric rAb P7278 in plant species found in 
India.................................................................................................................................84 
Fig. III-32: Dotblot analysis of transgenic tobacco T0 lines individually expressing heavy and 
light chains of the chimeric rAb P7278.............................................................................85 
Fig. III-33: Dotblot analysis of T1 generation of transgenic tobacco lines expressing heavy and 
light chains of the chimeric rAb P7278.............................................................................86 
Fig. III-34: Analysis of the progeny of six crosses made between transgenic tobacco T0  plant 
lines expressing the heavy and light chains of chimeric rAb P7278.................................87 
Fig. III-35: Estimation of accumulation levels of chimeric rAb P7278 in sixteen transgenic 
plants identified to be positive for the presence of the antibody by ELISA. ..................88 
Fig. III-36: Western blot analysis of the plants identified to be positive for the presence of the 
chimeric rAb P7278. .........................................................................................................88 
Fig. III-37: Calibration curve for the determination of endpoint response and slopes.............89 
Fig. III-38: Determination of the inhibitory constant of the chimeric rAb P7278. ....................90 
Fig. III-39:  Determination of the inhibitory constant of the mouse mAb P7278. .....................91 
Fig. III-40: Pharmacokinetics of mouse mAb P7278 in mice. ...................................................92 
Fig. III-41: Stability of mouse and chimeric rAb P7278 in human serum at 37˚C. ...................93 
Fig. III-42: Stages of estrus cycle observed in rats and mice. ..................................................94 
Fig. III-43: Effect of administration of single dose of monoclonal anti-LHRH antibody on 
cyclicity of rats. ...............................................................................................................95 
Fig. III-44: Effect of administration of two doses of monoclonal anti-LHRH antibody on 
cyclicity of rats. ...............................................................................................................96 
Fig. III-45: Effect of administration of chimeric anti-LHRH antibody on cyclicity of mice...97 
Fig. III-46: Monoclonal phage ELISA of the clones retrieved from the two rounds of panning 
using the NEB library......................................................................................................98 
Fig. III-47: Binding of mouse mAb P7278 to peptides displayed on phage particles. .............101 
Fig. III-48: Amino acid sequence of peptide variants of LHRH tested for binding activity to 
chimeric rAb P7278. .......................................................................................................103 
Fig. III-49: Endpoint response of the binding curves obtained from competition of the six 
selected LHRH variants with chimeric rAb P7278 using surface plasmon resonance. ..104 
  
 
 
  
 
 
 
References 
AMERSDORFER, P., WONG, C., CHEN, S., SMITH, T., DESHPANDE, S., SHERIDAN, R., 
FINNERN, R. and MARKS, J.D. (1997) Molecular characterization of murine humoral immune 
response to botulinum neurotoxin type A binding domain as assessed by using phage antibody 
libraries. Infection and Immunity 65, 3743-3752. 
AMOSS, M., BURGUS, R., BLACKWELL, R., VALE, W., FELLOWS, R. and GUILLEMIN, 
R. (1971) Purification, amino acid composition and N-terminus of the hypothalamic luteinizing 
hormone releasing factor (LRF) of ovine origin. Biochemical and Biophysical Research 
Communications 44, 205-210. 
ARIMURA, A., DEBELJUK, L. and SCHALLY, A.V. (1974) Blockade of the preovulatory surge 
of LH and FSH and of ovulation by anti-LH-RH serum in rats. Endocrinology 95, 323-325. 
ARIMURA, A., MATSUO, H., BABA, Y. and SCHALLY, A.V. (1971) Ovulation induced by 
synthetic luteinizing hormone-releasing hormone in the hamster. Science 174, 511-512. 
ARTSAENKO, O., PEISKER, M., NEIDEN, U.Z., FIEDLER, U., WEILER, E.W., MÜNTZ, K. 
and CONRAD, U. (1995) Expression of single chain Fv antibody against abscisic acid creates a wilty 
phenotype in transgenic tobacco. The Plant Journal 8, 745-750. 
ATWELL, J.L., PEARCE, L.A., LAH, M., GRUEN, L.C., KORTT, A.A. and HUDSON, P.J. 
(1996) Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and 
N9 neuraminidase. Molecular Immunology 33, 1301-1312. 
AUSUBEL, F.M., BRENT, R. and KINGSTON, R.E. (1994) Current protocols in molecular 
biology. Wiley Interscience, New York. 
BARBAS, C., KANG, A.S., LERNER, R.A. and BENKOVIC, S.J. (1991) Assembly of 
combinatorial antibody libraries on phage surfaces: the gene III site. Proceedings of the National 
Academy of Science 88, 7978-7982. 
 
 
142 
 
 
References 143
BARBAS, C.F.I. (1993) Recent advances in phage display. Current Opinion in Bio-
technology 4, 526-530. 
BARRIA, A., LEYTON, V., OJEDA, S.R. and LARA, H.E. (1993) Ovarian steroidal response to 
gonadotropins and beta-adrenergic stimulation is enhanced in polycystic ovary syndrome: role of 
sympathetic innervation. Endocrinology 133, 2696-2703. 
BEBBINGTON, C.R., RENNER, G., THOMPSON, S., KING, D., ABRAMS, D. and 
YARRANTON, G.T. (1992) High-level expression of a recombinant antibody from myeloma cells 
using a glutamine synthetase gene as an amplifiable selectable marker. Biotechnology 10, 169-175. 
BECKER, D. (1990) Binary vectors which allow the exchange of plant selectable markers and 
reporter genes. Nucleic Acid Research 18, 203. 
BECKER, D., KEMPER, E., SCHELL, J. and MASTERSON, R. (1992) New plant binary vectors 
with selectable markers located proximal to the left T-DNA border. Plant Molecular 
Biology 20, 1195-1197. 
BECKERS, T., BERND, M., KUTSCHER, B., R, R.K., HOFFMANN, S. and REISSMANN, T. 
(2001) Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor. 
Biochemical and Biophysical Research Communications 289, 653-663. 
BENNET, H.P.J. and McMARTIN, C. (1979) Peptide hormones and their analogues: distribution, 
clearance from the circulation, and inactivation in vivo. Pharmacological Review 30, 247-292. 
BENVENUTO, R., ORDAS, R.J., TAVAZZA, R., ANCORA, G., BIOCCA, S., CATTANEO, A. 
and GALEFFI, P. (1991) 'Phytoantibodies': a general vector for the expression of immunoglobulin 
domains in transgenic plants. Plant Molecular Biology 17, 865-874. 
BILLETTA, R. and LOBUGLIO, A.F. (1992) Chimeric Antibodies. International Journal of 
Immunology 10, 165-176. 
BIRD, R.E., HARDMAN, K.D., JACOBSON, J.W., JOHNSON, S., KAUFMAN, B.M., LEE, 
S.L., LEE, T., POPE, S.H., RIODAN, G.S. and WHITLOW, M. (1988) Single chain antigen 
binding proteins. Science 242, 423-426. 
BOCCARDO, F., RUBAGOTTI, A., PERROTTA, A. and AL, E. (1994) Ovarian ablation versus 
goserelin with or without tamoxifen in pre-perimenopausal pateinets with advanced breast cancer: 
Results of a multicentric Italian study. Annals of Oncology 5, 337-342. 
BOEUF, R.D.L., GALIN, F.S., HOLLINGER, S.K., PEIPER, S.C. and BLALOCK, J.E. (1989) 
Cloning and sequencing of immunoglobulin variable region genes using degenerate 
oligodeoxyribonucleotides and polymerase chain reaction. Gene 82, 371-377. 
BOULIANNE, G.L., NOBUMICHI, H. and SHULMAN, M.J. (1984) Production of chimeric 
mouse/ human antibody. Nature 312, 643-646. 
BOYLE, P., MAISONNEUVE, P. and NAPALKOV, P. (1995) Geographical and temporal patterns 
of incidence and mortality from prostate cancer. Urology 46, 47-55. 
BREITLING, F., MOSSMAYER, D., BROCKS, B. and DÜBEL, S. (2001) in Antibody 
Engineering: Construction of scFv from hybridoma by two step cloning. (Konterman, R., and Dübel, 
S., eds), Springer Verlag Ed., Springer-Verlag, Berlin Heidelberg., 41-55. 
 
 
 
 
 
 
References 144
BRUGGEMANN, M., WILLIAMS, G.T., BINDON, C.L., CLARK, M.R., WALKER, M.R., 
JEFFERIS, R., WALDMANN, H. and NEUBERGER, M.S. (1987) Comparison of the effector 
functions of human immunoglobulins using a matched set of chimeric antibodies. Journal of 
Experimental Medicine 166, 1351-1361. 
BRUGGEMANN, M., WINTER, G., WALDMANN, H. and NEUBERGER, M.S. (1989) The 
immunogenicities of chimeric antibodies. Journal of Experimental Medicine 170, 2153-2157. 
BRUYNS, A.M., JAEGER, G.D., DENEVE, M., DEWILDE, C., MONTAGU, M.V. and 
DEPICKER, A. (1996) Bacterial and plant produced scFv proteins have similar antigen-binding 
properties. Federation of European Biochemical Societies 386, 5-10. 
BURTON, D.R. and BARBAS, C.F.R. (1994) Human antibodies from combinatorial libraries. 
Advances in Immunology 57, 191-280. 
CARROL, W.L., MENDEL, E. and LEVY, S. (1988) Hybridoma fusion cell lines contain an 
abberrant kappa transcript. Molecular Immunology 25, 991. 
CARSON, A.F., MCCAUGHEY, W.J., MACKIE, D.P., HIGGINS, H.C. and STEEN, R.W.J. 
(1996) Production and biological activity of murine monoclonal anribodies against GnRH. 
Theriogenology 48, 193-207. 
CHEGINI, N., RONG, H., DOU, Q., KIPERSZTOK, S. and WILLIAMS, R.S. (1996) 
Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myo-
metrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells 
and interaction with ovarian steroids in vitro. The Journal of Clinical Endocrinology and 
Metabolism 81, 3215-3221. 
CHEN, A., YAHOLAM, D., BEN-AROYA, N., KAGANOVSKY, E., OKON, E. and KOCH, Y. 
(1998) A second isoform of gonadotropin-releasing hormone is present in the brain of human and 
rodents. FEBS Letters 435, 199-203. 
CHENG, K.W., NATHWANI, P.S. and LEUNG, P.C. (2000) Regulation of human gonadotropin-
releasing hormone receptor gene expression in placental cells. Endocrinology 141, 2340-2349. 
CHRISTOU, P. (1993) Particle gun-mediated transformation. Current Opinion in Bio-
technology 4, 135-141. 
CLACKSON, T., HOOGENBOOM, H.R., GRIFFITHS, A.D. and WINTER, G. (1991) Making 
antibody fragments using phage display libraries. Nature 352, 624-628. 
CLARKE, I.J. and CUMMINS, J.T. (1982) The temporal relationship between gonadotropin 
releasing hormone (GnRH) and luteinising hormone (LH) secretion in ovariectomised ewes. 
Endocrinology 111, 1737. 
CLAYTON, R.N., SOLANO, A.R., GARCIA-VELA, A., DUFAU, M.L. and CATT, K.J. (1980) 
Regulation of pituitary receptors for gonadotropin-releasing hormone during the rat estrous cycle. 
Endocrinology 107, 699-706. 
CLEMONS, M., DANSON, S. and HOWELL, A. (2002) Tamoxifen ('Nolvadex'): a review. 
Antitumour treatment. Cancer Treatment Reviews 28, 165. 
CONN, M.P. and CROWLEY, W. (1994) Gonadotropin-releasing hormone and its analogs. Annual 
Review of Medicine 45, 391-405. 
 
 
 
 
 
 
References 145
CONRAD, U. and FIEDLER, U. (1998) Compartment-specific accumulation of recombinant 
immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of 
physiological functions and pathogen activity. Plant Molecular Biology 38, 101-109. 
CWIRLA, S.E., PETERS, E.A., BARRETT, R.W. and DOWER, W.J. (1990) Peptides on phage: a 
vast library of peptides for identifying ligands. Proceedings of the National Academy of 
Science 87, 6378-6382. 
DEES, W.L., HINEY, J.K., SOWER, S.A., YU, W.H. and MCCANN, S.M. (1999) Localization of 
immunoreactive lamprey gonadotropin-releasing hormone in the rat brain. Peptides. 20, 1503-1511. 
DEES, W.L., SKELLEY, C.W. and KOZLOWSKI, G.P. (1985) Central effects of an antagonist 
and an antiserum to substance P on serum gonadotropin and prolactin secretion. Life 
Science 37, 1627-1631. 
DENECKE, J. (1996) Soluble endoplasmic reticulum resident proteins and their function in protein 
synthesis and transport. Plant Physiology and Biochemistry 34, 197-205. 
DENECKE, J., RYCKE, R.D. and BOTTERMAN, J. (1992) Plant and mammalian sorting signals 
for protein translocation in the endoplasmic reticulum contain a conserved epitope. 
EMBO 11, 2345-2355. 
DENEVE, M., DELOOSE, M., JACOBS, A., HOUDT, H.V., KALUZA, B., WEIDLE, U., 
MONTAGU, M.V. and DEPICKER, A. (1993) Assembly of an antibody and its derived antibody 
fragments in Nicotiana and Arabidopsis. Transgenic Research 2, 227-237. 
DEWILDE, C., NEVE, M.D., RYCKE, R.D., BRUYNS, A.M., JAEGER, G.D., MONTAGU, 
M.V., DEPICKER, A. and ENGLER, G. (1996) Intact antigen-binding MAK33 antibody and Fab 
fragment accumulate in intercellular spaces of Arabidopsis thaliana. Plant Science 114, 233-241. 
DIWAN, M., DAWAR, H. and TALWAR, G.P. (1998) Induction of early and bioeffective antibody 
response in rodents with the luteinising hormone-releasing hormone vaccine given as a single dose in 
biodegradable microsopheres along with alum. Prostate 35, 279-284. 
DOWER, W.J., MILLER, J.F. and RAGSDALE, C.W. (1988) High efficiency transformation of E. 
coli by high voltage electroporation. Nucleic Acid Research 16, 6127-6145. 
DUCHOSAL, M.A., EMING, S.A., FISCHER, P., LETURCQ, D., BARBAS, C.F.I., 
MCCONAHEY, P.J., CAOTHEIN, R.H., THORNTON, G.B., DIXON, F.J. and BURTON, D.R. 
(1992) Immunisation of hu-PBL-SCID mice and the rescue of human monoclonal Fab fragments 
through combinatorial libraries. Nature 355, 258-262. 
DUNSHEA, F.R., COLANTONI, C., HOWARD, K., MCCAULEY, I., JACKSON, P., LONG, 
K.A., LOPATICKI, S., NUGENT, E.A., SIMONS, J.A., WALKER, J. and HENNESSY, D.P. 
(2001) Vaccination of boars with a GnRH vaccine (Improvac) eliminates boar taint and increases 
growth performance. Journal of Animal Science 79, 2524-2535. 
DÜRING, K., HIPPE, S., KREUZALER, F. and SCHELL, J. (1990) Synthesis and self-assembly 
of a functional monoclonal antibody in transgenic Nicotiana tabacum. Plant Molecular 
Biology 15, 281-293. 
EMONS, G. and HEYL, W. (2000a) Hormonal treatment of endometrial cancer. Journal of Cancer 
Research and Clinical Oncology 126, 619-623. 
EMONS, G. and SCHULZ, K.D. (2000b) Primary and salvage therapy with LHRH analogues in 
ovarian cancer. Recent Results in Cancer Research 153, 83-94. 
 
 
 
 
 
 
References 146
ESSIG, N.Z., WOOD, J.F., HOWARD, A.J., RAAG, R. and WHITLOW, M. (1993) 
Crystallization of single-chain Fv proteins. Journal of Molecular Biology 234, 897-901. 
EVAN, G.I., LEWIS, G.K., RAMSAY, G. and BISHOP, J.M. (1985) Isolation of monoclonal 
antibodies specific for human c-myc proto-oncogene product. Molecular and Cellular 
Biology 5, 3610-3616. 
FÄGERSTAM, L.G., FROSTELL, A., KARLSSON, R., KULLMAN, M., LARSON, A., 
MALMQVIST, M. and BUTT, H. (1990) Detection of antigen-antibody interactions by surface 
plasmon resonance. Application to epitope mapping. Journal of Molecular Recognition 3, 208-214. 
FERRO, V.A., KHAN, M.A.H., LATIMER, V.S., BROWN, D., URBANSKI, H.F. and 
STIMSON, W.H. (2001) Immunoneutralisation of GnRH-I, without cross-reactivity to GnRH-II, in 
the development of a highly specific anti-fertility vaccine for clinical and veterinary use. Journal of 
Reproductive Immunology 51, 109-129. 
FERRO, V.A. and STIMSON, W.H. (1997) Immunoneutralisation of Gonadotropin releasing 
hormone: a potential treatment for oestrogen-dependent breast cancer. European Journal of 
Cancer 33, 1468-1478. 
FIEDLER, U., PHILIPS, J., ARTSAENKO, O. and CONRAD, U. (1997) Optimisation of scFv 
antibody production in transgenic plants. Immunotechnology 3, 205-216. 
FIREK, S., DRAPER, J., OWEN, M., GANDECHA, A., COCKBURN, B. and WHITELAM, 
G.C. (1993) Secretion of functional single chain Fv protein in transgenic tobacco plants and cell 
suspension cultures. Plant Molecular Biology 23, 861-870. 
FISCHER, R. and EMANS, N. (2000) Molecular farming of pharmaceutical proteins. Transgenic 
Research 9, 279-299. 
FISCHER, R., LIAO, Y.C., HOFFMAN, K., SCHILLBERG, S. and EMANS, N. (1999) 
Molecular farming of recombinant antibodies in plants. Biological Chemistry 380, 825-839. 
FISCHER, R., SCHUMANN, D., ZIMMERMANN, S., DROSSARD, J., SACK, M. and 
SCHILLBERG, S. (1999) Expression and characterization of bispecific single-chain Fv fragments 
produced in transgenic plants. European Journal of Biochemistry 262, 810-816. 
FRALEY, R.T., ROGERS, S.G., HORSCH, R.B., SANDERS, P.R., FLICK, J.S., ADAMS, S.P., 
BITTNER, M.L., BRAND, L.A., FINK, C.L., FRY, J.S., GALLUPPI, G.R., GOLDBERG, S.B., 
HOFFMANN, N.L. and WOO, S.C. (1983) Expression of bacterial genes in plant cells. Proceedings 
of the National Academy of Science USA 80, 4803-4807. 
FRASER, H.M. (1982) New prospects for luteinising hormone releasing hormone as a contraceptive 
and therapeutic agent. British Medical Journal 285, 990-991. 
FRASER, H.M. and BAKER, T.G. (1978) Changes in the ovaries of rats after immunization against 
luteinizing hormone releasing hormone. Journal of Endocrinology 77, 85-93. 
FRASER, H.M. and GUNN, A. (1973) Effects of antibodies to luteinising hormone releasing 
hormone in the male rabbit and on the rat oestrus cycle. Nature 244, 160-161. 
FROMM, M., CALLIS, J., TAYLOR, L.P. AND WALBOT, V. (1985) Electroporation of DNA 
and RNA into plant protoplasts. Methods in Enzymology 153, 351-366. 
 
 
 
 
 
 
References 147
GAVILONDO-COWLEY, J.V., COLOMA, M., VAZQUEZ, J., AYALA, M., MACIAS, A., 
FRY, K.E. and LARRICK, J.W. (1990) Specific amplification of rearranged immunoglobulin 
variable region genes from mouse hybridoma cells. Hybridoma 9, 407-417. 
GLOCKSHUBER, R., MALIA, M., PFITZINGER, I. and PLÜCKTHUN, A. (1990) A 
comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29, 1362-1367. 
GOLDENBEG, D.M. (1993) Monoclonal antibodies in cancer detection and therapy. American 
Journal of Medicine 94, 297-312. 
GONZALEZ-BARCENA, D., VADILLO-BUENFIL, M., CORTEZ-MORALES, A., FUENTES-
GARCIA, M., CARDENAS-CORNEJO, I., COMARU-SCHALLY, A.M. and SCHALLY, A.V. 
(1995) LH-RH antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced 
prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 45, 275-281. 
GOTTESMAN, M.E. and HENDRICKSON, W.A. (2000) Protein folding and unfolding by 
Escherichia coli chaperones and chaperonins. Current Opinion in  Microbiology 3, 197-202. 
GRIFFITHS, A.D., MALMQVIST, M., MARKS, J.D., BYE, J.M., EMBLETON, M.J., 
MCCAFFERTY, J., BAIER, M., HOLLIGER, K.P., GORICK, B.D., HUGHES-JONES, N.C., 
HOOGENBOOM, H.R. and WINTER, G. (1993) Human anti-self antibodies with high specificity 
from phage display libraries. EMBO 12, 725-734. 
GUPTA, S.K., SINGH, O. and TALWAR, G.P. (1985) Characterisation and bioefficacy of 
monoclonal anti-gonadotropin releasing hormone antibody. American Journal of Reproductive 
Immunology 7, 104-108. 
HAARD, H.J.D., KAZEMIER, B., BENT, A.V.D., OUSDSHOORN, P., BOENDER, P., 
GEMEN, B.V., ARENDS, J.W. and HOOGENBOOM, H.R. (1998) Absolute conservation of 
residue 6 of heavy chain variable regions of class IIA is required for correct folding. Protein 
Engineering 11, 1267-1276. 
HALMOS, G., SCHALLY, A.V., PINSKI, J., VADILLO-BUENFIL, M. and GROOT, K. (1996) 
Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by 
LH-RH antagonist Cetrorelix. Proceedings of the National Academy of Science 93, 2398-2402. 
HANAHAN, D. (1985) Techniques for transformation of E.coli. IRL Press. 
HASHOLZNER, U., STIEBER, P., MEIER, W. and LAMERZ, R. (1997) Value of HAMA--
determination in clinical practice--an overview. Anticancer Research 17, 3055-3058. 
HEGARTY, N.J., FITZPATRICK, J.M., RICHIE, J., SCARDINO, P., WHITE, R.W., 
SHRODER, F.H. and COFFEY, D.S. (1999) Future prospects in prostate cancer. 
Prostate 40, 261-268. 
HEIN, M.B., TANG, Y., MCLEOD, D.A., JANDA, K.D. and HIATT, A.C. (1991) Evaluation of 
immunoglobulins from plant cells. Biotechnological Progress 7, 455-461. 
HENDERSON, I.C. and CANELLOS, G.P. (1980) Cancer of the breast: the past decade. The New 
England Journal of Medicine 302, 78-90. 
HIATT, A. (1990) Antibodies produced in plants. Nature 29, 469-470. 
HIATT, A., CAFFERKEY, R. and BOWDISH, K. (1989) Production of antibodies in transgenic 
plants. Nature 342. 
 
 
 
 
 
 
References 148
HIATT, A. and MOSTOV, K. (1992) Assembly of multimeric proteins in plant cells: characteristics 
and uses of plant-derived antibodies. In Hiatt, A. (ed.) Transgenic Plants: Fundamentals and 
Applications.Marcel Dekker Inc., New York, pp. 221-236. 
HINEY, J.K., SOWER, S.A., YU, W.H., MCCANN, S.M. and DEES, W.L. (2002) Gonadotropin-
releasing hormone neurons in the preoptic-hypothalamic region of the rat contain lamprey 
gonadotropin-releasing hormone III, mammalian luteinising hormone-releasing hormone, or both 
peptides. Proceedings of the National Academy of Science 99, 2386-2391. 
HOCHULI, E., BANNWARTH, W., DÖBELI, H., GENTZ, R. and STÜBER, D. (1988) Genetic 
approach to facilitate purification of recombinant proteins with a novel metal chelate adsorbent. 
Biotechnology 6, 1321-1325. 
HOLLIGER, P., PROSPERO, T. and WINTER, G. (1993) "Diabodies": small bivalent and 
bispecific antibody fragments. Proceedings of the National Academy of Science 90, 6444-6448. 
HONG, S.S. and BOULANGER, P. (1995) Protein ligands of the human adenovirus type 2 outer 
capsid identified by biopanning of a phage-displayed peptide library on separate domains of wild-type 
and mutant penton capsomers. EMBO Journal 14, 4714-4727. 
HONNEGER, A. and PLÜCKTHUN, A. (2001) The influence of the buried glutamine or glutamate 
residue in position 6 on the structure of immunoglobulin variable domains. Journal of Molecular 
Biology 309, 687-699. 
HOOGENBOOM, H.R. (1997) Designing and optimizing library selection strategies for generating 
high-affinity antibodies. Trends in Biotechnology 15, 62-70. 
HOOGENBOOM, H.R., BRUINE, A.P.D., HUFTON, S.E., HOET, R.M., ARENDS, J.W. and 
ROOVERS, R.C. (1998) Antibody phage display technology and its applications.  Immuno-
technology 4, 1-20. 
HOOGENBOOM, H.R., GRIFFITHS, A.D., JOHNSON, K.S., CHISWELL, D.J., HUDSON, P. 
and WINTER, G. (1991) Multi-subunit proteins on the surface of filamentous phage: methodologies 
for displaying antibody (Fab) heavy and light chains. Nucleic Acids Research 19, 4133-4137. 
HOOYKAAS, P.J. and SCHILPEROORT, R.A. (1992) Agrobacterium and plant genetic 
engineering. Plant Molecular Biology 19, 15-38. 
HORSCH, R., FRY, J.E., HOFFMAN, N., EICHOLTZ, D., ROGERS, S. and FRALEY, R. 
(1985) A simple and general method for transferring genes into plants. Science 227, 1229-1231. 
HORTON, R.M., HUNT, H.D., HO, S.N., PULLEN, J.K. and PEASE, L.R. (1989) Engineering 
hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. 
Gene 77, 61-68. 
HU, G. (1993) DNA polymerase-catalyzed addition of nontemplated extra nucleotides to the 3' end of 
a DNA fragment. DNA Cell Biology 12, 763-770. 
HUDSON, P.J. and KORTT, A.A. (1999) High avidity scFv multimers; diabodies and triabodies. 
Journal of Immunological Methods 231, 177-189. 
HUIRNE, J.A. and LAMBALK, C.B. (2001) Gonadotropin-releasing-hormone-receptor antagonists. 
Lancet 358, 1793-1803. 
 
 
 
 
 
 
References 149
HUSTON, J.S., LEVINSON, D., HUNTER, M.M., TAI, M.S., NOVOTNY, J., MARGOLIES, 
M.N., RIDGE, R.J., BRUCCOLERI, R.E., HABER, E., CREA, R. and OPPERMAN, H. (1988) 
Protein engineering of antigen binding sites: recovery of specific activity in an anti-digoxin single 
chain Fv analogue produced in Escherichea coli. Proceedings of the National Academy of Science 
USA 85, 5879-5883. 
HUXSOLL, C.C., PRICE, E.O. and ADAMS, T.E. (1998) Testis function, carcass traits, and 
aggressive behavior of beef bulls actively immunized against gonadotropin-releasing hormone. 
Journal of Animal Science 76, 1760-1766. 
ILIADES, P., KORTT, A.A. and HUDSON, P.J. (1997) Triabodies: single chain Fv fragments 
without a linker form trivalent trimers. FEBS Letters 409, 437-441. 
JACOBS, E., WATSON, S.A., MICHAELI, D., ELLIS, I.O. and ROBERTSON, J.F.R. (1999) 
Anti-gonadotropin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer 
xenografts. British Journal of Cancer 80, 352-359. 
JAKESZ, R., HAUSMANINGER, H. and SAMONIGG, H. (2002) Chemotherapy versus hormonal 
adjuvant treatment in premenopausal pateints with breast cancer. European Journal of 
Cancer 38, 327-332. 
JESNOWSKI, R., NÄHRING, J. and WOLF, K. (1995) A rapid and reliable method for PCR based 
amplificationof chromosomal and mitochondrial DNA from intact yeast cells. Current 
Genetics 27, 318-319. 
JONES, P.T., DEAR, P.H., FOOTE, J., NEUBERGER, M.S. and WINTER, G. (1986) Replacing 
the complementary determining regions in a human antibody with those from a mouse. 
Nature 332, 323-329. 
JUNG, S., SPINELLI, S., SCHIMMELE, B., HONNEGER, A., PUGLIESE, L., CAMBILLAU, 
C. and PLÜCKTHUN, A. (2001) The importance of framework residues H6, H7 and H10 in 
antibody heavy chains: Experimental evidence for a new structural subclassification of antibody VH 
domains. Journal of Molecular Biology 309, 701-716. 
KAKAR, S.S., MUSGROVE, L.C., DEVOR, D.C., SELLERS, J.C. and NEILL, J.D. (1992) 
Cloning, sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor. 
Biochemical and Biophysical Research Communications 189, 289-295. 
KALUZA, B., BETZL, G., SHAO, H., DIAMANTSTEIN, T. and WEIDLE, U.H. (1992) A 
general method for chimerisation of monoclonal antibodies by inverse polymerase chain reaction 
which conserves authentic N terminal sequences. Gene 122, 321. 
KAMP, G.A., MUL, D., WAELKENS, J.J., JANSEN, M., DE, D.-V., WAAL, H.A., 
VERHOEVEN-WIND, L., FROLICH, M., OOSTDIJK, W. and WIT, J.M. (2001) A randomized 
controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment 
in children with idiopathic short stature and intrauterine growth retardation. Journal of Clinical 
Endocrinology and Metabolism 86, 2969-2975. 
KANG, S.K., CHENG, K.W., NATHWANI, P.S., CHOI, K.C. and LEUNG, P.C. (2000) 
Autocrine role of gonadotropin-releasing hormone and its receptor in ovarian cancer cell growth. 
Endocrine Reviews 13, 297-304. 
KAPILA, J., RYCKE, R.D., MONTAGU, M.V. and ANGENON, G. (1997) An agrobacterium 
mediated transient gene expression system for intact leaves. Plant Science 122, 101-108. 
 
 
 
 
 
 
References 150
KARLSSON, R., MICHAELSSON, A. and MATSSON, L. (1991) Kinetic analysis of monoclonal 
antibody-antigen interactions with a new biosensor based analytical system. Journal of Immunological 
Methods 145, 229-240. 
KARTEN, M.J. (1993) An overview of GnRH antagonist development: Two decades of progress. In 
Modes of Action of GnRh and GnRh Analogs (Crowley, W. F., and Conn, P. M., Eds.), Springer 
Verlag, Heidelberg. 
KATHURIA, S., SRIRAMAN, R., NATH, R., SACK, M., PAL, R., ARTSAENKO, O., 
TALWAR, G.P., FISCHER, R. and FINNERN, R. (2002) Efficacy of plant-produced recombinant 
antibodies against HCG. Human Reproduction 17, 2054-2061. 
KATHURIA, S.R., NATH, R., PAL, R., SINGH, O., FISCHER, R., LOHIYA, N.K. and 
TALWAR, G.P. (2002) Functional recombinant antibodies against human chorionic gonadotropin 
expressed in plants. Current Science 82, 1452-1457. 
KAY, R., CHAN, A., DALEY, M. and McPHERSON, J. (1987) Duplication of CaMV 35S 
promotor sequences creates a strong enhancer for plant genes. Science 236, 1299-1302. 
KERI, G., NIKOLICS, K., TEPLAN, I. and MOLNAR, J. (1983) Desensitisation of luteinising 
hormone release in cultured pituitary cells by gonadotropin releasing hormone. Molecular and 
Cellular Endocrinology 30, 109-120. 
KING, J.A. and MILLAR, R.P. (1995) Evolutionary aspects of gonadotropin-releasing hormone and 
its receptors. Cellular and molecular neurobiology 15, 5-23. 
KIPRIYANOV, S.M., MOLDENHAUER, G., MARTIN, A.C., KUPRIYANOVA, O.A. and 
LITTLE, M. (1997) Two amino acid mutations in an anti-human CD3 single chain Fv antibody 
fragment that affect the yield on bactrerial secretion but not on the affinity. Protein 
Engineering 10, 445-453. 
KOCH, Y., CHOBSIENG, P., ZOR, U., FRIDKIN, M. and LINDNER, H.R. (1973) Suppression 
of gonadotrophin secretion and prevention of ovulation in the rat by antiserum to synthetic 
gonadotrophin-releasing hormone. Biochemical Biophysical Research Communication 55, 623. 
KÖHLER, G. and MILSTEIN, C. (1975) Continuous culture of fused cells secreting antibody of 
predefined specificity. Nature 256, 495-497. 
KONCZ, C. and SCHELL, J. (1986) The promotor of TL-DNA gene 5 controls the tissue specific 
expression of chimeric genes carried by a novel type of Agrobacterium binary vector. Molecular & 
General Genetics 204, 383-396. 
KORTT, A.A., MALBY, R.L., CALDWELL, J.B., GRUEN, L.C., IVANCIC, N.M., 
LAWRENCE, M.C., HOWLETT, G.J., WEBSTER, R.G., HUDSON, P.J. and COLMAN, P.M. 
(1994) Recombinant antineuraminidase single chain Fv antibody: characterisation, formation of 
dimers and higher molecular mass multimers and the solution of the crystal structure of the scFv-
neuraminidase complex. European Journal of Biochemistry 221, 151-157. 
KREBBER, A., BURMESTER, S.B., HONNEGER, A., WILLUDA, J., BOSSHARD, H.R. and 
PLÜCKTHUN, A. (1997) Reliable cloning of functional antibody variable domains from hybridoma 
and spleen cells repertoires employing a reingineered phage display system. Journal of Immunological 
Methods 201, 35-55. 
KUZEL, T.M. and ROSEN, S.T. (1994) Antibodies in treatment of human cancer. Current Opinion 
in Oncology 6, 622-626. 
 
 
 
 
 
 
References 151
LADD, A., TSONG, Y., WALFIELD, A.M. and THAU, R. (1994) Development of an antifertility 
vaccine for pets based on active immunisation against luteinising hormone-releasing hormone. Biology 
of Reproduction 51, 1076-1083. 
LADD, A., TSONG, Y.Y., LOK, J. and THAU, R.B. (1985) Active immunisation against LHRH: 
Effects of  conjugation site and dose. American Journal of Reproductive and Immunological 
Microbiology 7, 258-268. 
LANE, D.P. and STEPHEN, C.W. (1993) Epitope mapping using bacteriophage peptide libraries. 
Current Opinion in Immunology 5, 132-136. 
LANGEDIJK, A.C., HONNEGER, A., MAAT, J., PLANTA, R.J., SCHAIK, R.C.V. and 
PLÜCKTHUN, A. (1998) The nature of antibody heavy chain residue H6 strongly influences the VH 
domain lacking the disulfide bridge. Journal of Molecular Biology 283. 
LARRICK, J.W., DANNIELSSON, L., BRENNER, C.A., ABRAHAMSON, M., FRY, K.E. and 
BORREBECK, C.A. (1989a) Rapid cloning or rearranged immunoglobulin genes from human 
hybridoma cells using mixed primers and the polymerase chain reaction. Biochemical and Biophysical 
Research Communications 160, 1250-1256. 
LARRICK, J.W., DANNIELSSON, L., BRENNER, C.A., WALLACE, E.F., ABRAHAMSON, 
M., FRY, K.E. and BORREBECK, C.A. (1989b) Polymerase chain reaction using mixed primers: 
cloning of human monoclonal antibody variable region genes from single hybridoma cells. Bio/ 
Technology 7, 934-938. 
LARRICK, J.W. and FRY, K.E. (1991) Recombinant Antibody. Human Antibody and 
Hybridomas 2, 172-189. 
LAU, H., ZHU, X., LEUNG, P., CHAN, L., CHEN, G., CHAN, P., YU, K. and CHAN, F. (2001) 
Detection of mRNA expression of gonadotropin-releasing hormone and its receptor in normal and 
neoplastic rat prostates. International Journal of Oncology 1193-201. 
LEI, S.P., LIN, H.C., WANG, S.S., CALLAWAY, J. and WILCOX, G. (1987) Characterization of 
the Erwinia carotovora pelB gene and its product pectate lyase. Journal of Bacterio-
logy 169, 4379-4383. 
LINCOLN, G.A. and FRASER, H.M. (1979) Blockade of episodic secretion of luteinizing hormone 
in the ram by the administration of antibodies to luteinizing hormone releasing hormone. Biology of 
Reproduction 21, 1239-1245. 
LoBUGLIO, A.F., WHEELER, R.H., TRANG, J., HAYNES, A., ROGERS, K., HARVEY, E.B., 
SUN, L., GHRAYEB, J. and KHAZAELI, M.B. (1989) Mouse/human chimeric monoclonal 
antibody in man: kinetics and immune response. Proceedings of the National Academy of Science 
USA 6, 4220-4224. 
LUMPKIN, M.D., DEPAOLO, L.V. and NEGRO-VILAR, A. (1984) Pulsatile release of follicle-
stimulating hormone in ovariectomized rats is inhibited by porcine follicular fluid (inhibin). 
Endocrinology 114, 201-206. 
MA, J.K. and HEIN, M.B. (1995) Plant antibodies for human therapy. Plant Physio-
logy 109, 341-346. 
MARKS, J.D., HOOGENBOOM, H.R., BONNERT, T.P., MCCAFFERTY, J., GRIFFITHS, 
A.D. and WINTER, G. (1991) By-passing immunisation. Human antibodies from V gene libraries 
displayed on phage. Journal of Molecular Biology 222, 581-597. 
 
 
 
 
 
 
References 152
MATSUO, H., BABA, Y., NAIR, R.M., ARIMURA, A. and SCHALLY, A.V. (1971) Classic 
pages in obstetrics and gynecology. Structure of the porcine LH-and FSH-releasing hormone. I. The 
proposed amino acid sequence. Biochemical and Biophysical Research Communi-
cations 43, 1334-1339. 
MILLAR, R., LOWE, S., CONKLIN, D., PAWSON, A., MAUDELSY, S., TROSKIE, B., OTT, 
T., MILLAR, M., LINCOLN, G., SELLAR, R., FAURHOLM, B., SCOBIE, G., KEUSTNER, 
R., TERASAWA, E. and KATZ, A. (2001) A novel mammalian recptor for the evolutionary 
concerved type II GnRH receptor. Endocrinology 143, 737-743. 
MILLAR, R.P. and KING, J.A. (1988) Evolution of Gonadotropin-releasing hormone: multiple 
usage of a peptide. New Phsiological Science 3, 49-53. 
MINARETZIS, D., JAKUBOWSKI, M., MORTOLA, J.F. and PAVLOU, S.N. (1995) 
Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. 
The Journal of Clinical Endocrinology and Metabolism. 80, 430-434. 
MIYAMOTO, K., HASEGAWA, Y., NOMURA, M., IGARASHI, M., KANAGAWA, K. and 
MATUSO, H. (1984) Identification of a second gonadotropin-releasing hormone in chicken 
hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct 
gonadotropin-releasing hormones in avian species. Proceedings of Natural academy of science 
USA 81, 3874-3878. 
MORRISON, C.A., FISHLEIGH, R.V., WARD, D.J. and ROBSON, B. (1987) Computer-aided 
design and physiological testing of a luteinising hormone-releasing hormone analogue for 'adjuvant-
free' immunocastration. FEBS Letters 214, 65-70. 
NEILL, J.D. (2002) GnRH and GnRH receptor genes in the human genome. Endo-
crinology 143, 737-743. 
NEILL, J.D., DUCK, L.W., SELLERS, J.C. and MUSGROVE, L.C. (2001) A gonadotropin-
releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochemical and Biophysical 
Research Communications 282, 1012-1018. 
NIEBA, L., KREBBER, A. and PLÜCKTHUN, A. (1996) Competition BIAcore for measuring true 
affinities: Large differences from values determined from binding chracteristics. Analytical 
Biochemistry 234, 155-165. 
NILSSON, B. (1995) Antibody engineering. Current Opinion in Structural Biology 5, 450-456. 
OH, W.K. and KANTOFF, P.W. (1998) Management of hormone refractory prostate cancer: current 
standards and  future prospects. Journal of Urology 160, 1220-1229. 
OHANIANCE, L.D., GOLDBERG, M.E. and FRIGUET, B. (1997) Measuring antibody affinity in 
solution. The practical approach series. Immunochemistry Vol 2. Edited by A P Johnstone 
IRL Press, 77-97. 
OLINS, P.O. and LEE, S.C. (1993) Recent advances in heterologous gene expression in Escherichia 
coli. Current Opinion in Biotechnology 4, 520-525. 
ORLANDI, R., GUSSOW, D.H., JONES, P.T. and WINTER, G. (1989) Cloning immunoglobulin 
variable domains for expression by the polymerase chain reaction. Proceedings of the National 
Academy of Science. USA 86, 3833-3837. 
 
 
 
 
 
 
References 153
OSTERMEIER, C. and MICHEL, H. (1996) Improved cloning of antibody variable regions from 
hybridomas by an antisense-directed RNAse H digestion of the P3-X63-Ag8.653 derived pseudogene 
mRNA. Nucleic Acids Research 24, 1979. 
PACHOLCZYK, T. and SWEADNER, K.J. (1997) Epitope and mimotope for an antibody to the 
Na,K-ATPase. Protein Science 6, 1537-1548. 
PAREKH, R., DWEK, R., SUTTON, B., FERNANDES, D., LEUNG, A., STANWORTH, D., 
RADEMACHER, T., MIZUOCHI, T., TANIGUCHI, T. and MATSUTA, K. (1985) Association 
of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total 
serum IgG. Nature 316, 452-457. 
PARTHASARATHY, V., PRICE, E.O., ORIHUELA, A., DALLY, M.R. and ADAMS, T.E. 
(2002) Passive immunization of rams (Ovis aries) against GnRH: effects on antibody titer, serum 
concentrations of testosterone, and sexual behavior. Animal Reproduction Science. 71, 203-215. 
PEI, X.Y., HOLLIGER, P., MURZIN, A.G. and WILLIAMS, R.L. (1997) The 2.0-A resolution 
crystal structure of a trimeric antibody fragment with noncognate VH-VL domain pairs shows a 
rearrangement of VH CDR3. Proceedings of the National Academy of Science 94, 9637-9642. 
PERISIC, O., WEBB, P.A., HOLLIGER, P., WINTER, G. and WILLIAMS, R.L. (1994) Crystal 
structure of a diabody, a bivalent antibody fragment. Structure 2, 1217-1226. 
PINSKI, J., LAMHARZI, N., HALMOS, G., GROOT, K., JUNGWIRTH, A., BUENFIL, M.V., 
KAKAR, S.S. and SCAHALLY, A.V. (1996) Chronic administration of the luteinizing hormone-
releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary 
LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology 137, 3430-3436. 
PLÜCKTHUN, A. (1994) Escherichia coli producing recombinant antibodies. Bioprocess 
Technology 19, 233-252. 
POPKIN, R. and FRASER, H.M. (1983) The effects of immunoneutralization of LHRH or LH on 
pituitary LHRH receptors during the rat oestrous cycle. Molecular Cell Endocrinology 33, 305-312. 
PRIMUS, F.J., PENDURTHI, T.K., HUTZELL, P., KASHMIRI, S., SLAVIAN, D.C., 
CALLAHAN, R. and SCHLOM, J. (1990) Chimeric B72.3 mouse/human (IgG1) antibody directs 
the lysis of tumor cells by lymphokine-activated killer cells. Cancer Immunology and 
Immunotherapy 31, 349-357. 
RADEMACHER, T., HOMANS, S., PAREKH, R. and DWEK, R. (1986) Immunoglobulin G as a 
glycoprotein. Biochemical Society Symposium 51, 131-148. 
RAVDIN, P.M. and JORDAN, V.C. (1988) Active immunisation of luteinising hormone releasing 
hormone to inhibit the indiction of mammary tumors in the rat. Life Science 43, 117-132. 
REYNOLDS, J.C., VECCHIO, S.D., SAKAHARA, H., LORA, M.E., CARRASQUILLO, J.A., 
NEUMANN, R.D. and LARSON, S.M. (1989) Anti-murine response to mouse monoclonal 
antibodies: Clinical findings and implications. Nuclear Medicine and Biology 16, 121. 
RIECHMANN, L., CLARK, M., WALDMANN, H. and WINTER, G. (1988) Reshaping 
antibodies for therpay. Nature 332, 323-327. 
ROTH, C., LEONHARDT, S., SEIDEL, C., LUFT, H., WUTTKE, W. and JARRY, H. (2000) 
Comparative analysis of different puberty inhibiting mechanisms of two GnRH agonists and the 
GnRH antagonist cetrorelix using a female rat model. Pediatric Research 48, 468-474. 
 
 
 
 
 
 
References 154
SAKUMA, Y. and PFAFF, D.W. (1980) LH-RH in the mesencephalic central grey can potentiate 
lordosis reflex of female rats. Nature 283, 566-567. 
SAMBROOK, J.E., FRITSCH, E.F. and MANIATIS, T. (1989) Molecular cloning- A labratory 
Manual. Cold spring Harbor Laboratory, New York. 
SANDOW, J. (1983) Clinical application of LHRH and its analogues. Clinical Endo-
crinology 18, 571. 
SANGER, F., NICKLEN, S. and COULSEN, A.R. (1977) DNA sequencing with chain terminating 
inhibitors. Proceedings of the National Academy of Science USA 74, 5463-5467. 
SAUNAL, H., KARLSSON, R. and REGENMORTEL, M.H.V.V. (1997) Antibody affinity 
measurements. The practical approach series. Immunochemistry Vol 2. Edited by A P Johnstone 
IRL Press, 1-29. 
SAVOY-MOORE, R.T., SCHWARTZ, N.B., DUNCAN, J.A. and MARSHALL, J.C. (1980) 
Pituitary gonadotropin-releasing hormone receptors during the rat estrous cycle. Science 209, 942-944. 
SCHALLY, A.V. (1999) Luteinising hormone-releasing hormone analogs: their impact on the control 
of tumorigenesis. Peptides, 1247-1262. 
SCHALLY, A.V., COMARU_SCHALLY, A.M., NAGY, A., KOVACS, M., SZEPESHAZI, K., 
PLONOWSKI, A., VARGA, J.L. and HALMOS, G. (2001) Hypothalamic hormones and cancer. 
Frontiers in Neuroendocriniology 22, 248-291. 
SCHALLY, A.V., COMARU-SCHALLY, A.M., PLONOWSKI, A., NAGY, A., HALMOS, G. 
and RAKASI, Z. (2000) Peptide analogues in the therapy of prostate cancer. Prostate 22, 158-166. 
SCOTT, J.K., LOGANATHAN, D., EASLEY, R.B., GONG, X. and GOLDSTEIN, I.J. (1992) A 
family of concanavalin A-binding peptides from a hexapeptide epitope library. Proceedings of the 
National Academy of Science 89, 5398-5402. 
SCOTT, J.K. and SMITH, G.P. (1990) Searching for peptide ligands with an epitope library. 
Science 249, 386-390. 
SEALFON, S.C., WEINSTEIN, H. and MILLAR, R.P. (1997) Molecular mechanisms of ligand 
interaction with the gonadotropin-releasing hormone receptor. Endocrine Reviews 18, 180-205. 
SECCAMANI, E., TATTANELLI, M., MARIANI, M., SPRANZI, E., SCASSELLATI, G.A. and 
SICCARDI, A.G. (1989) A simple qulaitative determination of human antibodies to murine 
immunoglobulins (HAMA) in serum samples. Nuclear Medicine and Biology 16, 167. 
SHERWOOD, N., LOVEJOY, D. and COE, I. (1993) Origin of mammalian gonadotropin-releasing 
hormones. Endocrine Reviews 14, 241-254. 
SHIRLEY, B., WOLINSKY, J. and SCHWARTZ, N.B. (1968) Effects of a single injection of an 
estrogen antagonist on the estrous cycle of the rat. Endocrinology 82, 959-968. 
SKERRA, A. (1993) Bacterial expression of immunoglobulin fragments. Current Opinion in 
Immunology 5, 256-262. 
SMITH, P.K., KROHN, R.I., HERMANSON, G.T., MALLIA, A.K., GARTNER, F.H., 
PROVENCANO, M.D., FUJIMOTO, E.K., GOEKE, N.M., OLSON, B.J. and KLENK, D.C. 
(1985) Measurement of protein using bicinchoninc acid. Analytical Biochemistry 150, 76-85. 
 
 
 
 
 
 
References 155
SOMERS, V.A., BRANDWIJK, R.J., JOOSTEN, B., MOERKERK, P.T., ARENDS, J.W., 
MENHEERE, P., PIETERSE, W.O., CLAESSEN, A., SCHEPER, R.J., HOOGENBOOM, H.R. 
and HUFTON, S.E. (2002) A panel of candidate tumor antigens in colorectal cancer revealed by the 
serological selection of a phage displayed cDNA expression library. Journal of 
Immunology, 2772-2780. 
STEPHEN, C.W., HELMINEN, P. and LANE, D.P. (1995) Characterisation of epitope on human 
p53 using phage-displayed peptide libraries: Insights into antibody-peptide intercations. Journal of 
Molecular Biology 248, 58-78. 
STEPLEWSKI, Z., SUN, L.K., SHEARMAN, C.W., GHRAYEB, J., DADDONA, P. and 
KOPROWSKI, H. (1988) Biological activity of human-mouse IgG1, IgG2, IgG3 and IgG4 chimeric 
monoclonal antibodies with antitumor specificity. Proceedings of the National Academy of Science 
USA 85, 4852-4856. 
STOJILKOVIC, S.S., REINHART, J. and CATT, K.J. (1994) Gonadotropin-releasing hormone 
receptors: structure and signal transduction pathways. Endocrinology Reviews 15, 462-499. 
STORTELERS, C., SOURIAU, C., LIEMPT, E.V., POLL, M.L.V.D. and ZOELEN, E.J.V. 
(2002) Role of the N-terminus of epidermal growth factor in ErbB-2/ErbB-3 binding studied by phage 
display. Biochemistry, 8732-8741. 
SUNDARAM, K., DIDOLKAR, A., THAU, R., CHAUDHURI, M. and SCHMIDT, F. (1988) 
Antagonists of luteinizing hormone releasing hormone bind to rat mast cells and induce histamine 
release. Agents Actions 25, 307-313. 
TALWAR, G.P. (1997a) Fertility regulating and immunotherapeutic vaccines reaching human trials 
stage. Human Reproduction Update 3, 301-310. 
TALWAR, G.P. (1997b) Vaccines for control of fertility and hormone-dependent cancers. 
Immunology and Cell Biology 75, 184-189. 
TALWAR, G.P., CHAUDHURI, M.K. and JAYASHANKAR, R. (1992) Antigenic derivative of 
GnRH. UK Patent 2228262. 
TALWAR, G.P., GUPTA, S.K., SINGH, V., SAHAL, D., IYER, K.S.N. and SINGH, O. (1985) 
Bioeffective monoclonal antibody against the decapeptide gonadotropin-releasing hormone: Reacting 
determinant and action on ovulation and estrus suppression. Proceedings of the National Academy of 
Science USA 82, 1228-1231. 
TALWAR, G.P., SINGH, V., SINGH, O., DAS, C., GUPTA, S.K. and SINGH, G. (1984) Pituitary 
and extra-pituitary sites of action of gonadotropin-releasing hormone: Potential uses of active and 
passive immunisation against gonadotropin releasing hormone. Hormone Receptors in Growth and 
Reproduction edited by B B Saxena et al. Raven Press. New York. 
TATICEK, R.A., LEE, C.W. and SCHULER, M.L. (1994) Large scale insect and plant cell culture. 
Current Opinion in Biotechnology 5, 165-174. 
TAVLADORAKI, P., BENVENUTO, E., TRINCA, S., MARTINIS, D.D., CATTANNEO, A. 
and GALEFFI, P. (1993) Transgenic plants expressing a functional single chain Fv antibody are 
specifically protected from virus attack. Nature 366, 469-472. 
TILBROOK, A.J. and CLARKE, I.J. (2001) Negative feedback regulation of the secretion and 
actions of gonadotropin-releasing hormone in males. Biology of Reproduction 64, 735-742. 
 
 
 
 
 
 
References 156
TOLLIS, G., ACKMAN, A., STELLOS, A., MEHTA, A., LABRIE, F., FAZEKAS, A.T.A., 
COMSRU-SCHALLY, A.M. and SCHALLY, A.V. (1982) Tumor growth inhibition in patients with 
prostatic carcinoma treated with luteinising hormone-releasing-hormone agonists. Proceedings of the 
National Academy of Science USA 79, 1658-1662. 
TÖPFER, R., PRÖLS, M., SCHELL, J. and STEINBISS, H.H. (1988) Transient gene expression 
in tobacco protoplasts: II. Comparison of the receptor gene systems for CAT, NPT II and GUS. Plant 
Cell Reports. 7, 225-228. 
TORRES, E., VAQUERO, C., NICHOLSON, L., SACK, M., STOGER, E., DROSSARD, J., 
CHRISTOU, P., FISCHER, R. and PERRIN, Y. (1999) Rice cell culture as an alternative 
production system for functional diagnostic and therapeutic antibodies. Transgenic 
Research 8, 441-449. 
VACHER, P. (1995) Gn-RH agonists in the treatment of prostatic carcinoma. Biomedicine & 
Pharmacotherapy 49, 325-331. 
VAQUERO, C., SACK, M., DROSSARD, J., SCHUSTER, F., MONECKE, M., SCHILLBERG, 
S. and FISCHER, R. (1999) Transient expression of a tumor-specific single-chain fragment and a 
chimeric antibody in tobacco leaves. Proceedings of the National Academy of Science 
96, 11128-11133. 
VAUGHAN, T.P., WILLIAMS, A.W., PRITCHARD, K., OSBOURN, J.K., POPE, A., 
MCCAFFETY, J., HODITS, R., A., W., J. and JOHNSON, K.S. (1996) Human antibodies with 
sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature 
Biotechnology 14, 309-314. 
VEHAERT, R.M., BEEKWILDER, J., OLSTHOORN, R., DUIN, J.V. and QUAX, W.J. (2002) 
Phage display selects for amylases with improved low pH starch-binding. Journal of 
Biotechnology, 103-118. 
VOSS, A., NIERSBACH, M., HAIN, R., HIRSCH, H., LIAO, Y., KREUZALER, F. and 
FISCHER, R. (1995) Reduced virus infectivity in N. tabacum secreting a TMV-specific full size 
antibody. Molecular Breeding 1, 39-50. 
WAXMAN, J., MAN, A., HENDRY, W.F., WHITFIELD, H.N., BESSER, G.M., TIPTAFT, 
R.C., PARIS, A.M. and OLIVER, R.T. (1985) Importance of early tumour exacerbation in patients 
treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. 
British Medical Journal (Clin Res Ed) 291, 1387-1388. 
WHITE, R.B., EISEN, J.A., KASTEN, T.L. and FERNALD, R.D. (1998) Second gene for 
gonadotropin-releasing hormone in humans. Proceedings of the National Academy of 
Science 95, 305-309. 
WHITELAM, G.S., COCKBURN, W. and OWEN, M.R. (1994) Antibody production in transgenic 
plants. Biochemical Society transactions. 22, 940-944. 
WHITLOW, M., BELL, B.A., FENG, S.L., FILPULA, D., HARDMAN, K.D., HUBERT, S.L., 
ROLLENCE, M.L., WOOD, J.F., SCHOTT, M.E. and MILENIC, D.E. (1993) An improved 
linker for single chain Fv with reduced aggregation and enhanced proteolytic stability. Protein 
Engineering 6, 989-995. 
WHITLOW, M., FILPULA, D., ROLLENCE, M.L., FENG, S.L. and WOODS, J.F. (1994) 
Multivalent Fvs: characterisation of single chain Fv oligomers and preparation of a bispecific Fv. 
Protein Engineering 7, 1017-1026. 
 
 
 
 
 
 
References 157
WINTER, G. and MILSTEIN, C. (1991) Man-made antibodies. Nature 349, 293-299. 
WU, D.Y., UGOZZOLI, L., PAL, B.K., QIAN, J. and WALLACE, R.B. (1991) The effect of 
temperature and oligonucleotide primer length on the specificity and efficiency of amplification by the 
polymerase chain reaction. DNA Cell Biology 10, 233-238. 
YAHOLAM, D., CHEN, A., BEN-AROYA, N., RAHIMIPOUR, S., KAGANOVSKY, E., 
OKON, E., FRIDNIK, M. and KOCH, Y. (1999) The gonadotropin-releasing hormone family of 
neuropeptides in the brain of human, bovine and rat: identification of a third isoform. FEBS 
Letters 463, 289-294. 
YANCIK, R. and RIES, L.A. (1994) Cancer in older persons. Magnitude of the problem--how do we 
apply what we know? Cancer 74, 1995-2003. 
YANG-FENG, T.L., SEEBURG, P.H. and FRANCKE, U. (1986) Human luteinizing hormone-
releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2----p21). 
Somatic Cell and Molecular Genetics 12, 95-100. 
YU, W.H., KARANTH, S., WALCZEWSKA, A., SOWER, S.A. and McCANN, S.M. (1997) The 
hypothalamic follicular-stimulating hormone-releasing decapeptide in the rat. Proceedings of the 
National Academy of Science 94, 9499-9641. 
ZAMBRYSKI, P. (1992) Chronicles from the Agrobacterium-plant cell DNA transfer story.  Annual 
Review of Plant Pysiology and Plant Molecular Biology 43, 465-490. 
ZHANG, M., SCHILLBERG, S., ZIMMERMAN, S., LIAO, Y., BREUER, G. and FISCHER, R. 
(2001) GST fusion proteins cause false positives during selection of virus movement protein specific 
single chain antibodies. Journal of Virological Methods 91, 139-147. 
 
 
 
 
 
 
 Acknowledgement 
 
It gives me great pleasure to acknowledge the guidance, help, encouragement and cooperation 
that I received from many people during this work.  
Prof. Dr. Rainer Fischer for giving me an opportunity to work in his lab and allowing me to 
stay on and complete this thesis after the Indo-German project came to an end. I am also 
thankful to him for the critical reading of the manuscript and the suggestions.  
Prof. G. P. Talwar for giving me a chance to work in his lab and for entrusting me with this 
project. His unrelenting love for science was and will continue to be a huge source of 
inspiration for me.  
Deutsches Zentrum für Luft und Raumfahrt for providing partial financial support under the 
project number INI 009/98 titled “Engineering and Expression of Humanised Therapeutic 
Antibodies for Reproductive Health”.  
Prof. Dr. Fritz Kreuzaler for reviewing the thesis and agreeing to be the co-examiner. 
Dr. Ricarda Finnern for her assistance, attention and those time-to-time “fill me in” meetings, 
which proved very helpful. 
Markus Sack for his suggestions, comments, help and encouragement during the course of my 
doctoral work. His scientific acumen, critical thinking and the wonderful knack for putting 
everything in the right perspective in the course of those long discussions will be always 
remembered.  
As the work in this thesis was spread over two continents, I had a chance to work briefly in 
NII, New Delhi. Special thanks go to Dr. Om Singh and Dr Rahul Pal for accepting me in 
their group. Thanks also to Roopali and Nidhi, I will always remember the time spent 
with them fondly.   
Dr. Ricarda Finnern, Markus Sack and Dr. Simone Dorfmüller for reading through my thesis 
and for all the valuable suggestions. Dr. Flora Schuster for her technical support and help in 
the stable transformation of tobacco plants.  
Sonal for her patience and understanding during all those years that we were together. Many 
thanks go to Greta, Siham, Hatice, Simone, Meltem, Kerstin, Markus, Holgi and Rajan for all 
those lighter moments we had in the lab. My sincere thanks are due to all members of the 
Institut für Biologie VII for their cooperation, kindness and for providing a conducive 
working atmosphere. 
Most of all, I thank my Mother, Father and Nidhi for their untiring support, love and the 
seemingly unlimited belief in me. I thank Anshuman, who has most closely experienced and 
shared all the ups and downs that came along during the course of this work. These past four 
years would have seemed like eons without him. 
 
158 
 
 
 
 
 Lebenslauf 
Persönliche Daten 
Name 
Geburtsdatum 
Geburtsort 
Familienstand 
Staatsangehörigkeit 
 
 
 
 
 
 
 
Richa Nath 
29.01.1974 
Lucknow, Indien 
verheiratet 
Indisch 
Ausbildung  
 
1980 – 1992  Central Board of Secondary education, Delhi, Indien 
1992 – 1995  Zoology -  ‘Bachelor of Science’ Studium an der Delhi 
University, Delhi, Indien 
1995 – 1997  Genetik – ‘Master of Science’ Studium an der Delhi  
Abschluß: Master of Science 
Thema der Arbeit: “Subcloning and expression of copper,  
cadmium and zinc resistance determinant from Pseudomonas 
Pickettii Strain US321“ 
 seit Juli 1998  Promotion am Institut für Biologie VII der RWTH Aachen 
unter Anleitung von Prof. Dr. Rainer Fischer 
Berufserfahrung 
1997 – 1998 
 
seit Juli 1998 
 
 
 
 
 
Wissenschaftliche Mitarbeiter im Talwar Research 
Foundation, New Delhi, Indien 
Wissenschaftliche Hilfskraft am Institut für Biologie VII der 
RWTH Aachen 
 
 
 
 
 
 
 
 
 
159 
 
 
 
 
  
                                      
 
 
160 
 
 
 
 
